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Glossary of main terms and abbreviations 
 
Asymptomatic Not displaying any (comparable) symptoms 
Carrier A person or animal that harbours a specific infectious agent 
in the absence of discernible clinical disease, and serves as 
a potential source of infection.  
Causality The relating of causes to the effects they produce.  
Determinant Any factor, whether event, characteristic, or other definable 
entity, that brings about change in a health condition or 
other defined characteristic.  
Endemic The constant presence of a disease or infectious agent 
within a given geographic area or population group. 
Exposure Contact with a source of a disease agent in such a manner 
that effective transmission of the agent or harmful effects of 
the agent may occur. 
Household One or more persons who occupy a dwelling, i.e. a place 
that provides shelter, cooking, washing, and sleeping 
facilities. This may or may not be a family. The term is also 
used to describe the dwelling unit in which the persons live. 
Incubation Period The time interval between invasion by an infectious agent 
and appearance of the first sign or symptom of the disease 
in question. 
Infectiousness A characteristic of a disease that concerns the relative ease 
with which it transmits to other hosts.  
Infectivity Period The time during which an infectious agent may be 
transferred directly or indirectly from an infected person to 
another person, from an infected animal to humans, or from 
an infected person to an animal. 
Isolate A population of microorganisms that has been isolated from 
a (in this case) host. 
Mode of infection How transmission of infection happens - by direct contact, 
droplet spread, or contaminated fomites. 
Pathogenicity The property of an organism that determines the extent to 
which overt disease is produced in an infected population, 
or the power of an organism to produce disease.  
Pilot A small-scale test of the methods and procedures to be 
used on a larger scale if the pilot study demonstrates that 
these methods and procedures can work. 
Rate A measure of the frequency of occurrence of a 
phenomenon. In epidemiology, demography, and vital 
statistics, a rate is an expression of the frequency with 
which an event occurs in a defined population in a specified 
period of time.  
Reservoir Places where the pathogen lives (this includes people, 
animals and insects, medical equipment, and environments 
such as soil and water). 
Risk Factor An attribute or exposure that is associated with an 
increased probability of a specified outcome, such as the 
occurrence of a disease. Not necessarily a causal factor. 
May be modifiable (intervention which decreases risk of 
disease). 
Sample A specimen taken for analysis or testing. 
xv 
 
Secondary spread The spread of disease to others from cases exposed 
through the original source of infection. 
Specimen A sample of tissue, blood, urine, or in this case, faeces, 
used for analysis and diagnosis. 








The underlying personal behaviours or characteristics which 
help the organism enter the body by supporting the mode of 
transmission. This can be person-to-person, foodborne, 
vector-borne, waterborne. 





AIDS Acquired Immunodeficiency Syndrome 
BSS Bristol Stool Scale 
CDC Centres for Disease Control (US) 
CI Confidence interval 
CRU Cryptosporidium Reference Unit 
EIA Enzyme immunoassay 
ELISA Enzyme-linked immunosorbent assay 
GP General practitioner 
GRADE  Grading of Recommendations, Assessments, Development 
and Evaluation 
HIV  Human Immunodeficiency Virus 
HPU Health Protection Unit 
IBD Inflammatory bowel disease 
IBS Irritable bowel syndrome 
IMD Index of multiple deprivation 
LA Local authority 
NIHR  National Institute for Health Research  
NOS  Newcastle-Ottawa Scale 
OECD  Organisation for Economic Co-operation and Development 
OR  Odds ratio 
PCR Polymerase chain reaction 
PHE Public Health England 
PHW  Public Health Wales 
PRISMA–P  Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses for Protocols 
RFLP Restriction fragment length polymorphism 
ROBINS-I Risk Of Bias In Non-randomized Studies of Interventions 
RR  Relative risk/Risk ratio 
SD Standard deviation 
TX Transmission 
UK  United Kingdom 





Exploring transmission pathways for cryptosporidiosis in England and Wales 
 
Globally, Cryptosporidium is thought to exact a considerable burden of disease with 
the highest prevalence observed among children under five years old, in particular 
the under twos. Annually, over 10,000 cases are detected and reported in Europe 
each year and the UK cases contribute around 40% of this. 
The risk factors and exposures for Cryptosporidium infection are often identified from 
outbreak investigations. Several main transmission pathways are repeatedly 
examined, including water, animal contact, food contamination, and contact with other 
cases. Despite studies that have investigated differences in risk for sporadic and 
outbreak disease, exposures and transmission pathways for sporadic disease are still 
unclear. Thus, eliciting the pathways to infection is important to assess the burden of 
Cryptosporidium, and in considering strategies to reduce risk and mitigate spread in 
certain groups or settings. 
In the work contributing to this thesis, I have taken three steps to further examining 
Cryptosporidium in England and Wales: 
1. Using the latest data to describe the distribution of this infection in the UK, as 
well as undertaking an audit describing laboratory detection methods and approaches 
to testing that underpin this. 
2. Conducting a literature review to describe the exposures examined and 
associated with sporadic disease. 
3. Designing and implementing an analytical observational study that examines 
transmission of Cryptosporidium in the home environment. 
 
I conclude that we are likely under ascertaining cases of sporadic illness, with local 
laboratories still testing short of the recommended amount, and stool consistency is 
a common selection criterion. The systematic review revealed that we might be under 
examining person-to-person spread as a pathway responsible for sporadic infection. 
I go on to suppose that secondary spread of infection from an initial case might a) 
represent a burden of sporadic disease and, b) have underlying associated exposures 
not yet well examined.  In addition, these may differ by species of infection. 
The analytical study demonstrates that additional cases of Cryptosporidium occur in 
over a quarter of homes with a case. This is likely to affect up to a third of the home 
and cause considerable burden of illness. This is especially common where the index 
is a young child, with mums and other siblings most at risk of secondary infection, 
and where homes have cases of C. hominis.  
Feasible recommendations from these investigations include: 
• To support Cryptosporidium testing in all stools submitted for the investigation of 
gastrointestinal pathogens regardless of consistency 
• Systematic changes to surveillance to support the inclusion of speciation data for 
Cryptosporidium samples in England and Wales 
• The consideration of specific clinical advice on prevention for high-risk homes; those 
with cases of C. hominis and/or children under five years old  
 
The work supports recognition of this pathogen as burdensome and of considerable 
significance in immunocompetent individuals, and further work proposed includes 









Infectious intestinal disease and an introduction to 1 
Cryptosporidium 2 
 3 
Infectious intestinal disease (IID) is an umbrella term often use to categorise 4 
symptomatic disease, usually with symptoms of diarrhoea and/or vomiting, caused by 5 
infection with microorganisms (World Health Organization, 2019). Agents of IID can 6 
include viruses, bacteria, and protozoa. Globally it represents a common cause of 7 
morbidity, and the impact on patients and services can be considerable, sometimes 8 
with significant economic burden in the less industrialised countries (Gauci et al., 9 
2007). The distribution of IID varies worldwide, and it is likely that there are wider 10 
determinants at play influencing this: variations in exposure might be due to sanitation, 11 
availability of clean drinking water, infrastructure, housing, and health factors such as 12 
acquired immunity and nutrition (Putignani and Menichella, 2010; Fletcher, McLaws 13 
and Ellis, 2013).  14 
Human cryptosporidiosis usually presents as gastrointestinal disease, transmitted via 15 
the faecal-oral route, although there is some evidence for respiratory cryptosporidiosis 16 
in specific populations (Sponseller, Griffiths and Tzipori, 2014; Morris et al., 2019). 17 
This thesis examines research likely only to relate to the faecal-oral transmission 18 
pathway and gastrointestinal disease. 19 
Globally, Cryptosporidium is thought to exact a considerable burden of disease 20 
(Putignani and Menichella, 2010; Kotloff et al., 2013): infection is reported in 1-3 21 
percent of immunocompetent patients with diarrhoea in industrialised countries and 22 
7-20 percent in developing countries (Leder and Weller, no date; Casemore, 1990; 23 
Current and Garcia, 1991; Jelinek et al., 1997; Muliyil et al., 2010). The highest 24 
prevalence is observed among children under five years old, in particular the under 25 
twos (Ajjampur et al., 2010; Kotloff et al., 2013). Like general IID, the distribution of 26 
Cryptosporidium varies geographically and it is a parasite of some socio-economic 27 
importance (Putignani and Menichella, 2010), joining the World Health Organization’s 28 
list of neglected tropical diseases in 2004 (Savioli, Smith and Thompson, 2006). A 29 
plethora of literature exists describing acute disease and longer-term sequelae 30 
including growth faltering and cognitive defects in developing countries. In 31 
industrialised countries significant impact has also been described including 32 
persistent gastrointestinal upset, irritable bowel syndrome (IBS), and a possible 33 
association between infection and colon cancer in cases as well as highlighting the 34 
considerable economic impact of outbreaks (Innes et al., 2020). Most of the 35 
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knowledge round transmission and exposures for Cryptosporidium is generated from 36 
outbreak investigations, and this is particularly true of the more industrialised 37 
countries, and in the UK. Therefore, the background work presented in this thesis 38 
considers infection mostly from industrialised countries, in order to better support the 39 
investigations and results described from an England and Wales-based study and to 40 
propose public health recommendations from a UK perspective. 41 
Annually, over 10,000 cases are detected and reported in Europe each year; UK 42 
cases contribute around 40% of this (n=~4,000), which is partly due to ascertainment 43 
and reporting differences (European Centre for Disease Control, 2017). Testing 44 
practices are changing and offering increased resolution, but these can differ locally 45 
and country-wide (Cacciò and Chalmers, 2016). In order to understand laboratory 46 
approaches, selection criteria, and capture of cases by our surveillance systems, I 47 
have undertaken an audit of a subset of local laboratories, which outlines testing 48 
practices in England and Wales.  49 
The risk factors and associated exposures for Cryptosporidium are often identified 50 
from outbreak investigations but we cannot be certain that transmission routes for 51 
sporadic disease are the same as those which drive outbreaks (Bouzid et al., 2013). 52 
Several main transmission pathways are repeatedly examined and reported including 53 
water exposures, animal contact, food contamination, and contact with other cases. 54 
Despite case control studies which have investigated differences in risk for endemic 55 
and outbreak disease (Hunter and Thompson, 2005; Yoder, Harral and Beach, 2010), 56 
exposures and transmission pathways for sporadic disease are still unclear. Thus, 57 
eliciting the pathways to infection is important to assess the burden of 58 
Cryptosporidium and in considering strategies to reduce risk and mitigate spread in 59 
certain groups or settings. I have undertaken a systematic review in order to examine 60 
relevant literature on sporadic disease and understand which exposures are 61 
examined and contribute to disease burden.  62 
The highest burden of cryptosporidiosis is observed in our most vulnerable 63 
populations, but sporadic disease in immunocompetent people is probably more 64 
common than we recognise (Food Standards Agency, 2000a; Adak, Long and 65 
O’Brien, 2002; Briggs et al., 2014; R. M. Chalmers et al., 2016).  Symptoms can range 66 
from severe to negligible, and asymptomatic infections have been reported (Davies 67 
et al., 2009; Johansen et al., 2014). Outbreaks are commonplace with this type of 68 
illness, probably given the range of transmission pathways and the infectivity potential 69 
of the responsible pathogens. However, it is well recognised that despite sensitive 70 
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case definitions to increase capture, official reports of IID fall way below the true 71 
incidence (Doorduyn, Van Pelt and Havelaar, 2012; Tam et al., 2012). Many 72 
outbreaks, particularly those within families/homes go unrecognised (Bloomfield, 73 
2001; Day, 2001), and sporadic cases may remain uncaptured (Tam et al., 2012). I 74 
have undertaken an analytical study to explore transmission in the home environment. 75 
This also seeks to describe burden and longevity of additional illness in the home. 76 
Next steps and objectives of the work 77 
In the work contributing to this thesis, I have taken three steps to further examining 78 
Cryptosporidium in England and Wales: 79 
Objective 1 80 
To describe the distribution and burden of this infection in the UK, as well as 81 
considering detection and approaches to testing that underpin the surveillance 82 
data. I will approach this by presenting the most recent surveillance data and 83 
undertaking a laboratory practices audit. 84 
Objective 2 85 
To examine and present exposures most associated with sporadic disease, 86 
and calculate how much these contribute to infection. I have conducted a 87 
literature review to describe the reported exposures examined and associated 88 
with sporadic disease in industrialised countries, and highlight any pathways 89 
to infection that should be further considered. 90 
Objective 3 91 
To explore transmission in the home environment, and calculate the burden 92 
this might have on people in the home, considering longevity and severity of 93 
illness. I carried out an analytical study in homes where there were known 94 
cases of Cryptosporidium. I calculated the burden of disease and examined 95 
those most at risk and the factors that might contribute to spread. I also 96 
attempted to describe longevity and severity of illness, and detect any 97 
asymptomatic infections. 98 
A note on terminology 99 
On reviewing papers in the course of this work, it became clear that terminology 100 
relating to means of transmission were not always standard, or indeed even intuitive. 101 
As I began to embark on the systematic review element of the thesis, it became more 102 
important to use clear, and standard, definitions, regardless of the terms used by 103 
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authors. For this reason, I use set definitions throughout the thesis when talking about 104 
exposures and the pathways under which infection occurs. 105 
Table 1 below shows how I use these terms in the thesis and these are designed to 106 
be specifically relevant to Cryptosporidium infection. Other relevant terms are defined 107 














Person-person contact Animal contact Water contamination Food contamination 
Some examples 
of exposures  
Nappy changing 
(Changing nappies, helping 
with potty training) 
Pet contact 
(Petting, feeding, cleaning 
domestic pets) 
Recreational water 
(Consuming or swallowing 
water during activities, 
taking part in water sports, 
both outdoor (e.g. lakes) 
and indoor (e.g. treated 
swimming pools)) 
Fresh produce 
(Salad and fruit 
contaminated at picking or 
processing, from 
contaminated water or from 
handlers, or fruit juices 
made with contaminated 
water) 
Childcare activities 
(Domestic care for a child, 
working in a school or 
Attending petting farms 
(Feeding animals e.g. 
bottle-feeding lambs, eating 
on farm site, poor hand 
Drinking water 
(Consuming drinking water, 
either treated (i.e. from a 
municipal tap) or untreated 
Meat 
(Meat from infected 
animals, contaminated by 
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nursery, feeding, assisting 
with toileting, bathing) 
hygiene, handling animals 
directly) 
(e.g. private water supply, 
drinking from a stream) 
staff or handlers, or from 
water) 
Case contact 
(Lack of personal hygiene 
following contact with a 
case, caring for a case, 
general social contact, 
sexual contact) 
Wild animal contact 
(Petting, feeding, touching 
animals in the wild) 
Droplets and spray  
(Inhalation from 
contamination or event, e.g. 
cleaning up an animal 
faeces spillage) 
Poor kitchen hygiene 
(Food that gets 
contaminated, especially in 
restaurant, linked to surface 
contamination from produce 
or staff because of poor 
hygiene) 
Sexual contact 
(Sexual contact with 
another person, or a case) 
Living on a farm 
(Direct contact with the 
animals – petting, feeding, 
caring, or indirect, such as 
walking around the farm, 
eating on the farm) 
Water used in food 
production and processing 
(Contaminated water runoff 
from vegetation where land 
is manured) 
Milk and dairy 
(Contaminated produce 






Thesis approach and outline 111 
In Chapter 2, I outline general information about Cryptosporidium including the 112 
clinical picture, treatment, management, and detection.  113 
I then go on in Chapter 3 to describe the epidemiology and burden of disease, using 114 
the most recently available England and Wales Cryptosporidium surveillance data. I 115 
outline the main transmission pathways hypothesised from the existing evidence. I 116 
use this chapter to set the scene for the work. 117 
In Chapter 4, I describe the surveillance capture of Cryptosporidium in the UK, and I 118 
incorporate into this chapter results from a laboratory audit, which explores testing 119 
practices used in England and Wales. 120 
In Chapter 5, I outline the methods and results of a systematic literature review 121 
describing exposures for sporadic Cryptosporidium reported in the literature. I 122 
combine results to report on the main transmission routes for infection, various 123 
genotypes reported, and any differences between them. I conclude by considering 124 
person-to-person spread as a pathway responsible for sporadic infection, and 125 
suppose that secondary spread of infection from an initial case might a) represent a 126 
burden of sporadic disease and, b) have underlying associated risks and exposures 127 
not yet well examined. I use this chapter to inform the design and approach of the 128 
subsequent analytical study. 129 
In Chapter 6, I present the methods and results of the epiCrypt Study - an 130 
investigation of transmission of Cryptosporidium in the home environment. This work 131 
tries to estimate the amount of spread of infection that happens in the home 132 
environment, describe any factors associated with spread in the homes in which this 133 
happens, and detect any asymptomatic infections. I present species-specific data 134 
from participants recruited into the study and examine the molecular characterisation 135 
of the cases. I make recommendations for further work and practice, which include 136 
considering specific clinical advice on prevention of spread in homes identified as 137 
high-risk and propose further work to identify true secondary transmission more 138 
accurately. 139 
In Chapter 7, I conclude the work with a short summary of discussions from each 140 
chapter, considering my thesis overall. I reiterate my recommendations for further 141 
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Chapter 2: Cryptosporidium background 144 
History 145 
Cryptosporidium has a somewhat short history compared to many other pathogens. 146 
The first real recorded observation of infection, and its association with disease, was 147 
in 1907, by Edward Tyzzer, who characterised the life-cycle of the parasite in mice 148 
(Tyzzer, 1907; Tzipori and Widmer, 2008). There were a handful of publications after 149 
that, but it wasn’t until the 1950s and later that the parasite began to be described 150 
more widely, albeit associated with infection in animals (Current and Garcia, 1991; 151 
Chalmers, 2013) such as turkeys (Slavin, 1955) and cattle (Panciera, Thomassen and 152 
Garner, 1971; Tzipori, 1983). In 1976 the first human cases were documented, both 153 
describing patients with watery diarrhoea and severe disease. One of these reports 154 
described infection and severe disease in a three year old child (Nime et al., 1976) 155 
and the other in an immunosuppressed adult male (Meisel et al., 1976): the sources 156 
of infection were never determined but both had contact with farm animals. A decade 157 
later, still fewer than 60 human cases had been published, reported in people with 158 
immune deficiencies, although these reports did at least demonstrate that this was a 159 
pathogen capable of causing enteric disease in humans. By 1980, it was still widely 160 
held that “cryptosporidiosis does not appear to cause a problem and tentatively it can 161 
be regarded, therefore, as an opportunistic pathogenic parasite” (Bird and Smith, 162 
1980). 163 
In the early 1980s the advent of a growing AIDS epidemic highlighted Cryptosporidium 164 
as a very serious pathogen of immunocompromised patients (Tzipori and Widmer, 165 
2008) and it was quickly labelled as an AIDS defining diagnosis (directly associated 166 
with advanced HIV infection (Centers for Disease Control, 2008)) (Hunter and 167 
Nichols, 2002). Survival in this patient group was significantly impacted by infection 168 
with Cryptosporidium, with a large longitudinal study in San Francisco reporting a 169 
relative hazard of death two times that of other AIDS-defining diagnoses (Colford et 170 
al., 1996). This association with AIDS was a significant milestone in our understanding 171 
of this infection. Disease began to be better described, and for the first time it became 172 
more widely recognised as a pathogen of clinical importance: not only chronic and 173 
often life-threatening in vulnerable patients, but also more generally wide-spread than 174 
first thought (Navin and Juranek, 1984). 175 
Additionally at this time, studies began to emerge that suggested that 176 
Cryptosporidium was not as host-specific as once thought, and that indeed infection 177 
could cross species, which had important implications for our understanding of the 178 
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pathways to human infection (Tzipori et al., 1980).  An investigation in 1981 implicated 179 
cryptosporidiosis in 4%–7% of sporadic cases of acute gastroenteritis in humans 180 
(Tzipori et al., 1983). This was one of the first studies to recognise that there might 181 
also be a burden of infection in immunocompetent populations, and to demonstrate 182 
that children were at greater risk. Additionally, this work began to describe the 183 
symptom profile in immunocompetent humans and was one of the first papers to 184 
suggest that that person-to-person transmission might occur. Supplementary in-depth 185 
descriptive epidemiology published in 1985 synthesised literature that supported 186 
these findings, adding that continued infectivity of cases made contact hazardous to 187 
other people with particular risk among immune-compromised populations 188 
(Casemore, Sands and Curry, 1985). Moreover, diagnosis in humans thus far had 189 
depended upon histological examination, but the advent of this increasing interest in 190 
human disease brought with it collaboration between veterinary and human health 191 
professionals. This initiated the application of veterinary techniques to determine and 192 
identify infection in humans. Staining techniques such as modified Ziehl-Neelsen were 193 
fast becoming the method of choice at this time, allowing for quicker and better 194 
identification and capture of cases (Henriksen and Pohlenz, 1981; Garcia et al., 1983). 195 
By the 1990s it was established that whilst still a clinical and devastating illness among 196 
the HIV population, this infection carried a considerable burden of illness in the 197 
general population. It was in the late 80s and early 90s that we began to see large 198 
outbreaks documented in the industrialised countries, such as Australia, USA, Europe 199 
and the UK, with those from drinking water sources receiving the most attention (Mac 200 
Kenzie et al., 1995; Cicirello et al., 1997; Percival, Walker and Hunter, 2000). These 201 
events led to massive public health responses (I. R. Lake et al., 2007) for 202 
Cryptosporidium generally, including changes in water regulations, and increased 203 
efforts in surveillance and detection (Nichols et al., 2006). Additionally during this time, 204 
several seminal papers were published which emphasised the diversity of 205 
transmission pathways for this infection, including changes to taxonomy of 206 
Cryptosporidium species and knowledge of host specificity (McLauchlin et al., 1999; 207 
Goh et al., 2004, 2005; Hunter, Hughes, Woodhouse, Syed, et al., 2004; Chalmers et 208 
al., 2009). Most notable among these works was the recognition of the C. parvum 209 
genotypes 1 and 2 as C. hominis and C. parvum, respectively, with different 210 
epidemiology, and C. hominis largely restricted to human hosts (Chalmers, 2013). 211 
Recognising the changes in burden and epidemiology of this pathogen, from 2000 212 
onwards many European countries introduced mandatory reporting and some 213 
surveillance for Cryptosporidium (European Centre for Disease Control, 2017). In the 214 
12 
 
UK Cryptosporidium was made notifiable in 2010 (Public Health England, 2019). This 215 
decade brought with it developments in our knowledge of species-specific pathways 216 
to infection and recognition of the separate epidemiology of Cryptosporidium species 217 
and genotypes, very notably in the UK (McLauchlin et al., 2000; Nichols and 218 
McLauchlin, 2003; Hunter, Hughes, Woodhouse, Syed, et al., 2004; Insulander et al., 219 
2013). Advances in laboratory techniques for oocyst detection began to enhance 220 
ascertainment and detection of this pathogen. Furthermore, moves to molecular 221 
methods for pathogen characterisation has allowed greater resolution of isolates (R 222 
M Chalmers, Elwin, et al., 2002). 223 
Biology and life cycle 224 
Cryptosporidium is a protozoal parasite: a single-celled microscopic organism that 225 
can live and multiply within animal cells, including humans. Cryptosporidium can infect 226 
the intestinal tract of all mammals, along with several species of birds, fish, reptiles, 227 
and amphibians, displaying some host-species specificity (Yaeger, 1996; Bouzid et 228 
al., 2013; Thompson, Koh and Clode, 2016). 229 
Protozoa that are infectious to humans are classified into four groups, one of which is 230 
‘Sporozoa’ – groups of protozoa, including Cryptosporidium, in which the life cycle 231 
includes a spore-forming stage (CDC, 2014). This oocyst-forming quality renders 232 
cryptosporidia particularly hardy, facilitating persistence in both hosts and the 233 
environment which has implications for transmission (Thompson, Koh and Clode, 234 
2016). The oocysts become infective during a process known as ‘sporulation’ and, 235 
quite uniquely, Cryptosporidium oocysts are sporulated in vivo, and thus are infective, 236 
by the time they are shed in faeces (Ryan and Caccio, 2010). These features have 237 
implications for understanding the endurance, transmissibility, and management of 238 
these organisms. 239 
The cycle of infection 240 
The cycle of infection begins with the ingestion (usually) of oocysts. These will already 241 
be infective and the transmission route is most likely to be faecal-oral (Cacciò et al., 242 
2005). Figure 1 243 
Following ingestion, inside the gastrointestinal tract of the host, the parasite emerges 244 
from the oocyst (Box 1) and undergoes a complex life cycle, distinctively characterised 245 
by both sexual and asexual stages. Because of these reproductive stages, oocysts 246 
develop and subsequently sporulate inside the infected host. Two different types of 247 
oocysts are produced: thick-walled oocysts - excreted in the faeces of the infected 248 
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host, infective and ready to be transmitted to another susceptible host, and thin-walled 249 
oocysts, which remain inside the host, prompting another cycle of infection (known as 250 
autoinfection). 251 
 
Box 1: Cryptosporidium parasites emerging from an infective oocyst 252 
Image courtesy of Public Health Image Library, www.cdc.gov 253 
 
The process from ingestion of oocysts to symptomatic disease can take anywhere 254 
from 2 to 26 days (Jokipii and Jokipii, 1986; DuPont et al., 1995; Hawker et al., 2020) 255 
and our understanding of the pathogenesis of this organism is still lacking. The 256 
presentation of disease following Cryptosporidium infection can vary from 257 
asymptomatic (but with shedding of oocysts) (DuPont et al., 1995; Chappell et al., 258 
2016) to very severe illness, and sometimes even be life-threatening (Bouzid et al., 259 
2013). An infected human might shed as many as 109 oocysts in one bowel movement 260 
(DuPont et al., 1995) and some animals even more than this (Nydam et al., 2001). 261 
Only a small number of these (10-30 oocysts) would be needed to cause infection in 262 
another person (Okhuysen and White Jr, 1999).  263 
Once oocysts are released into the environment via the host faeces, they are able to 264 
be immediately transmitted to another host and cause infection via a faecal-oral route. 265 
This might occur in a direct mode such as close contact with an infected person or 266 
animal. Alternatively, oocysts may contaminate the immediate environment, be 267 
transferred, and ultimately reach another host via an indirect mode such as food or 268 
water contamination. Mechanical transmission may also occur (e.g. on flies) although 269 
evidence is still varied, but this is not addressed in this thesis (Graczyk et al., 2000; 270 
Nichols, 2005). 271 
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Figure 1 shows the main elements of the life cycle of Cryptosporidium, followed by a 272 
brief narrative accompaniment. 273 
 
Figure 1: An overview of the main points along the life cycle of Cryptosporidium 274 
Amended from https://www.cdc.gov/parasites/crypto/pathogen.html (Copyright: Centers for Disease 275 
Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), 276 
Division of Foodborne, Waterborne, and Environmental Diseases (DFWED) ) and (Bouzid et al., 2013) 277 
 
Brief description to accompany figure (Nichols, 1992; Nydam et al., 2001; P. 278 
Hunter and Thompson, 2005; Chalmers and Davies, 2010; Bouzid et al., 2013; CDC, 279 
2014; Checkley et al., 2015; Thomson et al., 2017) 280 
Once a host has ingested oocysts, these oocysts reside in the lumen of the intestine. 281 
A process of excystation occurs, triggered by low pH and body temperature in the 282 
host, and sporozoites are released (a). These sporozoites are the infective agents.  283 
The sporozoites attach to and penetrate the epithelial cells (b) of the gastrointestinal 284 
tract and develop into trophozoites (c). Trophozoites absorb nutrients from the host’s 285 
body. 286 




These merozoites differentiate and initiate a phase of sexual multiplication producing 289 
the male microgamonts (g) and the female macrogamonts (female). 290 
(i) Macrogamonts are fertilised by the microgametes. This creates zygotes.  291 
(j) This zygote can develop into an oocyst. Two different types of oocysts are 292 
produced (k & l). 293 
Thin-walled oocysts (k), primarily involved in autoinfection, develop and sporulate in 294 
the infected host, taking the cycle back to the beginning (a).  295 
Thick-walled oocysts (l) develop and are excreted from the host in (usually) faeces. 296 
Oocysts are sporulated (infective) upon excretion.  297 
 
A note on genetic recombination 298 
It is increasingly recognised that our epidemiological understanding of this parasite 299 
could be clouded by genetic recombination that happens within hosts (Morris et al., 300 
2019). Recent work has demonstrated host infections with a genetically mixed 301 
population of oocysts, both intra- and inter-species (Grinberg and Widmer, 2016). 302 
Potentially, the sexual stage of the life cycle could result in an increased genetic 303 
variation in offspring: different fertilization scenarios could occur, where either the 304 
same genotypes are replicated, resulting in clonal, identical cells, or a random 305 
panmixia occurs, resulting in a range of genetic heterogeneity (Alizon, de Roode and 306 
Michalakis, 2013).  It is still unclear what impact these mixed populations may have 307 
on transmission, or how this might colour our understanding of the pathways to 308 
infection, given that dominant populations are those most likely detected. This thesis 309 
is not focused on detailed molecular characterisation, but nonetheless it is important 310 
to note this phenomenon when making conclusions about transmission routes by 311 
species, or at any greater resolution. 312 
Conclusions on the life cycle 313 
When we consider the complex life cycle of this parasite, and the numbers of oocysts 314 
generated, it is easy to see how oocysts become so ubiquitous, and how they 315 
effectively make their way into almost any environment. The hardy oocysts can persist 316 
in even harsh environments, including a wide range of temperatures, flooding, and 317 
disinfection, their thick wall protecting them (Robertson, Campbell and Smith, 1992; 318 
Leitch and He, 2011).   319 
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The main sources of human infection are wild and farm animals, possibly domestic 320 
pets, although to a lesser extent, and other humans (Figure 2). These are different for 321 
the two main species: sources for C. parvum include animals and humans, and human 322 
hosts for C. hominis. Infection from oocysts derived from these sources may happen 323 
on any of the transmission pathways already mentioned: person-to-person contact, 324 
animal contact, water contamination, food contamination. Outbreaks via person-to-325 
person (C. hominis and C. parvum) or animal-to-person (C. parvum) contact are 326 
common, as well as more indirect transmission routes through ingestion of water and 327 
food or contact with objects contaminated with infectious oocysts (Cacciò et al., 2005). 328 
Pathways and risks for infection are explored in more detail later (Transmission 329 
pathways and the underlying exposures for infection). 330 
In conclusion, several characteristics of Cryptosporidium render it effective, and 331 
particularly suited to a faecal-oral transmission route: 332 
 Cryptosporidia can infect the intestinal tract of a wide range of animals, making 333 
for a large reservoir, and exposure can come from many sources 334 
 The production of oocysts makes it a hardy pathogen, facilitating persistence 335 
in both hosts and the environment, challenging disinfection processes, and 336 
increasing disease and exposure 337 
 Excreted oocysts are immediately infective, as soon as they are shed, making 338 
direct contact with faeces of infected animals or humans very risky for infection 339 
 The organism has both sexual and asexual stages and can re-infect their host, 340 
leading to persistent infection and prolonged shedding, increasing the length 341 
of time a host can transmit the infection  342 
 A long incubation period between infection and disease might inadvertently 343 
support ongoing transmission 344 
 Oocysts are shed in large numbers but only a few are needed to cause 345 




Figure 2: Main reservoirs of infection that can affect humans, for C. parvum and C. 347 
hominis.  348 
Adapted from (Morris et al., 2019) with kind permission: Guy Robinson, Cryptosporidium 
Reference Unit, Swansea 
The thickness of the arrow represents the likely contribution of that exposure to 349 
human disease. 350 
 
Cryptosporidium infection and human disease 351 
Species that infect humans 352 
At the time of writing this, 39 species of Cryptosporidium are recognised, with 24 of 353 
these acknowledged as infecting humans, although with varying frequency (Morris et 354 
al., 2019). 355 
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Table 2 documents the species, demonstrating the major hosts and their detection in 356 
humans.  357 
Although C. parvum and C. hominis are the most prevalent species causing disease 358 
in humans (McLauchlin et al., 2000; Xiao, 2010; Morris et al., 2019), infections by C. 359 
felis (Caccio et al., 2002; Beser et al., 2015), C. meleagridis (Gatei et al., 2002), C. 360 
canis (Fayer et al., 2001; Xiao et al., 2007), and C. muris (Palmer et al., 2003) have 361 
also been reported. There is evidence that species infection patterns vary globally, 362 
which could be linked to differences in exposures. North and South America, 363 
Australia, and Africa tend to record more C. hominis, and C. parvum is more often 364 
reported in European countries, particularly the UK (Cacciò et al., 2005; Putignani and 365 
Menichella, 2010). An analysis of UK cases elicited differences between infecting 366 
species and the distribution of disease (Chalmers et al., 2009). C. parvum is 367 
commoner among younger cases, and C. hominis is observed in infants, and females 368 
between 15-44 years old.  369 
Differences in transmission pathways between species 370 
Increasingly, research has demonstrated heterogeneity in the transmission pathways 371 
between species of Cryptosporidium (Hunter, Hughes, Woodhouse, Syed, et al., 372 
2004; Nic Lochlainn et al., 2019). C. hominis is most often associated with human 373 
transmission pathways while C. parvum mostly zoonotic (Tzipori and Widmer, 2008). 374 
Despite this continual and increasing evidence for difference in species’ epidemiology 375 
(Xiao, 2010; Ryan, Fayer and Xiao, 2014) major shortcomings still exist in the 376 
reporting of this in the published literature (Introduction). Most basic laboratory 377 
methods for the detection of Cryptosporidium in stool samples will only identify to the 378 
genus level, and where it is employed as a specialist service, this is mainly in 379 
industrialised countries, with varied frameworks. In the UK, positive isolates from local 380 
laboratories are voluntarily submitted to the national Cryptosporidium Reference Unit 381 
(CRU) for speciation (Chalmers et al., 2019).  382 
Species sub-types 383 
Further sub-typing of isolates for greater discrimination is usually only undertaken in 384 
specific research, and practices are variable across Europe. The 60-kDa glycoprotein 385 
gene (gp60) is the most commonly used marker for subtyping of Cryptosporidium, 386 
mainly C. parvum and C. hominis, and is a useful tool to explore sources of infection 387 
and host diversity (Rojas-Lopez et al., 2020). In the UK, gp60 sub-typing has 388 
sometimes been undertaken to supplement epidemiological and outbreak data, 389 
allowing a better understanding of exposures with greater resolution in case definition 390 
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and identifying changes in the circulation of predominant subtypes (McKerr et al., 391 
2015; Chalmers and Caccio, 2016). 392 
Throughout Europe the prevalent C. hominis alleles are IbA10G2 and lbA12G3 393 
(Cacciò, 2005; Fournet et al., 2013). This is reflected in the UK using outbreak data 394 
(Chapter 3) and these types have most often been associated with water transmission 395 
pathways (Chalmers et al., 2019). C. parvum demonstrates greater diversity (Cacciò 396 
and Chalmers, 2016) and the predominant circulating types are IIaA15G2R1 and 397 
IIaA17G1R1, also most prevalent in England and Wales (outbreak data) and mostly 398 
associated with animal contact (Chalmers et al., 2019; Morris et al., 2019). Within 399 
country variation is observed and it is thought that, rather than being species-specific, 400 
variability is related to local exposures and host factors (Chalmers and Caccio, 2016). 401 
Further discrimination can be had using multi-locus genotyping (MLG) techniques 402 
which have typically only been employed in special studies so far (Morris et al., 2019). 403 
Using several loci can discriminate specific sub-populations within a gp60 sub-type 404 
and has previously been used to demonstrate concurrent outbreaks in Sweden 405 
(Mattsson et al., 2008) and in England (Hunter et al., 2008). As of yet no standard 406 
exists, making comparisons difficult, and the need to account for genetic 407 
recombination enhances the requirement for a standard sub-typing and multi-locus 408 
protocol (Feng et al., 2014). 409 
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Table 2: Cryptosporidium species, their major hosts, and reported human infections 410 
(adapted with kind permission from: Morris, Robinson, Swain and Chalmers (Morris et al., 2019) 411 
Copyright © 2019) 412 
Cryptosporidium species Major host(s) Infections reported in 
humans 
C. alticolis Voles No 
C. apodemi Mice No 
C. andersoni Cattle Yes (rarely) 
C. avium Birds No 
C. baileyi Birds No 
C. bovis Cattle Yes (rarely) 
C. canis Canids Yes (occasionally) 
C. cuniculus Lagomorphs, Humans Yes (occasionally) 
C. ditrichi Mice Yes (rarely) 
C. ducismarci Tortoises No 
C. erinacei   Hedgehogs Yes (rarely) 
C. fayeri Marsupials Yes (rarely) 
C. felis Felids Yes (occasionally) 
C. fragile Toads No 
C. galli Birds No 
C. homai Guinea Pigs No 
C. hominis Humans Yes (commonly) 
C. huwi Fish No 
C. macropodum Marsupials  No 
C. meleagridis Birds, Mammals Yes (occasionally) 
C. microti Voles No 
C. molnari Fish No 
C. muris Rodents Yes (rarely) 
C. occultus Rodents Yes (rarely) 
C. parvum Mammals Yes (commonly) 
C. proliferans Rodents, maybe Equids No 
C. proventriculi Birds No 
C. rubeyi Squirrels No 
C. ryanae Cattle No 
C. scrofarum Pigs Yes (rarely) 
C. serpentis Reptiles No 
C. suis Pigs Yes (rarely) 
C. testudinis Tortoises No 
C. tyzzeri Rodents Yes (rarely) 
C. ubiquitum Mammals Yes (occasionally) 
C. varanii Reptiles No 
C. viatorum Humans, Rodents Yes (occasionally) 
C. wrairi Guinea Pigs No 
C. xiaoi Sheep, Goats No 
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Clinical manifestation  413 
The subsequent disease following infection with Cryptosporidium is cryptosporidiosis. 414 
Symptoms of cryptosporidiosis are fairly general to IID, and include non-bloody and 415 
watery diarrhoea, abdominal cramps, vomiting and/or nausea, low grade fever, 416 
lethargy and general malaise (Adler et al., 2017). Diarrhoea can persist longer than 417 
that seen in most other IID (Robertson et al., 2002b; Shirley, Moonah and Kotloff, 418 
2012). This seemingly generic initial presentation can make identification of 419 
cryptosporidiosis difficult, and a confirmed laboratory test is required for diagnosis (R. 420 
Chalmers and Giles, 2010; Chalmers and Katzer, 2013). There is some evidence that 421 
prior infection with Cryptosporidium confers some protective immunity to subsequent 422 
infection or disease, particularly in reducing symptoms (Quilliam et al., 2013). 423 
Several studies have suggested differences not just in the presentation of 424 
cryptosporidiosis versus other gastrointestinal illness, but also between symptoms 425 
following infection with different Cryptosporidium species or genotypes. The clinical 426 
presentation of C. hominis cases specifically may include more non-gastrointestinal 427 
symptoms such as joint pain, lethargy, and headaches and eye pain (Kortbeek, 2009; 428 
Carter et al., 2019), and overall may be associated with more severe disease (Bushen 429 
et al., 2007).  A large study of sporadic disease in the UK reported a mean duration 430 
of symptoms of 13.5 days for patients with C. hominis and 11.3 days for C. parvum. 431 
Additionally, both C. hominis and C. parvum infection can cause some significant and 432 
often long-term health effects including joint pain, weight loss, and symptoms 433 
consistent with irritable bowel syndrome (IBS) (Hunter, Hughes, Woodhouse, Raj, et 434 
al., 2004; Stiff et al., 2017). In immunocompetent patients, persistent diarrhoea has 435 
been reported up to three months post-infection, and a follow-up study of 436 
Cryptosporidium cases after an outbreak reported this up to three years after original 437 
disease (Insulander et al., 2013).   438 
C. hominis cases in particular report post-infection joint pain, headache and fatigue 439 
(Hunter, Hughes, Woodhouse, Raj, et al., 2004; Carter et al., 2019) compared to C. 440 
parvum cases. Similar work in the Netherlands reported no differences in long-term 441 
symptoms by species, but did uncover symptoms lasting four months after initial 442 
diagnosis highlighting again the significant long lasting burden of this infection (Iglói 443 
et al., 2018).  444 
Immunocompromised patients commonly experience chronic and persistent disease 445 
and are an at-risk group for these relentless, burdensome infections. Those 446 
particularly vulnerable are cases with T-cell immune deficiency, including those with 447 
haematological malignancies (particularly children), and patients with HIV infection 448 
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and CD4 counts lower than 200 (Chalmers and Davies, 2010; Cacciò and Chalmers, 449 
2016). These sentinel patient groups report similar presentations to those described 450 
above, with more severe and protracted disease reported with C. hominis infections 451 
in particular and the more anthroponotic C. parvum subtypes (Cama et al., 2008; Xiao, 452 
2010; Adamu et al., 2014). 453 
Recrudescence 454 
Enteric symptoms can last up to three weeks, often with a recrudescence of illness 455 
after a period of recovery (Hunter and Nichols, 2002; Hunter, Hughes, Woodhouse, 456 
Raj, et al., 2004; Chalmers and Davies, 2010; R. Chalmers et al., 2016). A case-457 
control study of over 200 cases of cryptosporidiosis in England and Wales noted 458 
almost 41% of cases reported recurrence of at least one of their enteric symptoms 459 
after recovery from the initial infection (Hunter, Hughes, Woodhouse, Raj, et al., 460 
2004).  461 
This recurrence of symptoms can exact a heavy burden on the individual, but crucially 462 
can also amplify the chances of onward transmission, by increasing the length of time 463 
the oocysts are shed. It is well recognised that oocyst shedding does occur after 464 
cessation of symptoms, and this might go on for one or two weeks, sometimes longer  465 
(Jokipii and Jokipii, 1986; Chappell et al., 1996; Chalmers; et al., 2016). Oocyst 466 
shedding can, although this is less often documented, also occur in people without 467 
any symptoms of enteric disease. Add to this the complexity of recrudescence of 468 
illness, and it is clear that an infected person could be shedding infective oocysts 469 
intermittently for some time.  470 
Asymptomatic infection 471 
Asymptomatic infection is probably likely (Cicirello et al., 1997; Collinet-Adler and 472 
Ward, 2010), but only occasionally documented, and general carriage rates in the 473 
general population in industrialised countries seem to be low at between 0.1-1.3% 474 
(Tompkins et al., 1999; Davies et al., 2009). Identification of carriage is difficult, as we 475 
tend to capture diarrhoeal cases, so this requires special studies. Several manuscripts 476 
have documented the heavy toll of onward spread following outbreaks which included 477 
asymptomatic infections (Heijbel et al., 1987; Mac Kenzie et al., 1995; Johansen et 478 
al., 2014). In Brazil a prospective cohort study examined the transmission of 479 
Cryptosporidium infection in households where there was an identified case (Newman 480 
et al., 1994). Secondary cases of infection occurred in 58% of households, and only 481 
a quarter of the identified secondary cases had diarrhoea, indicating the presence of 482 
asymptomatic infection in almost three-quarters of the participants. Similar results 483 
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were reported from a longitudinal study in Bangladesh, where asymptomatic infection 484 
was more prevalent than diarrhoeal disease (Korpe et al., 2016).  Potentially, this 485 
finding is due to consistent sample collection and use of PCR detection with strict 486 
case definitions, and has been demonstrated before using these methods (Sarkar et 487 
al., 2014). 488 
Spread of this parasite on some of the transmission pathways may be driven in some 489 
part by the presence of asymptomatic infection. We know that there can be a period 490 
of recovery, followed by a recurrence of symptoms, and that shedding may occur 491 
anywhere along this phase (Jokipii and Jokipii, 1986; Chappell et al., 1996; Chalmers; 492 
et al., 2016).  493 
Incubation period 494 
Usually, acute diarrhoea follows an incubation period of between two and ten days, 495 
averaging about seven (DuPont et al., 1995; Hunter, Hughes, Woodhouse, Syed, et 496 
al., 2004; Adler et al., 2017). Incubations of over a month have been reported, albeit 497 
mostly in the developing countries, where results might be influenced by host features, 498 
and possibly by the infecting species (Bouzid et al., 2013; Chalmers and Caccio, 499 
2016). This comparatively long period of incubation might allow the parasite to spread 500 
more effectively, if oocysts are shed before symptoms arise, although this is not well 501 
understood, and evidence varies.  502 
Conclusions on the clinical presentation 503 
These clinical characteristics of Cryptosporidium; long incubation, asymptomatic 504 
shedding, and recrudescence of illness, are particularly suitable to a persistent and 505 
ubiquitous nature. Despite most cases in the UK occurring in immunocompetent 506 
populations, with a self-limiting recovering illness, this is not an inconsequential 507 
infection. Disease can be long, nasty, and protracted, with long-term health effects 508 
and considerable morbidity. Ongoing shedding of infective oocysts with or without 509 
symptoms means onward spread is possible.  510 
Treatment and management 511 
Currently, there is no specific licensed treatment for cryptosporidiosis in the UK and 512 
advice is that antibiotics should not routinely be administered for any gastrointestinal 513 
infection (NICE, 2009; R. Chalmers et al., 2016). In general, because most illness is 514 
self-limiting in immunocompetent persons, treatment focuses on supportive therapies 515 
to help restore and replace fluids and electrolytes (Sparks et al., 2015). 516 
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In the USA, nitazoxanide is the only drug approved by the Food and Drug 517 
Administration (FDA) for the treatment of cryptosporidiosis, and only in 518 
immunocompetent cases older than one year (Checkley et al., 2015). Nitazoxanide 519 
has been shown to decrease the duration and severity of symptoms in 520 
immunocompetent patients (Abubakar et al., 2007; Shirley, Moonah and Kotloff, 521 
2012) but is not indicated in the immunocompromised population (Amadi et al., 2009). 522 
The lack of available treatment means that strategic and population-level approaches 523 
to management are critical. The geographic distribution and the setting of cases 524 
determine the management of general outbreaks of cryptosporidiosis. Such events 525 
are usually managed by the appropriate local health protection team, according to 526 
locally existing procedures, normally involving local authorities, e.g. environmental 527 
health. In the UK, general gastrointestinal infection protocol is followed: these will 528 
include risk assessment, provision of hygiene advice, exclusion of symptomatic cases 529 
from school or work as necessary and the introduction of control measures where 530 
indicated (Public Health Wales, 2012; Public Health England, 2014). Sporadic cases 531 
in the UK are asked to detail possible exposures and clinical signs in a general 532 
gastrointestinal questionnaire which is then referred to the relevant health protection 533 
team for surveillance, but practice has historically been variable (R M Chalmers, 534 
Hughes, et al., 2002). 535 
Summary and next steps 536 
In this chapter, I presented background information on Cryptosporidium infection and 537 
disease, relevant to this thesis. This disease presents in all groups of people, although 538 
the greatest burden occurs in the most vulnerable: the very young and old, and the 539 
immunocompromised. I have discussed how some parasite characteristics might 540 
influence the ways in which people get infected.  541 
We know that the burden of this infection in England and Wales is significant: there 542 
are over 4,000 diagnosed cases each year across these two countries (Public Health 543 
England, 2017a). We are also confident that there are likely to be significantly more 544 
than this (Food Standards Agency, 2000a; Adak, Long and O’Brien, 2002). 545 
Surveillance practice, including patient presentation, mechanisms of the systems, and 546 
laboratory detection, contributes to this disparity in ascertainment. In the next two 547 
chapters, I go on to first present the surveillance data for England and Wales, with 548 
some analyses to describe the burden of this infection. Later I examine and describe 549 
surveillance and detection. I consider the impact this has, including presenting a 550 
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This section details the most recent epidemiological data for cases in the UK, and 553 
highlights some of the main transmission pathways likely to drive infection. Data are 554 
derived from Public Health England and Public Health Wales surveillance systems, 555 
with additional context added using pre-prepared work from colleagues at PHE’s 556 
National Infection Service, Colindale, London, United Kingdom, and Wales’ 557 
Cryptosporidium Reference Unit. These are the best available data at the time of 558 
writing, at the best resolution that I could access. (PHE, 2017; Public Health Wales 559 
NHS, 2018; Douglas et al., 2019) 560 
Figure 3 shows some of the global contributory factors which can lead to human 561 
infection with this parasite. Common factors associated with infection in the 562 
industrialised countries are age of case, season, and intrinsic pathogen factors, and 563 
less often, socioeconomic indices (Cacciò and Putignani, 2014). As commented on in 564 
Chapter 2, Cryptosporidium infection presents in all groups of people. The greatest 565 
burden occurs in the most vulnerable: the very young and old, and the 566 
immunocompromised. This is true of most of the industrialised countries, where 567 
epidemiological patterns are comparable to that in the UK. I touched on some of the 568 
factors that are likely contributing to variations in disease epidemiology including 569 
differences in ascertainment, prevalence of infecting species and variations in 570 
detection, and the severity of illness of cases. In addition to these, specific exposure 571 




Figure 3: Venn diagram of factors leading to Cryptosporidium infection. Parasite, 573 
host, and environmental indexes 574 
Reproduced from Putignani and Menichella, 2010 (Putignani and Menichella, 2010) 575 
Incidence and distribution in England and Wales  576 
Included data are from submitted faecal specimens. Data are courtesy of Richard 577 
Elson and Amy Douglas, National Infection Service, PHE. 578 
Figure 4 shows laboratory reports of Cryptosporidium in England and Wales from 579 
2008 to 2017.   580 
Overall incidence 581 
The number of annually reported cases ranged from 2,990 in 2011 (5.3/100,000) to 582 
5,925 in 2016 (10.1/100,000)1. The peak years were 2012, 2015 and 2016, all of which 583 
were had large identified outbreaks. the 2012 increase may have been part of a UK-584 
wide outbreak associated with ready-to-eat salad leaves (McKerr et al., 2015); in 585 
2015, a drinking water contamination event occurred (Drinking Water Inspectorate, 586 
                                               





2017) and 2016 saw large outbreaks associated with recreational water in England 587 
(Horne et al., 2017) and a petting farm in Wales (Public Health Wales, 2016). On 588 
average, thirteen outbreaks a year are reported (range 3-23). 589 
The chart indicates a general increase from 2013 onwards, although this could be due 590 
to better detection given the increasing use of more sensitive and specific detection 591 
methods (Chalmers et al., 2015). 592 
 
Figure 4: Annual laboratory reports of Cryptosporidium in England and Wales (2008 593 
to 2017) 594 
 
Reporting region 595 
Table 3 shows the number of reports, and rates, of Cryptosporidium in England and 596 
Wales in 2017. Across England, the contribution of each region to the overall numbers 597 
of cases varies considerably. The highest number of reports (n=590), and the highest 598 
rate at 10.6/100,000, was from the South West. The next greatest contributor was the 599 
South East (not including London) (n=582). The second highest rate (10.4/100,000) 600 
was reported from the North East, despite smaller absolute numbers. London reports 601 
the fewest numbers of cases. In 2017, the North West rate was 7.6/100,000. 602 
Historically, this area has reported sizable numbers of cases.  603 
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In Wales2, rates fluctuated from 8/100,000 to their highest in 2012 at 16/100,000. The 604 
mean number of cases reported annually is 300. This represents about 10% of all 605 
England and Wales cases, although due to lower populations, rates in Wales are 606 
higher.  607 
Table 3: Regional distribution of laboratory reports of Cryptosporidium in England 608 
and Wales: 2017 609 
Country Region Number of 
laboratory 
reports 
Rate per 100,000 
population3 
England London 250 2.8 
England North East 275 10.4 
England East Midlands 378 7.9 
England West Midlands 414 7.1 
England Yorkshire and the Humber 450 8.3 
England East of England 539 8.7 
England North West 554 7.6 
England South East 582 6.4 
England South West 590 10.6 
Wales Wales 260 8.3 
 
Multiple factors might contribute to geographical differences in disease and these data 610 
are not standardised for population structure or reporting practices. The geographic 611 
variation is probably linked to the risk of exposures on specific transmission pathways. 612 
For example, rural areas may be disproportionately affected because of increased 613 
livestock presence (Goh et al., 2004; Lake et al., 2009) or indeed, the susceptibility of 614 
the local population might be influenced by consistent, long-term exposures 615 
(Casemore, 1990). 616 
Differences in spatial distribution are sometimes confounded by socioeconomic 617 
factors. In low- and middle-income countries, Cryptosporidium infection is often 618 
associated with poverty and aspects of social inequality (Bouzid, Kintz and Hunter, 619 
2018) but in the higher income countries (as considered in this thesis), sporadic illness 620 
is more often observed among the less deprived areas and communities (Reeve, no 621 
date; Snel, Baker and Venugopal, 2009). Whilst relative poverty alone is unlikely to 622 
directly cause disease it is certain to expose cases to particular pathways or 623 
                                               
2 Wales’ most recent data are for 2007-2016 
3 Incidence rates were calculated using the relevant Office for National Statistics (ONS) mid-year 
population estimates for each year 
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transmission risks, or indeed reduce the availability of resources required to avoid 624 
exposure, either by personal behaviour/engagement, general health status or access 625 
to infrastructure (Snel, Baker and Venugopal, 2009; Ellis et al., 2017). A large USA-626 
based serological surveillance study reported correlates to seropositivity that included 627 
poverty and inequality measures. Prior work further strengthens this extract, by 628 
reporting that Hispanics, African Americans, and women, all had greater odds of 629 
reporting Cryptosporidium seropositivity (Frost et al., 2004). An understanding of the 630 
physical or social environment can lend context to individual-level relationships, 631 
behaviour, or risks, but this is difficult to elicit, and not really a focus of this thesis. 632 
Age and sex 633 
Cryptosporidium follows a clear bimodal age-related pattern in most industrialised 634 
countries; a peak in young children, and a peak in adulthood, different by gender with 635 
females in the 30-44 age range most affected and males in the infant age groups 636 
(Dietz and Roberts, 2000a; Nichols et al., 2006; Yoder and Beach, 2007). A Canadian 637 
2009 surveillance study confirmed a younger profile of Cryptosporidium cases versus 638 
other infectious intestinal diseases (Pintar et al., 2009), and the most reported age 639 
group in UK are 0-4 year olds, representing 30% of all reported cases in just a small 640 
age group (Public Health England, 2017a). 641 
Figure 5 is a population pyramid representing the age and sex distribution of 642 
laboratory reports of Cryptosporidium reported in England and Wales in 2017. The 643 
under tens, and in particular the under-fives, represent the highest burden of disease, 644 
with a preponderance of males. An additional analysis of these data confirmed 645 
diversity in the rates of cryptosporidiosis per 100,000 population between adults and 646 
children: higher rates were observed in male, compared to female, children (<1-14 647 
years) and the opposite relationship in teenagers (15-19 years) and adults (20 years 648 
and older). Overall, the of greatest burden of Cryptosporidium infection in children is 649 
in the 1-4 year-old age group, specifically males, and among the adult population is 650 




Figure 5: Age and sex distribution of laboratory reports of Cryptosporidium reported 652 
in England and Wales, 2017 653 
 
Age-related risks are difficult to disentangle and may be due to greater risk of 654 
exposure or susceptibility to infection, both of which are poorly understood and hard 655 
to collect information on. Case reports may also represent an ascertainment bias due 656 
to differences in severity or health-seeking behaviour among parents, or they might 657 
be over-represented due to criteria used for laboratory testing practices (Chapter 4). 658 
Certainly, the consistent profile of a preponderance in cases in both young children 659 
and women in the thirty-plus bracket does suggest a behavioural aspect. This 660 
distribution could be linked to person-to-person transmission, possibly associated with 661 
nappy use and caring responsibilities, which has previously been demonstrated 662 
(Hunter, Hughes, Woodhouse, Syed, et al., 2004), and the gender disparity among 663 
adult cases may reflect gender roles in the home (World Health Organization, 2007). 664 
The contribution of this pathway to this particular profile is still not entirely understood 665 
and there are only a few well-executed studies that have investigated this.  666 
Seasonality 667 
Figure 6 compares 2017 numbers to the previous five years, and illustrates the 668 
tendency for a small peak in spring, around April and May, followed by a much larger 669 
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increase beginning in August and stretching through September/October (Douglas et 670 
al., 2019).   671 
 
Figure 6: Number of laboratory reports of Cryptosporidium in England and Wales by 672 
week in 2017 and average number of reports by week in 2012 to 2016 673 
 
Cryptosporidium exhibits a seasonal pattern that is likely to be related to the most 674 
appropriate transmission pathway for the infecting species: C. parvum occurs more 675 
often in the spring and C. hominis more often in the autumn (Chalmers et al., 2009). 676 
In the UK, this was fairly equal until recently, and following the introduction of strict 677 
water control regulations, more C. hominis is now seen overall. Although it is accepted 678 
that the species exhibit different epidemiological profiles, seasonality may be linked 679 
to the preponderance of different sources and environmental factors at different times. 680 
Exposure to sources may be made more likely by behavioural factors which vary by 681 
season, e.g. taking part in recreational activities (Dale et al., 2009; Lake et al., 2009; 682 
Dufour et al., 2017), and the transmission pathways driving this seasonal distribution 683 
are still unclear. 684 
Travel among cases 685 
In the available data, 78% of records were not populated with case travel information. 686 
Of those that were populated, 6% reported recent travel abroad. With such a high 687 
33 
 
level of missing data, it is difficult to proceed with any meaningful analyses, and any 688 
differences in numbers are likely to be due to biases in data collection. Other sources 689 
report that foreign travel is captured by routine surveillance in about 10% of cases, 690 
often less, but additional work suggests that the true proportion of cases that have 691 
recently travelled might be as high as a quarter. Nonetheless, travel has consistently 692 
been associated with Cryptosporidium infection in the UK, often linked to outbreaks 693 
abroad. Cryptosporidium is often observed as a non-viral cause of gastrointestinal 694 
illness in returning travelers (Okhuysen, 2001) and travel might subject people to 695 
exposures for infection. As such it is not an exposure for disease intrinsically, and 696 
susceptibility may be linked to immunity, or lack thereof, of travelers on short term 697 
holidays in endemic areas (Shlim et al., 1999) as well as increased exposures in areas 698 
with lower hygiene or more frequent use of swimming pool in holiday resorts 699 
(Introduction). Given the relatively long incubation period of Cryptosporidium it is 700 
feasible that the autumn peak is somewhat driven by foreign-acquired cases returning 701 
to the UK after the summer break (McLauchlin et al., 2000; Hunter, Hughes, 702 
Woodhouse, Syed, et al., 2004). 703 
Transmission pathways and the underlying exposures for 704 
infection 705 
In an earlier part of the thesis (The cycle of infection) I described how the parasite is 706 
transmitted via the faecal-oral route, because of ingesting Cryptosporidium oocysts. 707 
The main transmission pathways are generally shared by C. hominis and C. parvum 708 
although some aspects are different. For C. hominis, humans are the major host, 709 
whereas for C. parvum, both humans and animals can act as reservoirs (Species that 710 
infect humans). Outbreaks via person-to-person transmission (C. hominis and C. 711 
parvum) or animal-to-person transmission (C. parvum) contact have been reported in 712 
various settings, as well as more indirect pathways such as ingestion of contaminated 713 
water and food, or contact with objects contaminated with infectious oocysts (Cacciò 714 
et al., 2005; Chalmers et al., 2019).715 
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Amended and reproduced from Caccio and Putignani (Cacciò and Putignani, 2014) 
 
Figure 7: Main host and transmission pathways for C. parvum and C. hominis 
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Reported exposures are often estimated from outbreak investigations and the most 716 
well known pathways for C. parvum and C. hominis include: 717 
Water 718 
Water exposures for both C. hominis and C. parvum can include consumption of 719 
contaminated drinking water (Goh et al., 2004, 2005; Hunter, Hughes, Woodhouse, 720 
Syed, et al., 2004; Pollock et al., 2008, 2014) and exposure to recreational waters 721 
(Stafford et al., 2000; Louie et al., 2004; McCann et al., 2014). C. parvum is found in 722 
sources of water abstracted for producing drinking water often contaminated from 723 
nearby animals. Agricultural run-off from grazing land, slurry and discharge of 724 
effluents from the treatment of wastewaters can lead to outbreaks following heavy 725 
rainfall (Lake et al., 2005). Outbreaks linked to mains drinking water can cause 726 
considerable illness: a 1993 drinking water outbreak in Milwaukee affected more than 727 
400,000 residents. Low quality standards most likely led to Cryptosporidium oocysts 728 
passing through the filtration system of the city's water-treatment plant (MacKenzie et 729 
al., 1995). In the UK drinking water outbreaks are now less common, following 730 
additional regulations for public water supplies that were introduced in 1999 (Sopwith 731 
et al., 2005; Nichols et al., 2006). Outbreaks caused by drinking water consumption 732 
only now account for around 1% of outbreak disease (Chalmers et al., 2019). 733 
A few studies have examined drinking water in connection with sporadic disease, but 734 
results are varied; well executed studies are few and exposures are often difficult to 735 
disentangle (Robertson et al., 2002b; Khalakdina et al., 2003; Abubakar et al., 2004; 736 
Goh et al., 2004; Hunter, Hughes, Woodhouse, Syed, et al., 2004). Studies in 737 
Scotland (Pollock et al., 2014) and England (Goh et al., 2005) have determined 738 
decreases in cases following enhanced filtration of water. 739 
In addition to drinking water, recreational water use, often in connection with foreign 740 
travel, is a common source of outbreaks of illness, especially in summer and autumn 741 
(Stafford et al., 2000; Louie et al., 2004; McCann et al., 2014; de Gooyer et al., 2017). 742 
Common risk factors linked to this are swallowing untreated outdoor waters 743 
(Valderrama et al., 2009), swimming in a treated pool, (Causer et al., 2006; 744 
Vythelingum, Cheesbrough and Woywodt, 2012; McCann et al., 2014), and time 745 
spent in pools (with children at highest risk) (Suppes et al., 2016). Faecal 746 
contamination, inadequate filtration, or breaks in equipment or suitable management 747 
are the likely events that lead to infection (Public Health Laboratory Service, 2000). 748 
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Animal contact 749 
C. parvum is most frequently associated with exposure to farm animals as they carry 750 
this zoonotic species (Hoek et al., 2008; Utsi et al., 2016). Farm animals, especially 751 
the new-borns of goats, sheep, and cows, are recognised sources (Ng et al., 2012). 752 
Both outbreak and sporadic cases have been associated with petting farms where 753 
visitors may touch the animals, and occur more often in the springtime when young 754 
animals are born (P. Hunter and Thompson, 2005; McGuigan, Steven and Pollock, 755 
2010). Outbreaks related to this exposure are detected and reported more commonly 756 
than sporadic cases. However, in a recent study in the UK, the proportion of C. 757 
parvum cases acquired from direct contact with farm animals was estimated to be 758 
25% but explained only 10% of all the reported Cryptosporidium cases (R M 759 
Chalmers, R Smith, et al., 2011). 760 
Contributory factors include direct contact with lambs, calves, kids, or animal faeces 761 
(R. M. Chalmers and Giles, 2010). Additionally, indirect contact with faecal material 762 
might occur via the environment; inadequate hygiene practice or hand-washing 763 
facilities on a farm might increase the risk of infection after exposure (Gormley et al., 764 
2011), and an almost double risk of infection was identified previously during an 765 
outbreak in farm goers who habitually bit their nails or sucked their thumbs (Evans 766 
and Gardner, 1996). Contamination of food from animals is documented (Budu-767 
Amoako et al., 2011), and even mechanical transmission on items such as farm 768 
vehicles, pram wheels, shoes etc. is possible. There has been some suggestion that 769 
the shift of large populations of young, susceptible children into often rural areas 770 
during the spring season might contribute to cases (Stefanogiannis, McLean and Van 771 
Mil, 2001; LeJeune and Davis, 2004). 772 
It is not thought that contact with domestic pets are a significant risk for 773 
Cryptosporidium infection at a population level (Chalmers and Giles, 2010) and in the 774 
UK studies confirm this (Hunter, Hughes, Woodhouse, Syed, et al., 2004; Smith et 775 
al., 2009). Individuals may however be at risk. A handful of studies have reported 776 
infections with cat (Caccio et al., 2002; Beser et al., 2015) and  dog (Fayer et al., 777 
2001; Xiao et al., 2007) associated species, but most identified cases have been 778 
reported in immunocompromised patients (Glaser et al., 1998) or in developing 779 
countries where the epidemiology and exposure risks differ (Cama et al., 2008). 780 
Having said that, many of the decent case-control studies were undertaken before 781 
laboratory methods improved in sensitivity and specificity. The lack of species 782 
differentiation might lead to invalid assumptions about the risk posed by domestic 783 
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animals. Further to this, recent work to characterise the gp60 sequence for C. felis 784 
isolates confirmed two accounts of zoonotic transmission, one of which revealed a 785 
variability in the sequence from the host (cat) to the human case (Rojas-Lopez et al., 786 
2020). A better understanding of infecting species, and their subtypes would help 787 
support ongoing evaluation of the risks of companion animal transmission (Irwin, 788 
2002). 789 
Food items 790 
Food-related outbreaks have been reported for both C. parvum and C. hominis 791 
species (Ethelberg et al., 2009; Robertson and Chalmers, 2013; Åberg et al., 2015; 792 
McKerr et al., 2015) and are likely contaminated via water or by food handlers. These 793 
are not yet particularly common, but the potential for foodborne transmission exists, 794 
and reports are increasing in frequency (Putignani and Menichella, 2010; Robertson 795 
and Chalmers, 2013). Globally, these are more likely to present in the industrialised 796 
countries: USA, Canada, Netherlands, Scandinavia, and the UK most frequently 797 
report risks associated with fresh produce and drinks. 798 
A recent global analysis reported that a fifth of outbreaks could be considered food 799 
related, and represented the more recent years’ reports (Putignani and Menichella, 800 
2010). Conversely, some studies of sporadic illness have identified decreased risks 801 
of illness associated with certain raw food/salad items, such as tomatoes (Goh et al., 802 
2004; Hunter, Hughes, Woodhouse, Syed, et al., 2004; Nic Lochlainn et al., 2019) 803 
raw carrots (Robertson et al., 2002b), and lettuce and mixed salad (Goh et al., 2004). 804 
A high prevalence of Cryptosporidium parasites in packaged salads and leafy greens 805 
has been detected and so the potential for infection exists (Dixon et al., 2013), as 806 
proven by outbreaks. Better detection, reporting and molecular resolution (Dixon et 807 
al., 2013; Robertson and Chalmers, 2013; McKerr et al., 2015) may increase our 808 
capture of these exposures in the future. 809 
Contact with other cases 810 
Contact with other cases has previously been highlighted as a possible factor in the 811 
transmission of Cryptosporidium, both in outbreak and sporadic cases, and often for 812 
C. hominis, the more anthroponotic of the human species (Hannah and Riordan, 813 
1988; Newman et al., 1994; Nichols et al., 2006; Johansen et al., 2014). An analysis 814 
of outbreak reports taken from surveillance data in Ireland reported that ingestion of 815 
water and person-to-person spread both represented the most important 816 
mechanisms of transmission in outbreaks (Garvey and McKeown, 2009). In the 817 
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United States, a case-control study evaluating sporadic cryptosporidiosis among 818 
immunocompetent persons, found one of the main risk factors associated with 819 
increased odds of illness was contact with a child with diarrhoea (Abubakar et al., 820 
2004). This result was supported in the UK, in a case-control study conducted in the 821 
North West of England examining species-specific risk factors for sporadic 822 
cryptosporidiosis (Hunter, Hughes, Woodhouse, Syed, et al., 2004). Crucially, this 823 
work found that that changing children’s nappies was a specific risk factor for infection 824 
with C. hominis, whether the child was symptomatic or not. This suggested some 825 
contribution of asymptomatic infection to spread. A later case-control study in the 826 
Netherlands (Nic Lochlainn et al., 2019) found similar results, specifying that for C. 827 
hominis, cases were more likely than controls to have been exposed to a case in the 828 
home. Additionally, the authors reported other indicators for both species, including 829 
living in smaller homes, and living with children. These findings are corroborated in 830 
the literature and even anecdotally, and could be not only because young children 831 
are at higher risk of Cryptosporidium (i.e. higher incidence), but also that caring 832 
responsibilities in the home put adults, more likely females (World Health 833 
Organization, 2007), at greater risk of exposure and thus infection. 834 
Contact with a case is likely to represent a person-to-person transmission pathway 835 
(Nic Lochlainn et al., 2019), and can happen in various settings including the home, 836 
nurseries, and healthcare institutions (J Hannah and Riordan, 1988; Gardner, 1994). 837 
Summary 838 
The data indicate that the age and sex profile of cases is comparable here to the main 839 
industrialised countries, and that seasonal differences and travel do contribute to 840 
disease patterns in the UK. When we consider these patterns, we can conclude that 841 
the variables are not always considered intrinsic risks for infection and instead are 842 
related to the behaviours of people that likely put them at risk of specific exposures. 843 
Examples of these have already been demonstrated, such as a female parent 844 
changing an infant’s nappy. 845 
Following on from this, I ended this chapter with a brief overview of the main 846 
transmission pathways, considering some of the underlying exposures and how they 847 
contribute to infection. The main pathways reported are water, with both drinking and 848 
recreational exposures, animal contact, food, and person-to-person, in various 849 
settings. Outbreaks related to all of these have been reported, and the frequency of 850 
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some are changing. However, we are not entirely sure if the contribution of these 851 
appears the same for sporadic disease.  852 
As part of my effort to describe and understand Cryptosporidium infection in the UK, 853 
I follow this chapter with a presentation of a laboratory audit, which helps us to 854 
understand how these data are captured and what we might do to better detect 855 
sporadic cases. This helps to meet my first objective, to understand the distribution 856 
and burden of this infection in the UK, as well as considering detection and 857 
approaches to testing that underpin the surveillance data. 858 
Later in Chapter 5, I follow up on these suppositions with a systematic literature 859 
review to describe the main exposures reported for sporadic cases. This approach 860 
allows us to understand the detail underneath some of these pathways and explore 861 








Surveillance, detection, and 
diagnosis of Cryptosporidium 




Much like testing practices, surveillance approaches differ geographically. In Europe, 864 
notification of cryptosporidiosis is mandatory in 20 EU Member States, Iceland, and 865 
Norway. No surveillance system exists in Austria, Denmark, France, Greece or Italy 866 
(European Centre for Disease Control, 2017). In the USA and Australia, systems 867 
similar to the UK models exist: in the states a National Notifiable Diseases 868 
Surveillance System (NNDSS) managed by the CDC and in Australia, a National 869 
Notifiable Diseases Surveillance System, overseen by the Australian Government 870 
Department of Health (Lal et al., 2015; Painter et al., 2015).  871 
In the UK, Cryptosporidium has been classed as a ‘statutory reportable causative 872 
agent’ since 2010 (Public Health England, 2019) meaning that should a laboratory 873 
identify it in a human sample, they have a duty to notify the relevant public health 874 
authority, usually within seven days (Public Health (Control of Disease) Act 1984, 875 
1984; The Health Protection (Notification) Regulations 2010, 2010). Systematic 876 
national surveillance of laboratory confirmed Cryptosporidium in England and Wales 877 
has been established for many years (Wall et al., 1996). Both Public Health England 878 
and Public Health Wales collect these notifications and publish analyses of local and 879 
national trends. Positive samples identified in the diagnostic laboratories are routinely 880 
forwarded to the national Cryptosporidium Reference Unit (CRU) that provides expert 881 
management, prevention and control advice as well as Cryptosporidium typing and 882 
confirmation services for speciation and surveillance (Public Health England, no 883 
date). 884 
Surveillance system descriptions 885 
I have included a brief overview of the systems in both England and Wales to provide 886 
some insight into how laboratory case data are reported, and subsequently counted. 887 
England 888 
Laboratory confirmations of Cryptosporidium sp. are reported to the surveillance 889 
system, Second Generation Surveillance System (SGSS), an application that stores 890 
and manages data on laboratory isolates and notifications. Laboratories use their own 891 
information management systems (LIMS), which may vary locally, to directly feed to 892 
SGSS, which is then updated in real-time for PHE end-users (Public Health England, 893 
2016). The data are stored in a central database within PHE and made available to a 894 





Laboratory confirmations of Cryptosporidium sp. detected in samples are reported to 898 
the Welsh surveillance system, Tarian. Tarian also provides a case and incident 899 
management system, which links to relevant information in the Wales LIMS. The 900 
pathology systems are all-Wales and compatible with LIMS. (The Welsh Government, 901 
2017). 902 
Speciation data 903 
Species identification reports are returned to the relevant submitting laboratories by 904 
paper and are captured by Tarian. In Wales, this means the local health protection 905 
teams can access the updated results. (Tarian also feeds into SGSS so informs PHE 906 
at national surveillance level, although this process that currently still being quality 907 
checked.) 908 
The burden of illness pyramid 909 
 
Figure 8: The burden of illness pyramid 910 
Adapted from (FoodNet Surveillance | FoodNet | CDC, no date)  911 
The burden of illness pyramid (Figure 8) is a model for understanding disease 912 
reporting, and the steps in the process that lead from true infection to ascertainment 913 
of cases. 914 
At the bottom of the pyramid, we imagine all the true infection that exists in the 915 
population or community of interest, and at the peak are the cases that reach the 916 
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national surveillance dataset and are reported. At each stage in this process, true 917 
cases drop out of the system, usually due to myriad reasons. 918 
Data from a study of infectious intestinal diseases (IID) estimated that, in the UK, 919 
there are likely to be up to around 15 true cases in the community for every case that 920 
makes it to a lab diagnosis (Adak, Long and O’Brien, 2002). This could potentially 921 
mean that there are about 64,000 Cryptosporidium cases per year (range 45,000-922 
88,000) at the bottom of the pyramid, compared to the four thousand or so cases 923 
actually captured by surveillance at the top (O’Brien et al., 2010). 924 
We know that outbreaks are not always the biggest contributor to disease, despite 925 
being well detected, and so the true burden in the UK is not well-understood (Tam et 926 
al., 2012). The cases of Cryptosporidium that are reported only represent diagnosed 927 
and usually symptomatic illness (O’Brien et al., 2010). Importantly, Cryptosporidium 928 
infected diarrhoea patients often exhibit a recrudescence of symptoms, and the 929 
spectrum of severity of symptoms may vary (Hunter, Hughes, Woodhouse, Raj, et al., 930 
2004; Hunter, Hughes, Woodhouse, Syed, et al., 2004). Thus, cases presenting to 931 
healthcare may have had symptoms for some time, or be in an interim asymptomatic 932 
period, and testing only diarrhoeic stools would certainly underestimate incidence. 933 
Additionally, variations in whether samples are tested and in primary diagnostic test 934 
used might contribute to differences in detection in stools after the acute clinical 935 
episode has passed (Chalmers et al., 2016).  936 
Detection and diagnosis in humans 937 
Cryptosporidium oocysts are small, about 5 μm in diameter (Leitch and He, 2011) and 938 
primary diagnosis of infection is usually by determining the presence of these in stool 939 
using microscopy. Sometimes small bowel aspirates, biopsies, or tissue samples may 940 
be required. More rarely, and usually as part of studies, exposure to Cryptosporidium 941 
might be examined by serological tests, although this does not detect the presence 942 
of current infection or indeed disease. 943 
In the UK, Standards for Microbiological Investigations (SMIs) recommend that 944 
routine laboratory diagnosis of Cryptosporidium in stools should be undertaken by 945 
either stained microscopy, using auramine phenol (AP) or modified Ziehl–Neelsen 946 
(mZN), or antigen detection by enzyme immunoassay (EIA) or DNA by PCR (UK 947 
Standards for Microbiology Investigations, 2017). Following EIA positive reaction, the 948 
diagnosis should be confirmed with a method of choice, and AP microscopy 949 
confirmed with mZN. From 2008, use of EIA has been reported increasingly (RM., 950 
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2008; Chalmers et al., 2015; Alexander et al., 2017).  EIA has been shown to have 951 
better diagnostic sensitivity for Cryptosporidium than mZN microscopy, while PCR is 952 
most sensitive (R. M. Chalmers et al., 2011).  Because none of these diagnostic tests 953 
identify Cryptosporidium species, laboratories are requested to send all 954 
Cryptosporidium-positive stools to the national Cryptosporidium Reference Unit 955 
(CRU) in Swansea for species identification, and subtyping. 956 
Despite SMI recommendations that ‘all faecal samples from symptomatic individuals 957 
should be tested for Cryptosporidium oocysts’, previous audits in the UK have 958 
reported differences in completeness of testing that varied geographically (RM., 2008; 959 
Chalmers et al., 2015; Alexander et al., 2017).  Selection criteria for testing were 960 
reported to differ, were inconsistent, and laboratories frequently used submitted stool 961 
consistency as a criterion, even though this is an unreliable predictor of 962 
Cryptosporidium positivity (D P Casemore, Armstrong and Sands, 1985).    963 
As part of the overall PhD work, I undertook a contemporary audit of some 964 
laboratories in England and Wales to describe the methods used and selection criteria 965 
applied. Continued understanding of laboratory practice is fundamental to 966 
understanding and interpreting surveillance data, estimating true disease burden, and 967 
implementing control measures for patient management and at the population level. 968 
The aim of this audit was to assess approaches and monitor changes to 969 
Cryptosporidium testing, reporting and referral, including methods used and selection 970 
criteria applied, among clinical microbiology laboratories serving the National Health 971 
Service (NHS) in England and Wales, and make recommendations to promote best 972 
practice. 973 
Laboratory audit: methods 974 
In March 2019, an online survey was cascaded via email to senior biomedical 975 
scientists (BMSs) or consultant microbiologists in England and Wales, via the Heads 976 
of Laboratories for England and directly to operational microbiology leads in Wales. 977 
The survey was designed and administered using Select Survey 978 
(www.selectsurvey.net), although a Microsoft (MS) Word version was available on 979 
request (Appendix 1). Questions were informed by a previous audit (Chalmers et al., 980 
2015) and covered selection criteria used for testing stools for Cryptosporidium, 981 
diagnostic tests employed and any predicted changes to these, referral of positive 982 
stools for species identification, and the mechanisms for reporting these results. The 983 
laboratories received a reminder after one month and the survey remained open for 984 
two months.  985 
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Data analysis  986 
Following closure of the survey, data were exported, cleaned, and stored in MS Excel. 987 
I managed all data and undertook the analyses and write up. 988 
Diagnostic laboratories in England were aggregated into larger geographical areas 989 
correspondent with Public Health England (PHE) regions (North, South, Midlands and 990 
East, London). Response rate was calculated as the number of responses divided by 991 
the number of laboratories receiving the survey. Proportions were reported, and 95% 992 
confidence intervals (CI) calculated where appropriate using the Wilson Score method 993 
for proportions (Wilson, 1927; Newcombe and Altman, 2000). Reported practices and 994 
approaches to testing were assessed with the contemporaneous version of SMI B31. 995 
 
Laboratory audit: results  996 
The questionnaire was cascaded to 90 laboratories in England and Wales, using 997 
email, via the senior BMS or head of the laboratory. In total, 45 usable responses 998 
were received from laboratories that tested stool samples, a response rate of 50%. 999 
The North of England represented the majority (42%) of the responses, followed by 1000 
the South (22%), Wales (16%), London (13%) and lastly the Midlands and East 1001 
providing the smallest proportion (7%).  1002 
Routine testing for Cryptosporidium and selection criteria applied  1003 
Laboratories were asked if they routinely tested for Cryptosporidium under their 1004 
current protocol. Of the 45 laboratories, 23 (51%; CI 37.0 - 65.0) reported routinely 1005 
testing all stool samples (i.e. not applying any selection criteria). The remaining 22 1006 
laboratories (49%; CI 35.0 - 63.0) reported that selection criteria were applied (Error! 1007 
Reference source not found.), although in nine laboratories this was selecting stools 1008 
from community cases of diarrhoea, i.e. excluding inpatients that developed diarrhoea 1009 
more than three days after their admission. This is sometimes called the ‘three-day 1010 
rule” and is generally applied on a local basis, taking positivity rates and submission 1011 
numbers into account (Bauer, 2001; Public Health England, 2014). Thus, in total, 1012 
32/45 (71%; CI 56.6 – 82.3) laboratories reported testing all stools from community 1013 
cases of diarrhoea.   1014 
Seven of the 45 laboratories (16%; CI 7.7 - 28.8) tested all non-formed stools. 1015 
Additionally, laboratories reported various other criteria or combination of factors 1016 
including; immune status of the case, travel and/or exposure history, age of the case, 1017 





Table 4: Selection criteria used for testing for Cryptosporidium, reported by audited 1019 
microbiology laboratories in England and Wales, 2019 (n=45) 1020 
 
Criteria for testing  
Number of laboratories 
reporting criterion (%)  
No criteria applied  
 
All stool samples  23 (51%)  
  
Criteria applied (more than one may apply)  22 (49%)  
  
All except inpatient for >3 days  9 (20%)  
All non-formed stool samples  7 (16%)  
Immunocompromised status  7 (16%)  
Travel history  6 (13%)  
Age group  6 (13%)  
Exposure history  4 (9%)  
At clinician’s request  3 (7%)  
  
 
In all six laboratories that selected specimens according to patient age, different 1021 
categories and cut-offs were reported: <5 years, 0-14 years, 017 years, any <16 1022 
years, >2 years, and 0-45 years.  1023 
Routine testing of all stools for Cryptosporidium (i.e. not applying any selection criteria 1024 
as recommended) varied by region, but the differences were not significantly different. 1025 
The highest proportion was in the North of England reported by 14/19 laboratories 1026 
(74%; CI 51.2 - 88.2), followed by 4/7 (57%; CI 25.0 - 84.2) in Wales, 4/10 (40%; CI 1027 
16.8 - 68.7) in the South of England and 1/3 (33%; CI 6.1 - 79.2) in the Midlands and 1028 
East. However, all six responding laboratories from the London region reported 1029 
applying selection criteria.  1030 
Test methods used  1031 
Figure 9 shows the reported primary diagnostic test methods used for 1032 
Cryptosporidium. Auramine phenol (AP) stained microscopy was most commonly 1033 
used, by 22/45 (49%; CI 35.0 - 63.0) responding laboratories, followed by EIA (n=10; 1034 
47 
 
22%; CI 12.5 – 36.3), PCR (n=8; 18%; CI 9.3 – 31.3) and mZN stained microscopy 1035 












Figure 9: Primary diagnostic methods for Cryptosporidium in stools, reported by 1044 
audited microbiology laboratories in England and Wales, 2019 (n=45)   1045 
 
Of those 22 laboratories that reported using AP stained microscopy as the primary 1046 
test, five (23%) confirmed positive reactions using mZN, and one (5%) reported 1047 
confirmation using an immunochromatographic lateral flow test (RIDA®QUICK 1048 
Cryptosporidium, R-Biopharm). The most commonly used EIA kit was the microplate-1049 
format GIARDIA/CRYPTOSPORIDIUM CHEK® (Techlab, Inc.) (7/10; 70%). The 1050 
remaining three laboratories reported either using the cartridge format 1051 
GIARDIA/CRYPTOSPORIDIUM QUIK CHEK™ kit (Techlab, Inc) or the microplate 1052 
format kits Cryptosporidium Stool Antigen EIA (IVD Research Inc.) or 1053 
CRYPTOSPORIDIUM II™ (Abbott). All ten laboratories using EIA reported confirming 1054 
positive reactions: five confirmed with the GIARDIA/CRYPTOSPORIDIUM QUIK 1055 
CHEK™ (Techlab, Inc) (50%), four (40%) with either mZN or AP stained microscopy, 1056 
and one (10%) requested a repeat specimen. All eight laboratories that reported using 1057 
PCR used the same assay, the EntericBio Gastro Panel 2 (SeroSep).    1058 
Auramine phenol 
stained 




Referrals for species identification  1059 
Over three quarters of laboratories (n=36, 80%) reported referring Cryptosporidium-1060 
positive stools to the CRU for species identification, and of these 24 (67%) reported 1061 
updating their own laboratory information management system (LIMS) with the result. 1062 
Thirty-one (86%) sent the samples routinely, while the other five laboratories reported 1063 
sending samples either on request or in an outbreak situation. I was unable to 1064 
ascertain reasons for not sending samples for species identification, but most 1065 
laboratories reported that they would be willing to do this in the future.   1066 
Changes to practice 1067 
  
Five of the 45 laboratories (11%) reported having made recent changes to practice, 1068 
all of which were adoption of PCR within the preceding year. Thirteen laboratories 1069 
reported plans for future changes, of which 12 (92%) included adoption of PCR. Two 1070 
laboratories expected to reduce their testing of stools to exclude inpatient samples 1071 
(3-day rule).  1072 
Discussion  1073 
Routine testing for Cryptosporidium and selection criteria applied    1074 
Overall, 69% (95% CI 54.3 - 80.5) of laboratories routinely tested all stools from 1075 
community cases of diarrhoea, higher than the 54% (95% CI 44.6 – 64.3) reported 1076 
from the preceding audit in 2013-2014 (Chalmers et al., 2015). However, selection 1077 
criteria were often applied, and testing remains below the recommendation in SMI 1078 
B31 (Public Health England, 2014), with regional differences in the proportion of 1079 
laboratories selectively testing stools. Different criteria are used to determine 1080 
selective testing, either alone or in conjunction with other criteria. Reassuringly, fewer 1081 
laboratories reported using stool consistency as a criterion than previously, reduced 1082 
from 19% (95% CI 11.9-28.4) (Chalmers et al., 2015), to 16% (95% CI 7.7-28.8) in 1083 
this study.  1084 
A prior inconsistency in the guidance for Cryptosporidium testing, highlighted by 1085 
Chalmers et al. in 2015 (Chalmers et al., 2015), led to clarification that all faecal 1086 
samples submitted for the investigation of diarrhoeal / gastrointestinal illness should 1087 
be tested for Cryptosporidium and that stool consistency should not be used as a 1088 
criterion for selective testing (Public Health England, 2014; UK Standards for 1089 
Microbiology Investigations, 2019). Stool consistency has long been considered an 1090 
unreliable predictor of Cryptosporidium positivity (D P Casemore, Armstrong and 1091 
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Sands, 1985; Jokipii and Jokipii, 1986), and asymptomatic infection has also been 1092 
demonstrated (Newman et al., 1999; Hunter, Hughes, Woodhouse, Syed, et al., 2004; 1093 
Davies et al., 2009; Johansen et al., 2014). 1094 
Also importantly, cryptosporidiosis patients often exhibit a recrudescence of 1095 
symptoms during acute episodes, and the spectrum of severity of symptoms may vary 1096 
(Palmer and Biffin, 1990; Hunter, Hughes, Woodhouse, Raj, et al., 2004). Thus, cases 1097 
presenting to healthcare may have had symptoms for some time, or be in an interim 1098 
asymptomatic period, and testing only liquid stools would certainly underestimate 1099 
incidence. Additionally, variations in primary diagnostic test used might contribute to 1100 
differences in detection in stools submitted after the acute clinical episode has 1101 
passed. Relapsing and recuperating patients remain infectious and could present a 1102 
transmission risk. A new syndromic UK SMI that supersedes SMI S7 (UK Standards 1103 
for Microbiology Investigations, 2019)  recommends inclusion of Cryptosporidium in 1104 
the primary test set for the investigation of gastroenteritis in community settings, 1105 
irrespective of whether the stool specimen presented takes the shape of container or 1106 
not.  1107 
Other selection criteria were inconsistent, with laboratories reporting differing age 1108 
groups, health status of case, overseas travel destinations, and known exposures. 1109 
Age selection in particular seemed inconsistent and without rationale, a finding 1110 
reported previously in the literature (RM., 2008; Chalmers et al., 2015; Alexander et 1111 
al., 2017). While a focus on the younger age groups is not without justification, the 1112 
adult age group represents an important proportion of all cases (Palmer and Biffin, 1113 
1990; KG. et al., 2010) and an excess of adult cases might well help identify particular 1114 
transmission vehicles, such as water supplies (KG. et al., 2010) or food items (McKerr 1115 
et al., 2015). Six laboratories reported foreign travel as a selection criterion. Whilst 1116 
this, in conjunction with other criteria, may broaden the samples selected for testing, 1117 
used alone it may exclude a substantial proportion of otherwise identified cases 1118 
(Public Health England, 2017c). Varied and inconsistent selective testing may 1119 
contribute to underestimation of incidence, spurious distribution patterns and 1120 
transmission being less well understood.   1121 
Test methods used  1122 
Choice of test may be influenced by several attributes including, automation, technical 1123 
skill required/available, the ability for multiple pathogens to be tested for 1124 
simultaneously, national guidelines, and costs. The majority of laboratories continued 1125 
to use microscopy to detect Cryptosporidium. Auramine phenol stained microscopy 1126 
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remained the most frequently used method in England and Wales, used by 49% (CI 1127 
35.0 - 63.0) laboratories. This was however lower than the 64% (52.9-73.0) reported 1128 
in the preceding audit in 2013-2014 (Chalmers et al., 2015) suggesting this is 1129 
decreasing in popularity.  1130 
There has been increasing use of EIAs over the past decade from 2.5% (CI 1.1 – 5.7) 1131 
of laboratories in 2008 (Chalmers, 2008) to 22% (CI 12.5 – 36.3) in this study. 1132 
Microplate format EIAs enable higher throughput than stained microscopy, which 1133 
became important when diagnostic services in the UK were centralised into fewer 1134 
laboratories testing more specimens.  1135 
The biggest change highlighted by this audit was the more widespread use of PCR; 1136 
18% (CI 9.3 – 31.3) of laboratories compared with just one laboratory in the 2013-1137 
2014 survey (Chalmers et al., 2015). This is likely to be an accelerating development 1138 
as 12 laboratories reported that they expect to introduce PCR testing in the near 1139 
future. Similar to EIA, this is a high-throughput test with lower training requirements 1140 
compared to microscopy. Whereas positive reactions generated by EIA should be 1141 
confirmed for Cryptosporidium, and all laboratories reported doing so even though 1142 
the methods used varied, there is no such requirement for PCR. Although all the PCR-1143 
adopted laboratories that answered this audit used the same test, we are aware that 1144 
other tests are in use. Our results are perhaps biased by over-representation of 1145 
responses from Wales where a Welsh Government initiative enabled harmonised 1146 
adoption of the EntericBio Gastro Panel 2 in four of the seven laboratories in 2018.  1147 
Approaches and changes in testing for Cryptosporidium may influence surveillance 1148 
numbers, and tests with greater sensitivity may more closely reflect true incidence. 1149 
Taking a multiplexed approach to pathogen testing, as offered by EIA 1150 
(Cryptosporidium and Giardia are commonly combined in these assays) and the 1151 
gastrointestinal diagnostic PCR panels, may accommodate loosening of any selection 1152 
and testing criteria for individual pathogens. The effects of this have been indicated 1153 
(Ellam et al., 2008) and will become clearer over time. We know the detection ability 1154 
of these tests differ, with immunofluorescence microscopy (IFM) sensitivity around 1155 
97.4 %, more than other standard tests applied (D P Casemore, Armstrong and 1156 
Sands, 1985)  and mZN or AP perhaps less able to detect parasite oocysts after 1157 
clinical symptoms had ceased (R. Chalmers et al., 2016) (24). Five out of the 46 1158 
laboratories reported making recent changes to practice, four of which were moves 1159 
to PCR from prior methods so increases in numbers may become apparent, as a 1160 
move to PCR may allow criteria to be loosened. 1161 
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Referrals for species identification  1162 
Over three quarters of responding laboratories referred samples to the CRU for 1163 
species identification, and subtyping in outbreaks, and most of the remainder reported 1164 
that they would be willing to do this in the future. However, there may be some bias 1165 
in responses towards the most engaged laboratories, and important gaps in referrals 1166 
(for example in the south west, Yorkshire and London) have been identified by the 1167 
reference unit (unpublished data; personal communication Prof. R Chalmers). We will 1168 
continue efforts to encourage referral, to coincide with the introduction of automated 1169 
data capture from the reference unit that will better enable systematic national 1170 
surveillance, ensure characterisation of outbreaks, and improve our understanding of 1171 
Cryptosporidium epidemiology and transmission. 1172 
 
Recommendations 
Despite cautious interpretation of the results, we continue to reiterate the message 1173 
supported by the SMI and recommend that stool consistency not be used as a 1174 
selection criterion for testing for Cryptosporidium and that it is included in the primary 1175 
test set for the investigation of gastroenteritis. Additionally, we encourage the revision 1176 
of selection criteria especially where applied inconsistently, for example age groups. 1177 
 
Limitations 1178 
The overall response rate was 50%, perhaps reflecting survey overload, which had 1179 
been reported anecdotally. Whilst the results generated important findings and allow 1180 
recommendations for best practice to be made, a key limitation is the low and 1181 
regionally variable response rate. Results may therefore not be applicable across the 1182 
country. All seven microbiology laboratories in Wales responded and so a good rate 1183 
of capture here is informative.  1184 
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The audit conducted across a sample of England and Wales laboratories highlights 1191 
that the sensitivity of methods is increasing and that fewer laboratories are using stool 1192 
consistency as a selection criterion. However, selection criteria were still applied, and 1193 
testing was still below the expected and recommended amount, with regional 1194 
differences in the proportion of laboratories selectively testing stools.  1195 
In that sense, we can be fairly confident the data reported by the surveillance systems 1196 
in these two countries is accurate for those cases presenting at healthcare. 1197 
Nonetheless, some inconsistencies do still exist, and the audit does demonstrate that 1198 
we are likely seeing some presentation and testing biases in specific groups 1199 
(immunocompromised, younger children). Although this does help us to capture the 1200 
most vulnerable of patients, and detect outbreaks, there are likely to be other 1201 
unnoticed sporadic cases in the general population. Additionally, genotyping and 1202 
characterisation of samples does not always take place, leading to biases in our 1203 
understanding of the different contribution of transmission pathways to disease 1204 
burden. Frequently stool consistency is used as a criterion, even though this is known 1205 
to be an unreliable predictor of Cryptosporidium positivity (D. P. Casemore, 1206 
Armstrong and Sands, 1985). Reassuringly, in our audit, we observed that a 1207 
decreasing number (16%) of laboratories used stool consistency as a criterion.  1208 
Next steps  1209 
The previous chapters have allowed an exploration of the epidemiology of 1210 
Cryptosporidium, including transmission pathways that we usually see in outbreaks 1211 
in the UK, and testing practices that might mean we are missing cases. 1212 
It is clear that the ascertainment of this pathogen is below 100% and it is likely that 1213 
there are more community cases than we actually see. We know exposures are often 1214 
only investigated in outbreak situations. A better understating of the sporadic cases 1215 
that often go un-investigated might shed light on risks and exposures for infection.  1216 
From these introductory chapters, I propose that: 1217 
 There are likely to be uncaptured sporadic cases in the general population  1218 
 Sporadic cases’ exposures for infection might be different than the ones we 1219 
usually consider 1220 
 Exposures and transmission pathways may be different between C. parvum 1221 
and C. hominis 1222 
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In the next chapter, Chapter 5, I go on to present a systematic review, which helps 1223 
to highlight some of the main transmission pathways likely to drive infection. I use 1224 
this chapter overall to consider remaining gaps in our knowledge and propose 1225 
next steps for investigation. This helps to meet my first objective, to understand 1226 
the distribution and burden of this infection in the UK, as well as considering 1227 
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We know from previous chapters that reported exposures for both C. parvum and C. 1230 
hominis often overlap, and include consumption of contaminated drinking water and 1231 
exposure to recreational waters, (Stafford et al., 2000; Louie et al., 2004; McCann et 1232 
al., 2014) and food-related outbreaks (Ethelberg et al., 2009; Robertson and 1233 
Chalmers, 2013; Åberg et al., 2015; McKerr et al., 2015). C. parvum is frequently 1234 
associated with exposure to farm animals (Hoek et al., 2008; Utsi et al., 2016) and C. 1235 
hominis, more anthroponotic, with person-to-person spread (Hannah and Riordan, 1236 
1988; Newman et al., 1994; Nichols et al., 2006; Johansen et al., 2014). However, 1237 
exposures are often identified during the course of outbreak investigations, which may 1238 
only represent a small proportion of cases (Chalmers and Giles, 2010).  As a 1239 
consequence, we cannot be certain that transmission pathways for sporadic disease 1240 
are the same (Bouzid et al., 2013). Despite case control studies which have 1241 
investigated differences in risk for endemic and outbreak disease (P. R. Hunter and 1242 
Thompson, 2005; Yoder, Harral and Beach, 2010), pathways to sporadic infection are 1243 
still unclear and a substantial subset of reported cases remain unexplained.  1244 
Given the absence of any systematic synthesis of reported evidence in the UK, and 1245 
the few number of reviews in other industrialised countries, the aim of this work was 1246 
to search the literature to describe exposures associated with sporadic infection with 1247 
Cryptosporidium in industrialised countries. 1248 
Research question: In industrialised populations, what exposures are associated with 1249 
sporadic human Cryptosporidium? 1250 
This work contributes to my second objective to examine exposures most associated 1251 
with sporadic disease, and calculate how much these contribute to infection. 1252 
Methods 1253 
This review has been registered: PROSPERO number CRD42017056589 1254 
Where relevant, methods followed recommendations made in the Cochrane 1255 
Handbook for Systematic Reviews of Interventions (Higgins JPT and Collaboration, 1256 
2011) and reporting followed guidance from “Preferred Reporting Items for 1257 
Systematic Reviews and Meta-Analyses” (PRISMA) (Moher et al., 2009; Shamseer 1258 
et al., 2015).  1259 
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Search strategy 1260 
The search terms included the following MeSH terms/ keywords: (Cryptosporidium 1261 
OR cryptosporidiosis) AND (epidemiolog* OR risk factors OR exposure OR 1262 
transmission OR association) OR (cohort OR case-control OR “case control” OR 1263 
case-crossover OR “disease outbreaks” OR meta-analysis OR longitudinal OR 1264 
ecological). (Appendix 3)  1265 
The last published search date was 15th May 2018, and grey literature on 21st May 1266 
2019. 1267 
Three steps were used to identify the literature including electronic database 1268 
searching; reference list trawling from relevant papers; and an exploration of the grey 1269 
literature. The choice of databases was following advice from a University of Liverpool 1270 
Medicine and Dentistry Liaison Librarian, as those deemed to be most relevant to the 1271 
re-search question and likely to yield the highest number of relevant papers. 1272 
Step one—peer-reviewed literature 1273 
One reviewer (CMCK) conducted electronic searches in the following databases of 1274 
published literature considered most likely to yield the relevant papers: 1275 
 PubMed 1276 
 Web of Science 1277 
 Scopus 1278 
 Embase 1279 
Search terms were sought within the title, abstract, and keywords of the documents 1280 
contained in each database. Filters within the three databases were applied if 1281 
required to restrict the results as appropriate according to inclusion criteria. The 1282 
publications captured using the final agreed search terms were exported into 1283 
reference managing software (Mendeley) and duplicates removed. The remaining 1284 
publication titles will then be screened for relevance by two reviewers (CMCK  and  1285 
WS),  using  the  inclusion  and exclusion criteria. 1286 
Step two — hand searching in papers 1287 
Reviewers (CMCK and WS) will search reference lists to identify any further literature 1288 
or relevant publications not previously captured in the other strategies. The abstracts 1289 
of any references considered potentially relevant were sought and screened for 1290 
inclusion using the inclusion and exclusion criteria. 1291 
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Step three—accessing grey literature 1292 
One reviewer (CMCK) accessed grey literature relevant to the review question using 1293 
published online resources which included bulletins and reports from relevant 1294 
agencies, conference proceedings, and other relevant published outputs. A search of 1295 
Google Scholar (and any other relevant agencies’ sites, e.g. WHO) was undertaken 1296 
by entering the term ‘cryptosporidium’ with ‘risk factors’, ‘outbreak(s)’, ‘sporadic’, 1297 
‘endemic’, and/or ‘transmission’ into the application and reviewing the first 100 results 1298 
for relevance. Using the same search terms and inclusion criteria, the same reviewer 1299 
carried out an additional search for un-published theses work in the ProQuest 1300 
database. Following agreement on inclusion, the work would be reviewed as per 1301 
protocol. To refine and clarify the inclusion criteria and search terms and ensure that 1302 
the criteria were applied consistently, the selection process was piloted by applying 1303 
criteria to a sample of papers.  1304 
Abstract and paper selection 1305 
Following title selection, abstracts of the final included publications were screened 1306 
independently by two members of the review team (CMCK and WS) to ensure 1307 
consistency in the application of the inclusion and exclusion criteria. Any 1308 
discrepancies were discussed and re-examined until we reached an agreement. A 1309 
third reviewer (KP) was available for irreconcilable opinions on inclusion. The full texts 1310 
for all included works were retrieved via the online library where possible and, if 1311 
required, with the help of the University Liaison Librarian or by contacting authors. All 1312 
full-text studies were screened independently by the same reviewers (CMCK and AW) 1313 
to ensure that they conformed to the inclusion and exclusion criteria and 1314 
discrepancies tackled as before. Full-text papers, which appeared in a language other 1315 
than English, were shared with colleagues in the Health Protection Research Unit 1316 
(HPRU) and wider university teams for assistance with translation. Searching ceased 1317 
when no further relevant and/or not previously identified work was discovered 1318 
Eligibility and inclusion 1319 
Databases were initially searched with no restriction on year of publication. There 1320 
were no restrictions on language, provided the abstract was available in English for 1321 
the first round of screening. 1322 
Studies conducted in industrialised countries (defined using OECD category of 1323 
countries (UNICEF National Committees, 2017) and reporting on human subjects 1324 
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were included. All observational studies were included where they reported 1325 
exposures and relevant quantitative results. Individual case reports were excluded. 1326 
Study selection process 1327 
Results were managed using the Covidence tool (Veritas Health Innovation, 2018). 1328 
Screening of results and title screening was undertaken in duplicate by two reviewers, 1329 
to ensure consistency in the application of the inclusion and exclusion criteria. There 1330 
was a change in second reviewer during the abstract review however, the first and 1331 
third reviewers did not change which maintained consistency.  Discrepancies were 1332 
discussed and re-examined, and a third reviewer was available for irreconcilable 1333 
opinions on inclusion. Two papers were sent to the third reviewer for decision.   1334 
Data management 1335 
Data were extracted in duplicate using a standardised form developed in MS Access. 1336 
The minimum data set for data extraction is available in Appendix 4. Data items were 1337 
merged, and discrepancies discussed, prior to the agreement of which data were 1338 
used for analysis.  1339 
Studies were allocated a unique identifier (automatically generated) and categorised 1340 
according to the following groups:  1341 
 Included studies—studies that meet the eligibility criteria and are included in 1342 
the review 1343 
 Excluded studies—studies that do not meet the eligibility criteria and are 1344 
excluded from the review 1345 
 Studies awaiting classification—relevant studies that have been identified but 1346 
cannot be assessed for inclusion until additional data or information are 1347 
obtained  1348 
 Ongoing studies—studies that are ongoing and meet(or appear to meet thus 1349 
far) the eligibility criteria 1350 
Quality assessment 1351 
Papers were scored using the Newcastle-Ottawa Scale (NOS) (Wells et al., 2000). 1352 
This instrument is well piloted and is specific to non-randomised study types. The 1353 
NOS was completed independently by both reviewers for all studies. Results were 1354 
then amalgamated, and areas of discrepancy discussed prior to agreement on final 1355 
scores. This instrument provides an overall judgement on quality using a scoring 1356 
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system by evaluating three parameters (selection, comparability, and outcome) 1357 
across eight specific domains. The maximum score for each study is eight: four stars 1358 
for selection, one star for comparability and three stars for exposure/outcome 1359 
domains could be awarded if factors were unlikely to introduce bias. The studies were 1360 
considered of high quality if NOS score was 6–8 stars (Bouzid, Kintz and Hunter, 1361 
2018), moderate quality for a score of 5 stars and studies having fewer than five points 1362 
considered at high risk of bias (Luchini et al., 2017).    1363 
Data synthesis 1364 
Data were summarised presenting the papers' main findings including population 1365 
under study, outcome(s) measured/case definition, effect measures and reported 1366 
statistics, and exposures. Exposures, depending on how they were measured, were 1367 
grouped into transmission pathways, following discussion and consensus with 1368 
authors. Broadly the pathways considered included water, animals, food, and person-1369 
to-person spread. We further sub-categorised exposures following discussions with 1370 
the study group, in order to better represent specific known transmission risks for 1371 
Cryptosporidium, with possible differences between species highlighting the 1372 
anthroponotic versus mostly zoonotic pathways.  1373 
We did not proceed with a traditional meta-analysis as for each exposure, as fewer 1374 
than five studies were included. 1375 
We proceeded with a visual and narrative analysis of results for each exposure in the 1376 
transmission pathways. Where appropriate, available data were pooled in a visual 1377 
analysis combining the exposures across studies using GraphPad Prism 8.3.0 1378 
(GraphPad Software, 2019). Where a usable effect measure was not reported in the 1379 
study, but data were available, odds ratios or relative risks were calculated. Where 1380 
available, the multivariable-level effect measure was used in preference to the crude 1381 
to ensure where possible we were using adjusted variables which remained 1382 
significant predictors of infection after controlling for covariates.  All results whether 1383 
statistically significant or not, and those either showing the exposure as increasing or 1384 
reducing risk of outcome, were considered in the analysis. For those studies where 1385 
we used multivariable analysis, all results will have remained in the final, most 1386 
parsimonious model. 1387 
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Changes to the published protocol 1388 
The full methods and approach have previously been reported and a copy of the 1389 
published manuscript is provided in Appendix 2 (McKerr et al., 2018). 1390 
Two changes were made to the published protocol approach, which are described 1391 
and justified below. 1392 
Additional exclusion criteria 1393 
Following full text review, additional restrictions on type of cases and time period were 1394 
applied to refine the selection of papers taken forward for data extraction.  1395 
It became apparent to the authors that many of the included papers described 1396 
(mostly) outbreaks in detail, with very different, but specific, settings and widely 1397 
variable metrics for exposures. This made it difficult to synthesise meaningfully the 1398 
papers’ outcomes within the scope of this review. Additionally, outbreak-focused 1399 
papers were often specific to one event, exposure, or setting, and posed the 1400 
additional problem of more granular exposures and led to difficulties with quantifying 1401 
direct exposure. As the focus of the review was sporadic, community cases, we 1402 
applied additional criteria after full-text screening of papers to remove those 1403 
describing outbreak investigations. 1404 
Additionally, the older studies were less relevant for describing contemporary risks, 1405 
and often traversed changes in policy and practice (such as changes to municipal 1406 
water supply regulations) which may contribute to changes in reported exposures for 1407 
disease over time. Therefore, in order to focus the synthesis on the most relevant and 1408 
contemporaneous data we restricted inclusion at the data extraction stage to reports 1409 
within the last ten years (2008-18). 1410 
Change of ROB tool 1411 
In the original protocol, I intended to employ ROBINS-I as a tool to assess risk of bias 1412 
(Sterne et al., 2016).  When I began to pilot this tool to the detail in the papers that I 1413 
had extracted, I felt that it did not fit the scope, as I was not looking at interventions. 1414 
Additionally, I had had a change of reviewers in the team, a new reviewer with no 1415 
experience of the ROBINS-I tool, and less capacity meant that we had to rethink our 1416 
resource. I considered amending the tool for exposures, but following changes in 1417 
capacity of the review team, and a discussion with the systematic review team at 1418 
LRiG at University of Liverpool, I decided to use the NOS tool. This is well-validated, 1419 
straightforward to use, and did not require un-validated amending. A key reason for 1420 
using the very structure quality assessment ROBINS-I tool was to support meta-1421 
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analyses, but as we were not proceeding with these fairly early on, myself and the 1422 
team were satisfied that NOS was a suitable fit for this work. I go on to consider 1423 
limitations of the NOS later in the systematic review discussion section. 1424 
All changes were considered by the full review team, and all reached 1425 
agreement. 1426 
All protocol changes have been registered on Prospero, and are approved. 1427 
Results 1428 
The combined initial database search retrieved 2,115 articles. An additional article 1429 
was found by screening reference lists, and one pre-print was included following a 1430 
routine refresh of the search terms on PubMed. This reduced to 1,797 after removal 1431 
of duplicates. The inclusion of Embase did not yield any additional papers not 1432 
captured by PubMed, Web of Science, and Scopus. 1433 
Based on title and abstract screening, 338 full-text articles were procured and 1434 
retained for potential inclusion (Figure 10: PRISMA diagram showing manuscript 1435 
capture and inclusion). 1436 
After full-text screening, 208 peer-reviewed papers were excluded and the remaining 1437 
130 taken forward to data extraction. We excluded papers which were part of wider 1438 
studies and which reported on the same aspects of the study to prevent inappropriate 1439 
weighting to one study reported multiple times.  1440 
The application of additional selection criteria (as previously described) at this stage 1441 
were two-fold: 1442 
 To restrict the inclusion of papers to the past 10 years 1443 
 To restrict the review to studies of sporadic disease 1444 
These further restrictions resulted in the inclusion of eight articles (comprising 11 1445 
studies), of which seven (comprising 10 studies) were suitable for further synthesis. 1446 
The single paper excluded from any quantitative analysis did not have enough 1447 
information for further analysis or calculations, and no reply was received from 1448 
authors to our request for additional data. 1449 
None of the identified grey literature articles were included (searched between May 1450 
and Sept 2019) as they all described outbreaks and/or were outside the time. Six 1451 
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relevant theses were captured but were out of area or outside the time scope or were 1452 



















n = 2 
Records  
n = 2,117 
Records screened on title and abstract 
n = 1,797 
Records excluded 
n = 1,459 
Full-text articles assessed for eligibility 
n = 338 
Full-text articles excluded, with 
reasons 
n = 208 
No case exposure data (n=57) 
No measures of association (n=29) 
Review(s) (n=28) 
Descriptive epidemiology (n=25) 
Duplicates and grey literature (n=18) 
Unable to source paper (n=17) 
Incompatible outcomes (n=15) 
Non-human cases/not crypto (n=12) 
Outside geographical scope (n=7) 
Articles taken forward to data extraction 
n = 130 
Included in a quantitative synthesis 










Application of additional refining criteria to include 
only sporadic cases since 2008 
Articles excluded 
n = 122 
Studies included in overall review 
n = 11 studies (from 8 articles) 
 
Articles excluded from further 
quantitative synthesis 
n = 1 
Effect measure incomparable with 
the other studies (n=1) 
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General characteristics of included studies  1454 
A total of eight papers describing 11 individual studies4 were included for review and 1455 
potential analysis. Table 5 shows the NOS scores allocated to each of the articles, 1456 
and reports on general strengths and weakness of the study designs. (For the 1457 
Tollestrup cohort studies across three sites, (Tollestrup et al., 2014) the overall article 1458 
score was taken, as the study designs were the same and thus of identical quality).  1459 
Almost all studies (n=7) were at least of moderate quality, although some specific 1460 
biases were observed in the individual domains. Non-response rate in particular, and 1461 
the description of and differences in responses in participants, was of some concern 1462 
in almost all of the studies. A key quality aspect was risk of bias in the ascertainment 1463 
of the exposure and its comparability to case exposure. In a couple of the articles, it 1464 
was felt that case representativeness introduced a likely bias.  1465 
Table 7 shows the main characteristics of the included studies. 1466 
Four of the studies described case-control methods; two were case-case studies and 1467 
one cross-sectional. Four studies (across two papers) reported outcomes based on 1468 
serology and thus were classed as serological studies. All but one of the studies had 1469 
over 100 participants5, with three comprising several thousand participants – these 1470 
tended to be those that selected cases from large, nationwide surveillance databases. 1471 
Study year ranged from 1999 to 2017 and the studies were conducted in five, large 1472 
countries in three continents: Europe (UK and the Netherlands), North America (USA, 1473 
Canada), and Australia. The European focus on the UK and the Netherlands might 1474 
be explained by differences in the approach to detection and legislation (Putignani 1475 
and Menichella, 2010).1476 
                                               
4 The Fournet et al paper described three studies from the UK, Germany, and the Netherlands: we 
excluded the Germany study due to lack of available data and report this paper as two separate studies 
from the UK and the Netherlands.  
The Nic Lochlainn et al paper includes only results for the overall study period, not individual years, to 
avoid duplicate counting. 
The Tollestrup et al. paper described one large cohort study of 600 participants, but analysed data by 
residence of participants across three sites: we report results for the Tollestrup paper as three individual 
studies. 
5 Study numbers for the smaller case-case study in the Fournet (2) UK paper were not reported 
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Surveillance data provided a rich data set 
which can be accessed with minimal 
resource burden 
Multiple exposures could be investigated 
Authors were able to clearly exclude 
known outbreak-related cases 
Surveillance data can bias participation as 
only included captured cases 
Relevant to a specific area, which may 
decrease generalisability of results 
Compared cases to other enteric pathogens, 
so the exposure results are relative to other 



































Timely administration of questionnaire so 
recall of past exposure(s) may be more 
accurate 
Laboratory diagnosed so less chance of 
misclassification of cases 
Large-scale and representative 
Surveillance data can bias participation as 
only includes captured cases 
Exposures reported over 3 years, separately 
but lack of raw data means we could only use 
the final model 
Possibility of selection bias among those who 















































































Frequency matching allows control for any 
confounding role of age 
Had a clear hypothesis for exposure and 
outcome 
Collect exposure data 14 days prior to 
illness, comparable with Cryptosporidium 
exposure window 
Small numbers affects power and 
representativeness of results 
Followed an increase in cases that was not 
classed an outbreak, but may bias results 
towards a point source 
Controls were contacted in a different time 


































Controls randomly selected and 
representative 
Good control to case ratio 
Matching allows control for any 
confounding role of age and sex 
Followed an increase in cases that was not 
officially classed an outbreak, but may bias 




































Two controls per case 
Matching allows control for any 
confounding role of age and geography 
Controls randomly selected and 
representative 
 
Low response rate/small numbers 
Followed an increase in cases that was not 
classed an outbreak, but may bias results 
towards a point source 
Controls were contacted in a different time 














































































Surveillance data provides a rich data set 
which can be accessed with minimal 
resource burden 
Multiple exposures could be investigated 
Followed an increase in cases that was not 
classed an outbreak, but may bias results 
towards a point source 
Compared current cases to case in previous 
years, so identified exposures may reflect an 
undetected outbreak or single source 
The case-case study was in a small area and 
the authors did not report numbers so results 




























Looked at a reasonably long time period 
Authors were able to exclude travel and 
outbreak cases 
Laboratory diagnosed so less chance of 
misclassification of cases 
Compared cases to other enteric pathogens, 
so the exposure results are relative to other 
IID (with similar pathways) 
 








































































Used a well-established, representative 
and systematically collected dataset 
(NHANES) 
Case was defined as a positive IgG 
response to both markers, strengthening 
the case definition 
Large numbers 
Restricted to ages 6-49 which might exclude 
key age groups 
This type of large-scale data collection might 
bias towards a certain characteristic(s) or 
responder 
General methodological issues with serology 
studies for Cryptosporidium, including; 
- Increasing response with age 
- Hard to measure impact of non-
transient exposures 
- Not clear when infection or disease 
occurred so difficult to establish 
accurate exposure window 









































































At least one study ran for more than a year 
Good study size 
Able to collect environmental data and 
blood samples 
Multiple exposures could be investigated 
 
 
Restricted to adults only which might exclude 
key groups 
General methodological issues with serology 
studies for Cryptosporidium, including; 
- Increasing response with age 
- Hard to measure impact of non-
transient exposures 
- Not clear when infection or disease 
occurred so difficult to establish 
accurate exposure window 
- Cannot distinguish species 
Cannot establish temporal association 
between exposure and outcome - markers 
may reflect chronic, long-term exposure(s) 
Environmental samples collected after 
exposure 







Table 6: Hypothesis and main exposures investigated in each of the included studies 1478 




main exposures investigated 
Ravel et al 





Clinical, demographic and exposure variables associated with sporadic, 
domestically acquired parasitic disease.   
Cases were assigned transmission routes based on: animal-person, 
environment, water, food, person-person routes 
NicLochlainn et al  






General risk factors for sporadic cryptosporidiosis:  
demographics, symptoms, medical history, foreign travel, contact with 
animals, contact with ill persons, recreational activities, and food and 
drink consumption 
de Gooyer et al  
 
(de Gooyer et al., 
2017) 




To identify risk factors associated with region-wide increase in 
cryptosporidiosis with specific focus on recreational water activities as a 
hypothesis 
Fournet et al (1) 
NL 
 
(Fournet et al., 
2013) 





To identify risk factors for an increase in sporadic cases compared to 
previous years, with a focus on accepted transmission routes:  








main exposures investigated 
Valderrama et al 
 







To identify risk factors for an increase in sporadic summer cases, 
specifically for community disease.  
Exposures included food and water consumption, recreational water, 
childcare, animal contact, person-to-person contact, and travel history 
Fournet et al (2) 
UK 
 
(Fournet et al., 
2013) 




To identify risk factors for sporadic cases compared to previous years, 
with a focus on accepted transmission routes:  
farm animals, recreational water, drinking water, including bottled, and 
travel history 
Pintar et al  
(Pintar et al., 2009) 
2005 - 2007 
Canada 
Case-case 
Determining exposures for sporadic, endemic disease - addressed three 
routes of exposure based on a priori hypotheses: recreational water, 
environmental, and person-to-person transmission 
Becker et al  
 









Investigated correlates of social inequality (food adequacy, annual 








main exposures investigated 
Tollestrup et al  
(a,b,c) 
 
(3 studies at 
separate sites)  
 




a: 2004 - 2005 
b: August 2006-
February 2007 








Investigated if wastewater from onsite systems and private water 
supplies correlated to serological response:  
Hypothesis: that participants living in households with onsite wastewater 
systems and private wells would be more likely to have elevated 
serological responses compared to those living in households using 





Transmission pathways and exposures investigated 1480 
In discussion with the review team, recognising the faecal-oral transmission route for 1481 
Cryptosporidium infection in humans, the following transmission pathways were 1482 
established capturing the predominant exposures measured in the included studies:  1483 
 Animals – pets and farm animal exposures 1484 
 Food – eating spoiled foods, raw or fresh produce, unpasteurised beverages, 1485 
and proxy exposures such as eating outside the home, killing/preparing own 1486 
meat 1487 
 Outdoor activities/environmental exposures – activities such as gardening 1488 
and hiking/camping, and environments such as living on a farm 1489 
 Person-to-person spread – contact with a case (close contact, 1490 
caring/toileting capacity, and sexual contact) and general social 1491 
contact/activities 1492 
 Water – drinking water and recreational water contact/water sports 1493 
 Travel - any travel away from usual area of domestic residence 1494 
 Season – season of infection, usually extracted from surveillance data 1495 
 1496 
Main findings are found in Table 7, which outlines the main exposures measured (as 1497 
defined by the studies) and the main results reported with a relevant transmission 1498 
pathway added.   1499 
The included papers measured over 200 exposures across the 11 studies. Exposures 1500 
measured were multiple and varied in detail and definition across each of the studies, 1501 
and even within studies. Generally, studies were exploratory in nature. The 2015 de 1502 
Gooyer et al study in Australia (de Gooyer et al., 2017) was centred on a specific 1503 
hypothesis about exposure to recreational water, but the rest of the studies tended to 1504 
look at myriad exposures, following the main known routes to infection for 1505 
Cryptosporidium. Exposure to animals was a popular pathway, with six studies 1506 
investigating this and both livestock/farm animal exposure and pets and domestic 1507 
animal contact were well investigated. Food items were investigated in five studies 1508 
and personal contact (with a case or general social contact) in seven. All bar one 1509 
study investigated some water exposures, the most commonly investigated pathway 1510 
for Cryptosporidium cases. 1511 
 1512 
The Becker (2015) (Becker, Oloya and Ezeamama, 2015), Pintar (2009) (Pintar et 1513 
al., 2009), and Tollestrup (2014) (Tollestrup et al., 2014) studies also included risk 1514 
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factors relating to patient/case demographics and characteristics. We include a short, 1515 
narrative overview of this content. 1516 
 1517 
Clinical variables, case demographics and social factors 1518 
Pintar’s 2005-7 case-case study of the Canadian Integrated Enteric Disease 1519 
Surveillance System (C-EnterNet) reported that the odds of a Cryptosporidium case 1520 
being between six and twelve years old was five times greater than the other enteric 1521 
pathogens. The non-Cryptosporidium controls had an older profile than the cases 1522 
(mean:cases=21.7 years, controls=31.8 years, p=0.01). Among the serological 1523 
studies, increased odds of seropositivity was observed with increasing age: in those 1524 
over 60 years old compared to a wider baseline of under 40 years at two sites in the 1525 
Tollestrup studies, and with increasing age in the Becker study (p<0.001). However, 1526 
it is well known that cases exhibit a bi-modal age distribution pattern and serological 1527 
studies can report increased serological positivity with increasing age (Pollock and 1528 
Ramsey, 2011), which may reflect time and intensity of exposure or elevated 1529 
serological responses increasing likelihood of detection (Chalmers et al., 2013). 1530 
In the Tollestrup (b) study, the authors reported a reduced odds of positive serological 1531 
response to Cryptosporidium antigens in people reporting higher education levels.  In 1532 
the higher income countries, sporadic illness is more often observed among the less 1533 
deprived areas and communities (Reeve, no date; Snel, Baker and Venugopal, 2009). 1534 
In these countries, rurality is associated with increasing wealth while more deprived 1535 
areas tend to be located in the city. Additionally, associated activities such as 1536 
swimming and travel are likely to be less prevalent in the more deprived areas and 1537 
as such the profile of Cryptosporidium in relation to deprivation is converse to that in 1538 
the less industrialised areas (Lake et al., 2009; Bouzid, Kintz and Hunter, 2018). 1539 
Conversely, Becker et al analysed data extracted from the USA National Health and 1540 
Nutritional Examination Survey (NHANES)6, between 1999 and 2000, and found that 1541 
correlates to C. parvum included several poverty and inequality measures including 1542 
country of birth other than USA (p<0.001) and ethnic groups other than non-Hispanic 1543 
whites (p<0.001). These results are supported by similar work reporting that 1544 
Hispanics, African Americans, and women, all had greater odds of reporting 1545 
Cryptosporidium seropositivity (Frost et al., 2004). Whilst relative poverty alone is 1546 
                                               
6 NHANES is series of surveys which examines about 5,000 persons each year in the USA and is 
considered to be a nationally representative sample. The NHANES interview includes demographic, 
socioeconomic, dietary, and health-related questions as well as medical, dental, and physiological 
measurements (Centers for Disease Control and Prevention (CDC), 2017). 
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unlikely to directly cause infection with Cryptosporidium, it might steer exposure to 1547 
particular pathways or risks, or indeed reduce the availability of resources required to 1548 
avoid exposure, either by personal behaviour/engagement, general health status or 1549 
access to a health infrastructure (Snel, Baker and Venugopal, 2009; Ellis et al., 2017). 1550 
However, assessing individual risk alongside population-level characteristics often 1551 
introduces fallibility, especially when using surveillance data which may introduce a 1552 
bias in participants based on their access to healthcare. Further work on specific 1553 
population-level characteristics would be useful and may help contextualise some of 1554 
the individual-level relationships between these characteristics and exposure to 1555 
infection. 1556 
Exclusions 1557 
Whilst it is important to note these demographic-focused findings, these parameters 1558 
are likely to be risk factors associated with exposures to Cryptosporidium: we only 1559 
used metrics that could be categorised into Cryptosporidium transmission pathways 1560 
in the further analysis, thus excluding case characteristics. 1561 
Three studies looked at travel as a risk for disease (any travel away from usual 1562 
domestic residence) but most often it was an exclusion criterion in order to ensure 1563 
investigation of endemic indigenous cases. Cryptosporidium is often observed as a 1564 
non-viral cause of gastrointestinal illness in returning travelers (Okhuysen, 2001) and 1565 
travel might subject people to risk exposures. As such it is not an exposure for disease 1566 
intrinsically, and susceptibility may be linked to immunity, or lack thereof, of travelers 1567 
on short term holidays in endemic areas (Shlim et al., 1999) as well as increased 1568 
exposures in areas with lower hygiene or more frequent use of swimming pool in 1569 
holiday resorts. We excluded travel from any further detailed analysis.  1570 
Additionally, there were insufficient papers reporting on season or outdoor activities 1571 



























Transmission pathway (or risk factor) Exposure measured 
Measure of association 
(reported)7 






























Animals Contact with household pets Proportion exposed = 49 34-64 - 
  
Animals Visited a farm, a petting zoo or fair Proportion exposed = 18 9-32 - 
Food Ate food prepared outside home Proportion exposed = 43 28-58 - 
Food Ate meat from any place other than the 
grocery store 
Proportion exposed = 26 14-40 - 
Food Drank/ate any unpasteurised milk, 
juice, or dairy products 
Proportion exposed = 8 2-19 - 
Food Shopped at a supermarket Proportion exposed = 93 82-99 - 
Food Shopped at butcher shop Proportion exposed = 20 9-34 - 
Food Shopped at farm Proportion exposed = 7 1-18 - 
Food Shopped at farmer’s market Proportion exposed = 4 1-15 - 
Outdoor activities/environmental exposure Canoed, kayaked, hiked, or camped Proportion exposed = 16 7-30 - 
Outdoor activities/environmental exposure Gardening Proportion exposed = 13 5-26  -  
Outdoor activities/environmental exposure Lived on a farm or country property Proportion exposed = 30 18-45  -  
Person-to-person Attended social gatherings Proportion exposed = 18 9-32  -  
Person-to-person Hosted or attended a barbeque Proportion exposed = 33 20-49  -  
Person-to-person 
Knew anyone outside the household 
with a diarrhoeal illness  
Proportion exposed = 13 5-25  -  
Travel Domestic travel Proportion exposed = 100 69-100  -  
Water Bottled water Proportion exposed = 53 39-67  -  
                                               
 

























Transmission pathway (or risk factor) Exposure measured 
Measure of association 
(reported)7 
95% CI p Level 
Water City water Proportion exposed = 49 35-63  -  
Water Drank untreated/raw water Proportion exposed = 11 4-24  -  
Water Private well Proportion exposed = 31 19-46  -  
Water 
Swam in/gone into ocean, lake, river, 
pool, hot tub 
Proportion exposed = 46 31-61  -  
Water 
Used an in-home treatment system for 
drinking water 




































 Food Ate tomatoes aOR=0.6 0.5-0.8 0.001 
MVA 
Food BBQ food aOR=1.8 1.4-2.3 0.001 
Person-to-person Household person-to-person 
transmission 































Person-to-person Household member with diarrhoea aOR=12.6 2.13-75.1 0.006 MVA 
Water Drank bottled water aOR=6.31 1.39-28.7 0.017 MVA 
Water Waterpark aOR=36.9 3.12-435 0.004 MVA 
Water Spa use aOR=26.4 1.47-472 0.026 MVA 
Water Recreational water OR=3.18 1.15-8.79 0.023 UVA 
Water Waterpark OR=73.5 6.74-802 0.000 UVA 
Water Public pool OR=1.07 0.44-2.60 0.89 UVA 
Water Private pool OR=1.96 0.65-5.96 0.225 UVA 
Water Natural bodies of water OR=1 0.31-3.25 1 UVA 
                                               
 
























Transmission pathway (or risk factor) Exposure measured 
Measure of association 
(reported)7 









































Water Drank bottled mineral water aOR=2.72 1.10-6.76 0.03 MVA 
Animals Contact with farm animals 
Difference in Proportions 
(case v control) = 33% vs 
40% 
- 0.3 UVA 
Travel Travel 
Difference in Proportions 
(case v control) = 36% vs 
22% 
- 0.03 UVA 
Water Drank tap water on daily basis 
Difference in Proportions 
(case v control) = 67% vs 
78% 
- 0.07 UVA 
Water 
Exposure to swimming pool, sea, river 
or lake 
Difference in Proportions 
(case v control) = 70% vs 
66% 






























Consumption of produce from 
farm/farm stand 
aOR=0.2 0.1-0.9  -  
MVA 
Person-to-person Attending social event aOR=0.4 0.1-0.9  -  
Person-to-person 
Contact with child in child-care or in 
diapers 
aOR=3.8 1.5-9.6  -  
Water 
Drinking untreated water from lake, 
river, or stream 
aOR=8.0 1.3-48.1  -  




































Animals Dog ownership 
Difference in Proportions 
(year 2012 vs 2009-11) = 
46% vs 25% 
























Transmission pathway (or risk factor) Exposure measured 
Measure of association 
(reported)7 
95% CI p Level 
Food Ate food prepared outside the home 
Difference in Proportions 
(year 2012 vs 2009-11) = 
32% vs 4% 
- 0.001 
Travel Travel 
Difference in Proportions 
(year 2012 vs 2009-11) = 
54% vs not reported 
- 0 
Water Bottled water 
Difference in Proportions 
(year 2012 vs 2009-11) = 
11% vs 10% 
- 0.44 
Water Swimming pool use 
Difference in Proportions 
(year 2012 vs 2009-11) = 



























Animals Visited a farm OR=1.6 1-2.5 0.032 UVA 
Case characteristics  Age 0-5 OR=2.8 0.84-9.1 0 UVA 
Case characteristics  Age 6-12 OR=5.5 1.7-18 0 UVA 
Case characteristics  Age 13-17 -- 0-0 0 UVA 
Case characteristics  Age 18-24 OR=1.7 0.38-7.9 0 UVA 
Case characteristics  Age 25-39 OR=2.2 0.65-7.4 0 UVA 
Case characteristics  Age 40-59 Ref grp -- -- -- 
Case characteristics  Age >60 OR=0.8 0.15-4.6 0 UVA 
Food Ate a ready-to-eat product OR=2.1 0.5-9.3 0.276 UVA 
Food Ate at a fast food restaurant OR=1.5 0.7-3.4 0.273 UVA 
Food Ate at a food vendor OR=2.8 0.6-13 0.186 UVA 
Food Killed own food OR=2.3 0.5-10 0.245 UVA 
Food Meat from butchers OR=0.8 0.2-3.5 0.516 UVA 
Outdoor activities/environmental exposure Hiking, camping, or canoeing OR=2.1 0.8-5.7 0.135 UVA 
























Transmission pathway (or risk factor) Exposure measured 
Measure of association 
(reported)7 
95% CI p Level 
Person-to-Person Attending social event OR=0.23 0.05-0.99 0 MVA 
Person-to-Person Family member with diarrhoea OR=2.86 1.28-6.38 0 MVA 
Person-to-Person Non-family member with diarrhoea OR=2.1 0.64-6.87 0 MVA 
Person-to-Person Attended a social gathering OR=0.3 0.1-1.1 0.068 UVA 
Person-to-Person Family member ill OR=3 1.4-6.3 0.003 UVA 
Person-to-Person Non-family member with diarrhoea OR=1.9 0.7-5.3 0.184 UVA 
Season Autumn vs spring as ref grp OR=5.8 0.74-46 0 UVA 
Season Summer vs spring as ref grp OR=5.6 0.74-42 0 UVA 
Season Winter vs spring as ref grp OR=1.4 0.08-22 0 UVA 
Water Municipal water supply OR=2.43 1.05-5.65 0.04 MVA 
Water Swimming in natural water OR=2.91 1.14-7.38 0 MVA 
Water Municipal water supply (vs private) OR=2.2 1-4.8 0 UVA 
Water 
Swimming in untreated water lake or 
river 
OR=3.1 1.4-6.7 0.004 UVA 
Water Swimming pool OR=1.9 0.8-4.8 0.154 UVA 
























Case characteristics Age (year increments from 6-49 years) aOR=1.06 1.05-1.07 <0.001  
MVA 
Case characteristics  Black ethnicity (vs White) aOR=1.88 1.42-2.53 0.001 
Case characteristics  Country of birth Mexico (vs USA) aOR=2.96 1.99-4.25 0.001 
Case characteristics  Country of birth Other (vs USA) aOR=2.27 1.53-3.28 0.001 
Case characteristics  Hispanic ethnicity (vs White) aOR=1.76 1.38-2.28 0.001 
Case characteristics  Other ethnicity (vs White) aOR=2.13 1.1-4.07 0.04 
Other 
Annual income more than $45,000 (vs 
<$25,000) 
aOR=0.61 0.41-0.9 0.03 
Other 
Food adequacy (not enough vs 
enough) 
























Transmission pathway (or risk factor) Exposure measured 
Measure of association 
(reported)7 
95% CI p Level 
Other Poverty income ratio high (vs low) aOR=0.75 0.51-1.1 0.14 




























 Animals Handled livestock OR=0.53 0.29-0.97 -- 
MVA 




















Water Private wastewater system/well OR=1.28 0.74-2.21 -- 
MVA 
Water Plumbing work done in home OR=2.11 1.10–4.03 -- 
Animals Handled pets OR=2.83 1.24–6.49 -- 
Case characteristics  Age 18-39 Ref grp -- -- 
Case characteristics  Age 40–49 OR=0.89 0.40–2.01 -- 
Case characteristics  Age 50–59 OR=1.8 0.80–4.03 -- 
Case characteristics  Age 60+  OR=4.2 1.79–9.89 -- 




















Water Private wastewater system/well OR=0.85 0.49–1.46 -- 
MVA 
Case characteristics  Age 18-39 Ref grp -- -- 
Case characteristics  Age 40–49 OR=1.76 0.74–4.18   
Case characteristics  Age 50–59 OR=1.92 0.83–4.43   
Case characteristics  Age 60+ OR=3.69 1.61–8.46   
 
                                               





Transmission pathways 1576 
We excluded the entire Ravel et al (2013) study from any further analysis as measures 1577 
reported were proportion exposed rather than odds or risk, and the data were not 1578 
available to enable calculation of an effect measure that was comparable with the other 1579 
studies. Ravel et al (2013) used Canada’s C-EnterNet10 surveillance system to link 1580 
confirmed cases of sporadic, domestically acquired Cryptosporidium, Giardia and 1581 
amoebiasis with exposures grouped by the main pathways: Water, 1582 
animal/environment, person-to-person, and exposure to high-risk food, analysing each 1583 
infection separately. For cryptosporidiosis cases, travel within Canada (100%), contact 1584 
with household pets (49%), and swimming (46%) were the most frequently reported 1585 
exposures. The animal/environment-to-person transmission pathway remained the 1586 
most important factor in Cryptosporidium cases’ exposure(s) (72%). This was followed 1587 
by water-based transmission routes (52%) and exposure to risk foods (50%). We were 1588 
unable to look at odds of Cryptosporidium using the other cases (amoebiasis and 1589 
giardiasis) as 'controls', given the differences in the system characteristics and the lack 1590 
of individual response data.  1591 
 1592 
We further sub-categorised the transmission pathways following discussions with the 1593 
study group, in order to better analyse the underlying exposures for Cryptosporidium 1594 
(Figure 11). This level of granularity in exposures helps highlight differences between 1595 
anthroponotic and zoonotic pathways, important in recognising differences between 1596 
infecting species and when considering targeted public health messages. Although this 1597 
made the numbers of studies within each category lower, the team felt that aggregating 1598 
to top-level pathways lost important detail that is imperative in understanding 1599 
Cryptosporidium. 1600 
As no exposure included more than four studies, a traditional meta-analysis was 1601 
considered inappropriate (Bruce, Pope and Stanistreet, 2008).  However, a visual 1602 
analysis allows us to easily see which studies reported on the main underlying 1603 
exposures investigated in each pathway and discuss each of the results in light of the 1604 
characteristics of the studies. 1605 
                                               
10 C-EnterNet is an integrated enteric pathogen surveillance system based on a sentinel site surveillance 
model collecting information on both cases of infectious gastrointestinal illness and sources of exposure 
within defined communities. 
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Ten studies (across seven papers) were included in a further analysis allocating the 1606 
exposures investigated in the studies into the relevant transmission pathway (where 1607 
we could allocate a main route). 1608 
All results whether statistically significant or not, and those showing the exposure as 1609 
increasing or reducing risk of outcome, were considered in the analysis. We used 1610 
multivariable results where we had them for the comparable exposure. Charts show 1611 
the study name, study sample size, measure of association reported, and confidence 1612 





Figure 11: Transmission pathways and underlying exposures used to categorise variables measured in the included studies 
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Results and discussion by transmission pathway 1615 
Transmission pathway - Animal contact 1616 
Animal contact exposure results were reported from five of the included studies. Animal 1617 
exposures were categorised as livestock (n=3) and pets (n=2).  1618 
Farm animals 1619 
 
Figure 12: Exposure measured and results: Animal contact – Farm animals 1620 
 
One study reported a statistically significant increased odds of disease (Pintar; OR=1.6; 1621 
95% CI=1.1-2.5) and another reported reduced odds of seropositivity (Tollestrup (a), 1622 
OR=0.53; 95% CI=0.29-0.97). The remaining study reported an insignificant result 1623 
below 1.0 (Fournet (1), 2013; OR=0.74, 95% CI=0.41–1.32). 1624 
The metric used in the Pintar study was “visited farm, petting zoo, or fair” which 1625 
approximates animal contact but there was no detail about physical contact with 1626 
animals. In their univariate analysis, they had an environmental exposure variable 1627 
which was living on a farm. There is plausibility to this result, as direct contact with 1628 
animals has been previously identified as an important risk factor for cryptosporidiosis 1629 
(Kiang et al., 2006; Grinberg et al., 2011; Lange et al., 2014), but this is often outbreaks 1630 
and not sporadic disease. 1631 
The Tollestrup (study a) exposure measured direct handling of livestock and the study 1632 
reported reduced odds. Although curious, this could be due to repeat or continuous 1633 
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exposure to the animals producing an elevated serological response in some 1634 
participants. The use of a long-term marker, such as 27-kDa, as an outcome for 1635 
demonstrating Cryptosporidium infection, has an impact on the interpretation of results. 1636 
Pets/Domestic animals 1637 
 1638 
Two studies11 found significant positive associations with owning or handling pets. 1639 
(Fournet (2), OR=2.56; 95% CI=2.3-2.84 and Tollestrup (b), OR=2.83; 95% CI=1.24-1640 
6.29). 1641 
 
Figure 13: Exposure measured and results: Animal contact – Pets1642 
                                               
11 The Tollestrup (c) study did also investigate this exposure and it remained in the model; we have not 
reported it here with the other studies as it was related to the 15/17-kDa marker, and our results reflect 
positivity using 27-kDa. 
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Specifically, the Fournet (2) UK study considered dog ownership and as most of the 1643 
cases were C. hominis, a more anthroponotic species, this is a peculiar result. 1644 
However, we know that in this study exposures for cases were compared between 1645 
years, and it may be a chance effect that dog ownership in the population changed, or 1646 
indeed that it is a proxy exposure for an uncaptured variable.  1647 
These results are unusual: little epidemiological evidence exists to suggest pets have 1648 
any role to play in the transmission of disease (Robertson et al., 2002b; Hunter, 1649 
Hughes, Woodhouse, Syed, et al., 2004; Pollock and Ramsey, 2011) especially for the 1650 
two main species. The quality and robustness of these two studies do not allow 1651 
complete confidence in the results: the Fournet (2) UK study reported on cases 1652 
between time periods, and the Tollestrup (b) study used serological responses as a 1653 
marker for infection and so must be interpreted differently to current disease. Yet, there 1654 
is some evidence that oocyst shedding in cats and dogs can occur (Smith et al., 2009; 1655 
Chalmers and Giles, 2010) and species-specific infections have, albeit rarely, been 1656 
detected in humans (Chalmers et al., 2002; Chalmers et al., 2009). 1657 
This theory requires further investigation to be fully understood and described, and the 1658 
addition of species identification in any study of this exposure may help better 1659 
understand the true risks and pattern of infections in both domestic pets and their 1660 
owners. 1661 
Transmission pathway - Food exposures 1662 
Results for food exposures were reported in three of the included studies (four 1663 
variables) and this was the least investigated exposure route when considering all of 1664 
the studies’ upfront designs. All found significant results. Figure 14 shows results with 1665 
the specific metric included: due to the variability of measures and the small number of 1666 
results reported in the pathway, we did not separate exposures. Two variables (eating 1667 
from a farm stand and eating tomatoes) were associated with reduced odds of illness 1668 




Figure 14: Exposure measured and results: Food 1670 
 
Two variables (eating BBQ food and eating outside the home) were associated with an 1671 
increased risk of illness (Nic Lochlainn; OR=1.8, 95% CI=1.4-2.3; and Fournet (2) UK 1672 
study; OR=11.32, 95% CI=9.36-13.7). The Pintar study did study several food variables 1673 
appropriate to eating outside the home, but none remained in the final models, likely 1674 
due to the limitations of using surveillance data (Pintar et al., 2009).  1675 
Previous work in Europe has increasingly demonstrated risks associated with food 1676 
(Casemore, 2001; Ethelberg et al., 2005, 2009; McKerr et al., 2015; EFSA, 2018). Our 1677 
results indicate a range of risks, but exposures measured were specific to each study 1678 
and its setting, making comparisons and assessment overall difficult. However, ‘eating 1679 
tomatoes’ is consistent with the literature where raw, salad food item appear to be 1680 
associated with reduced disease risk, such as carrots (Robertson et al., 2002a) and 1681 
tomatoes (Hunter, Hughes, Woodhouse, Syed, et al., 2004)  1682 
Eating outside the home is often a risk factor for any infectious intestinal disease but in 1683 
the case of Cryptosporidium might be confounded by multiple factors. The profile of 1684 
food-borne disease is shifting, affected by globalisation and changes in food practices 1685 
(Waltner-Toews, 2019). Additionally, advances in diagnostic methods and surveillance 1686 
systems have extended the range of protozoa that may be linked to food (EFSA, 2018) 1687 
and this exposure should be further explored (Nichols, 2000; Robertson and Gjerde, 1688 
2001).  1689 
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Transmission pathway - Person-to-person 1690 
Person-to-person, as a transmission pathway, was well investigated overall (five 1691 
studies, four included) and represents the most consistent finding so far. 1692 
Contact with a case of diarrhoea 1693 
All three studies reporting on person-to-person contact with a symptomatic individual 1694 
demonstrated correlations between exposure and disease (Pintar: OR=2.86; 95% 1695 
CI=1.28-6.38 and OR=2.1, 95% CI=0.64-6.87; Nic Lochlainn: OR=2.2; 95% CI=1.7-3.0; 1696 
and de Gooyer: OR=12.6; 95% CI=2.13-75.1).   1697 
 
Figure 15: Exposure measured and results: Person-to-Person - Contact with a case 1698 
of diarrhoea 1699 
 
Variables included both home and outside-the-home contact, perhaps demonstrating 1700 
the importance of differences between case contact in a household where caring and 1701 
close contact is more likely and contact in a non-shared space. The de Gooyer and 1702 
NicLochlainn studies, and one Pintar variable, all related to household transmission. 1703 
The Pintar non-household contact variable reported lower odds and wider confidence 1704 
intervals crossing 1.0, suggesting that transmission within the home is more important 1705 
as a risk factor for sporadic disease. Additionally, this study excluded cases that initially 1706 
had reported other illness in the home in order to accurately identify community index 1707 
cases. This would suggest that any known cases came after the index illness, indicating 1708 
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that onward spread is more prevalent in Cryptosporidium than the other enteric 1709 
illnesses. 1710 
Contact with a case is a well-known, and plausible, transmission pathway to disease 1711 
and exposures underlying this pathway are varied including childcare, and sexual 1712 
transmission (Hannah and Riordan, 1988; Hellard et al., 2003; Hunter et al., 2004; 1713 
Artieda et al., 2012; Johansen et al., 2014). This makes biological sense given the 1714 
faecal-oral route of transmission and the high prevalence in younger children who may 1715 
require help with toileting. The high odds ratios demonstrate the importance of this 1716 
pathway to disease, particularly in the home environment. The included studies here 1717 
have investigated symptomatic contact, but asymptomatic carriage has also been 1718 
identified as a possible factor in transmission of sporadic disease in the home 1719 
environment (Newman et al., 1994; Hunter, Hughes, Woodhouse, Syed, et al., 2004; 1720 
Johansen et al., 2014). 1721 
General contact 1722 
Variables that investigated social contact without the prerequisite of contact with a 1723 
symptomatic individual were classed under general social contact, and ranged from 1724 
quite specific, e.g. child-care, to broad, e.g. any social contact. All of the results were 1725 
statistically significant. 1726 
Two studies showed a decreased risk of disease associated with general person-to-1727 
person contact measured as attendance at ‘any social gathering/event’ (Pintar: 1728 
OR=0.23; 95% CI=0.05-0.99) and (Valderrama: OR=0.4, 95% CI=0.1-0.9). 1729 
 
Figure 16: Exposure measured and results: Person-to-person – General contact 1730 
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Both of these variables were investigating general social contact and might cover a 1731 
range of activities and undoubtedly have a high exposure in all groups, thus the result 1732 
is likely to be spurious. 1733 
The Valderrama, 2009 study explored ‘contact with a child in diapers’ among 1734 
community cases of disease and found an almost four-fold risk of disease (OR=3.8, 1735 
95% CI=1.5-9.6). This could be driven by the higher prevalence observed in younger 1736 
children, as well as the possible contribution of asymptomatic spread and is probably 1737 
best considered separately to ‘general social contact’. It has also been demonstrated 1738 
that young children are drivers of secondary spread of disease, whether they are 1739 
symptomatic or not (Hunter, Hughes, Woodhouse, Syed, et al., 2004). 1740 
Considering the person-to-person exposures together, it seems reasonable to suggest 1741 
that the contribution of cases to onward spread warrants further investigation. This 1742 
seems to apply particularly to the home environment, where we might identify easy and 1743 
meaningful public health interventions to mitigate spread (Bloomfield et al., 2012).  1744 
Additionally, when symptoms are used to define a case, we might be losing vital 1745 
information on asymptomatic disease, and how much that contributes to spread of 1746 
infection.  1747 
Transmission pathway - Water 1748 
Water exposures were investigated in nine of the ten included studies. This pathway 1749 
was further disaggregated into drinking and recreational water exposures, with nine 1750 
and five studies investigating these, respectively. 1751 
Drinking water  1752 
This was categorised as treated (n=2); untreated (n=5); and bottled (n=3).  1753 
Treated 1754 
One study (Pintar, 2009) found a significant result between consumption of municipal 1755 




Figure 17: Exposure measured and results: Drinking Water – Treated 1757 
 
There had been a sharp increase in cases or Cryptosporidium in this area just prior to 1758 
the study period. It is possible that the association between municipal war supplies was 1759 
due to a specific contamination and perhaps represents an outbreak, or was a proxy 1760 
for another association, such as rural versus urban residence. The other study 1761 
(Fournet, (1) 2013 shows an insignificant decreased risk of disease (OR=0.56; 95% 1762 
CI=0.29-1.05), with a smaller sample size. The metric was, “drank tap water on daily 1763 
basis” which is likely a prevalent and difficult to accurately measure metric. This study 1764 
was based on an observed increase in cases and comparisons were made between 1765 
years – it is feasible that drinking treated water may appear to have a protective effect 1766 
in comparison to drinking from an untreated or contaminated water source, particularly 1767 
if the increase was actually an undetected outbreak. Additionally, the odds ratios for 1768 
the Fournet, (1) NL study were calculated using presented data and are not those 1769 
reported in the manuscript. As such we are unable to comment on any confounders or 1770 
control for effects. 1771 
An interesting finding here is that although water exposures were commonly 1772 
investigated, examinations were not often directed at drinking water, and more often 1773 
studies considered variables related specifically to drinking from untreated sources. 1774 
Although drinking water is often the cause of outbreaks and is considered to be the 1775 
main point for public health intervention only two of our studies reported final results 1776 
allocated to this pathway, and both studies were following an undetermined increase in 1777 
cases, which may not truly represent sporadic disease. It may be that following recent 1778 
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water treatment and regulatory requirements this is now considered a less burdensome 1779 
transmission pathway for disease (I. R. Lake et al., 2007). 1780 
Untreated 1781 
Two studies reported significant positive effects between the consumption of untreated 1782 
drinking water and odds of infection with Cryptosporidium, ranging from almost two-fold 1783 
(Tollestrup (a): OR=1.98; 95% CI =1.11-3.55) to an increased risk of eight times that of 1784 
controls (Valderrama: OR=8.0; 95% CI=1.3-48.1).  1785 
 
Figure 18: Exposure measured and results: Drinking Water – Untreated 1786 
 
The 2009 Valderrama study had wide confidence intervals, the lower end of which was 1787 
close to 1.0, despite quite a high odds ratio (8-fold). The data analysed were based on 1788 
surveillance data extractions and so there are possible limitations on questions asked 1789 
and answered. The authors grouped all and any untreated water consumption. 1790 
Additionally, although not reported as an outbreak, this study was in response to an 1791 
increase in cases across the state of Colorado, USA, and it may be possible that the 1792 
elevated risks are a result of an outbreak driven by a specific untreated water source 1793 
during the study period, although controls were matched by geography which should 1794 
mitigate this to some extent. 1795 
The Tollestrup (a) study included 200 of the 600 cohort participants, taking place in a 1796 
semi-rural area, where there was a significantly higher percentage of participants using 1797 
onsite wastewater systems or private wells than participants using municipal systems 1798 
(p=0.048). It is also important to consider that the outcome measured in this study was 1799 
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serological response to 27kDa antigen rather than diarrhoeal illness and so our 1800 
confidence in comparability may be reduced. Ongoing non-transient exposure to 1801 
oocysts, perhaps in an untreated system, could result in a positive, and increasingly 1802 
high, serological response in residents in this area. This may not, however, necessarily 1803 
reflect current or prior disease. 1804 
The remaining non-significant results were all fairly close to 1.0 with narrow confidence 1805 
intervals. Results from the Becker (2015) study were not significant and close to no 1806 
effect (aOR=1.19; 95% CI=0.97 - 1.45), despite being a large study of high quality. As 1807 
with the Tollestrup studies, the outcome metric was serological response to a 1808 
Cryptosporidium marker, which might indicate differences in exposure windows and 1809 
actual infection cannot be accurately pinpointed. 1810 
It is interesting to see that this is a well-investigated pathway, and it is biologically 1811 
plausible that exposure to untreated drinking water could represent a source of 1812 
Cryptosporidium oocysts. Nevertheless, even with the studies’ limitations in mind, these 1813 
results do not seem to indicate that this pathway is a major contributor to sporadic 1814 
disease. 1815 
Bottled 1816 
All of the studies including results for this pathway reported positive associations with 1817 
disease. Two of the three studies found a significant positive effect between drinking 1818 
bottled water and increased odds of Cryptosporidium infection, ranging from almost 1819 
three-fold (Fournet (1) NL study, 2013: OR=2.72, 95% CI=1.1-6.76) to more than five-1820 
fold (De Gooyer, 2017: OR=6.31, 95% CI=1.39-28.7).  1821 
 
Figure 19: Exposure measured and results: Drinking Water - Bottled 1822 
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The odds ratio for the Fournet (1) study in the Netherlands was calculated using their 1823 
reported data: They reported a 21% vs 11% exposure in cases and controls 1824 
respectively. Most cases in the study were infected with C. hominis (GP60 subtype 1825 
IbA10G2) which usually suggests either anthroponotic spread or perhaps sewage 1826 
contamination.  1827 
The de Gooyer study investigated sporadic cases in Australia, where the consumption 1828 
of bottled water in the general proportion is fairly high (de Gooyer et al., 2017) and, in 1829 
this study, 86% of cases vs 54% of controls exposed was reported. Although exposure 1830 
prevalence in the control group was lower, it still represents a reasonable amount of 1831 
non-diseased participants that cannot be explained by that exposure.  1832 
The Fournet (2) UK study was large and reported narrow confidence intervals yet did 1833 
not demonstrated a difference in effect. However, the controls in this study were cases 1834 
from different years: it is reasonable that drinking bottled water may have no effect on 1835 
disease incidence in comparison to a period of time where cases were driven by an 1836 
undetected outbreak with a single other source.  1837 
If exposure to bottled water was a risk for sporadic disease (and not outbreaks following 1838 
a specific contamination) we might expect to see exposure to tap water generally 1839 
associated with a decreased risk of illness in those exposed, but two case-control 1840 
studies in areas close to the de Gooyer investigation in Australia demonstrated no such 1841 
effects of water associated with Cryptosporidium (Robertson et al., 2002b). Also, 1842 
paradoxically, water consumption consistently free from Cryptosporidium oocysts may 1843 
lower ongoing exposure and thus immunity, opening people up to risk of disease from 1844 
other infection pathways (Ramsay et al., 2014) but this is still poorly understood (Frost 1845 
et al., 2005; Hunter and Thompson, 2005). However, C. hominis has been detected in 1846 
finished mineral water samples following an outbreak in the UK (Nichols, Campbell and 1847 
Smith, 2003) and Australia (Weinstein et al., 1993) suggesting some plausibility in 1848 
these results. In these studies, definitions of ‘bottled water’ varied and information was 1849 
not specifically collected on amounts consumed to enable further examination of this 1850 
association. Additionally, sociodemographic factors associated with bottled water use 1851 
have previously been described (Hu, Morton and Mahler, 2011) and so there is a 1852 
possibility that these results might be open to uncontrolled confounding. 1853 
On balance, there is some evidence for bottled water as a risk for sporadic illness, but 1854 
these studies offer insufficient quality and detail to make a resolute conclusion. 1855 
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Recreational water  1856 
This was categorised as treated (n=4); and untreated (n=3). 1857 
Treated 1858 
 
Figure 20: Exposure measured and results: Recreational water – Treated 
 
Three studies reported on four exposures that were categorised as treated recreational 1859 
water, and all found significant results. Two studies reported an increased risk of 1860 
disease associated with exposure to recreational water (Valderrama, 2009: OR=4.6, 1861 
95% CI=1.4-4.6; de Gooyer, 2017: OR=26.4, 95% CI=1.47–472 for spa use, and 1862 
OR=3.18, 95% CI=1.85–8.79 for general recreational water exposure).   1863 
The de Gooyer study reported two significant variables related to recreational water 1864 
exposure: using a spa and having any recreational water exposure. These were wide 1865 
ranging definitions and captured any recreational water exposures (except those that 1866 
might be specifically described as untreated). As such, we cannot be certain that 1867 
specific exposures in this group are necessarily treated waters. This could misclassify 1868 
the exposure and overestimate the effect. Using a spa was significantly associated with 1869 
illness, although only 13% (4/30) of cases reported this exposure and the confidence 1870 
intervals are wide. We also know that this work was examining an increase in cases 1871 
that may have been linked to a particular recreational waterpark, although was not 1872 
considered an outbreak. If these cases were linked to a particular water source, this 1873 
could skew the results towards a positive effect.  1874 
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It is also worth noting that in Australia, recreational water exposures are a common 1875 
cause of outbreaks and the prevalence of this recreational activity is high (Hellard et 1876 
al., 2000; Puech et al., 2001). These activities represent a biologically plausible route 1877 
to infection with Cryptosporidium, considering its faecal-oral transmission route and the 1878 
likelihood of swallowing water, the chlorine resistant nature of oocysts, and the poorer 1879 
hygiene habits of younger children (Stafford et al., 2000).  1880 
One of the studies reported decreased odds of disease (Fournet (1), 2013: OR=0.37, 1881 
95% CI=0.33-0.42). This study originally reported proportions and we used these data 1882 
to calculate odds ratios – thus these are not adjusted or controlled for any other factors, 1883 
which may skew the effect measure. Also, the study is considering cases from one time 1884 
period versus another, rather than comparing exposures between diseased and non-1885 
diseased participants. It is reasonable that the reported effect could be an artefact if 1886 
recreational water exposure was the cause of the increase in the prior years. Whilst we 1887 
may be able to confidently say that exposure to treated recreational water was not 1888 
causing the increase in the study time period, we can be less confident that the results 1889 
are generalisable and that they represent the true relationship between exposure and 1890 
sporadic disease.  1891 
It is likely that treated recreational water represents some risk for cryptosporidiosis, and 1892 
this would be supported in other literature. However, these results suggest that it may 1893 
well be more associated with outbreaks, or specific incidences of increases in disease. 1894 
Untreated 1895 
One of three studies reporting on untreated recreational water exposures found a 1896 
significant result, demonstrating a three-fold increased risk of illness (Pintar, 2009; 1897 




Figure 21: Exposure measured and results: Recreational water – Untreated 
 
After adjusting for age and season in the multivariable model, swimming in an untreated 1899 
water venue (river or lake) (p=0.01) was associated with increased odds of illness. The 1900 
proportion of cases exposed was, however, small at 25% (9/36) versus 10% (79/801) 1901 
for the controls (79/801). This study used other cases of enteric illness as controls, 1902 
including Giardia, which has similar exposure routes. This could make it more difficult 1903 
to detect small differences in risk between case and controls by over-representing 1904 
exposures and biasing towards the null, so in actual fact this effect measure could be 1905 
underestimated (Voetsch et al., 2009). The data were however, taken from surveillance 1906 
records, and cases were only asked about exposures in the seven days preceding 1907 
illness which might not accurately capture the exposure window for Cryptosporidium.  1908 
The remaining two studies were statistically insignificant, and both reported no effect 1909 
of this exposure on risk of disease in their study population (Fournet (1) (OR=1.15, 95% 1910 
CI=0.63-2.1) and de Gooyer (OR=1.0, 95% CI=0.31-3.25). 1911 
Overall, the contribution of this exposure to disease in this review is not considerable. 1912 
This is interesting in light of the more positive effects we report for treated recreational 1913 
water. This may be due to untreated activities being associated with other 1914 




Publication Bias 1917 
Due to the small number of studies against each exposure category (n<5), we did not 1918 
consider a statistical analysis into heterogeneity and publication bias appropriate.  1919 
Conclusions 1920 
The case-characteristics collected from our included studies reflected the bimodal age-1921 
related pattern that Cryptosporidium follows in the US and the UK; a peak in young 1922 
children, and a peak in adulthood (Dietz and Roberts, 2000b; Nichols et al., 2006; Yoder 1923 
and Beach, 2007).   1924 
The animal transmission pathway was commonly investigated, although was not 1925 
considered a main hypothesis for sporadic disease in any of the papers. We report a 1926 
couple of unusual associations with disease and pet contact, specifically cats and dogs, 1927 
although these should be considered in light of some of the methodological 1928 
weaknesses of the studies concerned. Evidence for this route is conflicted and more 1929 
research is needed to support or refute this pathway as a contributor to sporadic 1930 
infection.  1931 
Food exposures were not so frequently investigated, and metrics used were specific to 1932 
the niche study population or hypothesis. Given that food items are increasingly 1933 
identified in outbreak investigations  (Casemore, 2001; Ethelberg et al., 2005; McKerr 1934 
et al., 2015). this exposure, and protozoa that may be linked to food, should be further 1935 
explored (Nichols, 2000; Robertson and Gjerde, 2001; EFSA, 2018).  1936 
The person-to-person pathway was well investigated overall and represents the most 1937 
consistent finding so far. Considering the person-to-person exposures, it seems 1938 
reasonable to suggest that the contribution of cases to onward spread warrants further 1939 
investigation. This seems to apply particularly to the home environment which is 1940 
increasingly understood to be a significant setting for spread of Cryptosporidium 1941 
infection (Newman et al., 1994; Perry et al., 2005; Bloomfield et al., 2012; Johansen et 1942 
al., 2014) and would support public health messaging on preventing spread of disease 1943 
at home (Public Health England, 2019). 1944 
Our included papers investigated water exposures most frequently despite evidence 1945 
that in industrialised countries in recent years, drinking treated mains water is unlikely 1946 
to cause a significant amount of sporadic cryptosporidiosis (Sopwith et al., 2005; 1947 
Pollock et al., 2014). However, despite improved legislation for drinking water quality 1948 
(Lake et al., 2007) deficiencies can persist and it is important to keep monitoring this 1949 
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pathway (Nichols et al., 2009; Griffiths, 2017). We present some risks associated with 1950 
bottled water, although this is likely to be a high prevalence exposure and may be 1951 
confounded by socio-economic variables. 1952 
Recreational water is more frequently associated with outbreaks and was not a major 1953 
source of sporadic illness in this review, perhaps reflecting the episodic nature of pool 1954 
water contamination events. Nonetheless, we know that standard treatment practices 1955 
for recreational water, such as chlorination, are unsuccessful in eliminating 1956 
Cryptosporidium oocysts (World Health Organization:, 2009). This does seem a well 1957 
understood pathway (Chalmers, 2012; Cacciò and Putignani, 2014).  1958 
When considering exposures for sporadic disease, it may be more pertinent for future 1959 
studies to focus on food exposures, and research in this area is on the increase 1960 
(Redmond and Curnin, 2018). 1961 
Secondly, our results demonstrate that further detail is required on the person-to-1962 
person transmission pathway: although well investigated, exposures were variable, and 1963 
no study hypothesised this as a risk for infection, with most results incidental to the 1964 
study. We should seek to quantify and ascertain spread of infection in the home 1965 
environment and build a profile of asymptomatic infections, through better 1966 
observational studies and more routine sub-typing of isolates (Davies et al., 2009; 1967 
Chalmers and Katzer, 2013).  1968 
Limitations  1969 
As with any work that seeks to combine various different studies, significant limitations 1970 
exist which should be considered in any synthesis. 1971 
The main imitations to this work were the low number of papers included, which meant 1972 
meta-analysis was not possible. Although we did not quantify heterogeneity, 1973 
anecdotally, there were differences between the studies included in terms of study 1974 
design, populations studied, data collected and variables measured, and outcomes, 1975 
which may have made meta-analyses difficult regardless. 1976 
In the studies, often several variables were measured which represented the same 1977 
exposure, and participants may have been counted in either as they were not 1978 
necessarily mutually exclusive. This is common to epidemiological studies, which are 1979 
often undertaken in response to outbreaks, and defined by particular settings and 1980 
putative exposures (Briggs et al., 2014). The breadth of this makes the extrapolation of 1981 
our results less robust, and context must be considered in assessing results. This might 1982 
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dilute any differences between exposures driving sporadic disease and outbreaks. A 1983 
suggestion for further work would be to extend the time period to look specifically at the 1984 
magnitude of changes in exposures and to review outbreaks in that context. 1985 
Unfortunately, this was beyond the scope of this work. 1986 
Additionally, there could be bias associated with the personal subjectivity of 1987 
categorising exposures into pathways, especially without the granular detail of raw data 1988 
or knowing the specifics of questions asked of participants. However, our robust 1989 
methodological approach and commitment to duplicating all tasks in this review 1990 
hopefully mitigates this as far as possible. 1991 
Two included papers (Tollestrup et al., 2014; Becker, Oloya and Ezeamama, 2015) 1992 
measured their outcome using serological response to the 15/17kDa an 27kDA antigen 1993 
groups, which can identify previous, as well as recent infection and cannot distinguish 1994 
between species or genotypes (Leav, Mackay and Ward, 2003). Because we had two 1995 
papers with this outcome, which judged it differently, we used response to the 27kDa 1996 
to indicate a strong serological response and therefor count as infection. However, this 1997 
has a longer positivity than the 15/17kDa, and could represent infection as long as nine 1998 
months prior (Chalmers et al., 2013). This might have meant we were correlating 1999 
current or recent exposures to old infection and making inferences when in fact there 2000 
was no link. However, as we were looking at sporadic infection as opposed to outbreak 2001 
disease, it may be appropriate to consider more static exposures, in any case. 2002 
Additionally, diarrhoeal disease from Cryptosporidium infection may well recur and has 2003 
comparative longevity, that might well underpin some health seeking behaviour, so the 2004 
other studies are also at some small risk of correlating exposures with disease in a 2005 
different time frame. Furthermore, even those studies that do have accurate and recent 2006 
onsets are often a) vulnerable to recall biases and b) have different windows of 2007 
exposure for cases and controls (Food Standards Agency, 2000a). 2008 
Often crucial detail was absent from the manuscript, and so allocation of measured 2009 
variables to our exposures was occasionally arbitrary. However, we moderated this as 2010 
far as possible by following a systematic approach and utilising our third reviewer for 2011 
any discord. We would recommend that future research include large-scale 2012 
observational studies with enough resource to achieve high study quality whilst 2013 
maintaining resolution in exposures measured. 2014 
In assessing study quality, we recognised that the NOS has significant limitations for 2015 
use in this type of systematic review (Ioannidis, 2011).  A number of studies we 2016 
reviewed used surveillance data rather than more traditional study designs which 2017 
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meant that the NOS was not always directly applicable. Where this was the case, we 2018 
have had to apply the tool as appropriately as possible and in discussion with reviewers. 2019 
At present, there is no risk of bias tool that encompasses both case-control studies and 2020 
surveillance data.  2021 
Despite the limitations considered, this is the first systematic review considering routes 2022 
of transmission in industrialised countries for sporadic Cryptosporidium and highlights 2023 
that food routes are under investigated, and that person-person transmission, although 2024 
recognised, is not thoroughly investigated.  2025 
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Case contact as an exposure for infection 2035 
In the previous chapter, I presented results from a systematic review that sought to 2036 
outline the main exposures reported for sporadic cryptosporidiosis. All of the included 2037 
studies that considered person-to-person spread as a transmission route 2038 
demonstrated an increased risk of illness or infection associated with prior contact 2039 
with a symptomatic individual (Pintar et al., 2009; de Gooyer et al., 2017; Nic 2040 
Lochlainn et al., 2019). Hence, onward spread of infection from exposure to a case 2041 
might represent a risk for sporadic disease, but how much remains unclear. Metrics 2042 
included in these studies encompassed contact both ‘in the home’ and ‘outside-the-2043 
home’, with the authors considering them to be different settings. Results in support 2044 
of general contact, which included metrics such as attending any social event and 2045 
any general contact with people were not as consistent, and reduced odds of illness 2046 
were reported. This suggested transmission within the home as a particular setting in 2047 
the pathway to infection, and that case contact is additionally risky in the household 2048 
where close contact is more likely. This makes biological sense given the faecal-oral 2049 
route of transmission and the higher prevalence of infection in younger children who 2050 
may require help with toileting (Dietz and Roberts, 2000b; Hunter, Hughes, 2051 
Woodhouse, Syed, et al., 2004; Nichols et al., 2006; Pintar et al., 2009). This has 2052 
been further buttressed by large-scale reports of spread in the home following 2053 
outbreaks (Osewe et al., 1996; Johansen et al., 2014) which may well drive additional, 2054 
sporadic cases.  2055 
Contribution of asymptomatic contact  2056 
Whilst the contribution of symptomatic case contact is plausible and measurable, 2057 
identifying asymptomatic spread poses more difficulty: Cryptosporidium is not 2058 
diagnosed based on symptoms alone and ordinarily only cases presenting with 2059 
symptoms would be tested (Detection and diagnosis in humans). The burden of 2060 
asymptomatic infection and its influence on spread is less well documented in 2061 
Cryptosporidium research than for some other infections, particularly in countries like 2062 
the UK. A study in the UK reported a point prevalence of 1.3% among asymptomatic 2063 
pre-school children (Davies et al., 2009) suggesting that a small amount of 2064 
asymptomatic infection does occur. Furthermore, a Norwegian study looking at 2065 
follow-on spread after two outbreaks observed asymptomatic secondary transmission 2066 
(Johansen et al., 2014). Additionally, although not representative of true 2067 
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asymptomatic infections, oocysts can be detected in stool after case symptoms cease 2068 
and this period may present a risk of transmission (Chalmers et al., 2016). The 2069 
contribution of asymptomatic persons to the spread of infection warrants further 2070 
investigation to better understand transmission risks and mitigate spread (Bloomfield 2071 
et al., 2012). 2072 
Risks specific to C. hominis and C. parvum 2073 
Few papers included in the systematic review reported on infecting species and this 2074 
information is still generally lacking despite developments in methodologies to 2075 
determine this. In a study in the UK, Hunter et al. found that changing children’s 2076 
nappies was a risk factor specific to C. hominis (Hunter, Hughes, Woodhouse, Syed, 2077 
et al., 2004) and the Netherlands recently reported similar results (Nic Lochlainn et 2078 
al., 2019), specifying that C. hominis cases were more likely than controls to have 2079 
been exposed to a case in the home. Additionally, the authors reported corroborating 2080 
indicators supportive of this exposure, including living in smaller homes, and living 2081 
with children.  2082 
The home as an infectious disease environment 2083 
With general cases of IID, there is an assumption that infections are mostly due to 2084 
eating contaminated food or drinking contaminated water, but it is increasingly 2085 
recognised that this is imprecise (Wheeler et al., 1999; Food Standards Agency, 2086 
2000b). Cryptosporidium especially suffers somewhat from perception as a 2087 
waterborne pathogen, but outbreaks associated with this are far fewer now 2088 
(Transmission pathways and the underlying exposures for infection). Humans as a 2089 
source of enteric disease in the home have been reported for Salmonella (Evans et 2090 
al., 1998; Le Baigue et al., 2000) and Escherichia coli (Le Baigue et al., 2000; Werber 2091 
et al., 2008; Friedrich, 2011) infections. In Germany, a review of gastrointestinal 2092 
outbreaks revealed over a third could be attributed to person-to-person spread and 2093 
the household was the most common setting for this (Krause et al., 2007). 2094 
Surveillance is unlikely to pick this up in most systems, and in-home outbreaks or 2095 
clusters probably represent an unidentified burden of disease (Day, 2001; Leder et 2096 
al., 2009). Work in Denmark on bacterial infections reported variation in the ability of 2097 
organisms to cause household outbreaks, highlighting the contribution of heretofore 2098 
under-recognised person-to-person spread (Ethelberg et al., 2004). Differences in 2099 
parameters of spread, such as serial interval, compared to other infections are likely 2100 
for Cryptosporidium, reflecting specific differences in its infectivity and pathology 2101 
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(Biology and life cycle). An assessment of case and home attributes where onward 2102 
spread and person-to-person transmission are suspected might help elucidate 2103 
relevant higher risk characteristics such as crowding, age, immune status, of length 2104 
of episode of illness (Perry et al., 2005; Snedeker et al., 2009). 2105 
The risk of exposure to specific pathogens at home will depend on the extent to which 2106 
they can be spread in that setting, via hands, contamination of fomites or food, 2107 
exposure to pets, and close personal activities. Underlying exposures and risk factors 2108 
may be multiple  and it remains important to try to assess some of these in any 2109 
analytical study (Bloomfield, 2001). A 2009 review by the International Scientific 2110 
Forum on Home Hygiene described that outbreaks of IID in the home are largely 2111 
preventable just by better general hygiene practices (Bloomfield et al., 2012). The 2112 
chain of infection and the features required for transmission of infection in the home 2113 
can be simplified to that shown (Figure 22). These will differ according to organism, 2114 
but considering characteristics of the Cryptosporidium parasite, the chain is likely to 2115 
be mainly a direct faecal-oral route and spread based on a person-to-person pathway.  2116 
 2117 
Figure 22: The chain of infection transmission in the home (bold are features likely 2118 
key to Cryptosporidium) adapted from: Bloomfield, 2001 2119 
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Rationale for the epiCrypt study 2120 
It seems reasonable to suggest that the contribution of cases to onward spread 2121 
warrants further investigation. This might apply particularly to the home environment 2122 
which is increasingly understood to be a significant setting for spread of 2123 
Cryptosporidium infection (Newman et al., 1994; Perry et al., 2005; Bloomfield et al., 2124 
2012; Johansen et al., 2014) and would help inform public health messaging on 2125 
preventing spread of disease at home (Public Health England, 2019). 2126 
An assessment of the previous work on secondary spread12 in this particular setting, 2127 
in conjunction with the systematic review, led to a clear justification for an analytical 2128 
study in the UK population, which might be exploratory in nature, examining spread 2129 
of Cryptosporidium infection in the home environment. I designed an observational 2130 
study that recruited cases from across North West England and Wales. I aimed to 2131 
identify index cases (the first case in a home identified in the surveillance system) of 2132 
Cryptosporidium, and then determine if there were any other infections with 2133 
Cryptosporidium in that home, either before or after the index case. Additionally, I 2134 
sought to describe any home-level, case, or organism characteristics that might be 2135 
associated with transmission in this environment.  2136 
This study helps to meet my third objective to explore transmission in the home 2137 
environment, and calculate the burden this might have on people in the home, 2138 
considering longevity and severity of illness. 2139 
Methods 2140 
The protocol for this study has been published and a manuscript is attached in 2141 
Appendix 5 (McKerr et al., 2019). 2142 
Aims and objectives 2143 
The aims of this study were to: 2144 
 estimate how much additional Cryptosporidium infection happens in the home 2145 
where there is a case, and, 2146 
 describe characteristics associated with transmission in the home. 2147 
                                               
12 I use the term ‘secondary spread’ to mean any apparent onward transmission of disease originating 
from an index case, whilst recognising that this may be secondary or even tertiary level of spread. 
108 
 
In order to meet these aims, I identified several measurable objectives, based on 2148 
theories identified following the previous exploration of the literature: 2149 
Objectives: 2150 
 To estimate the number of additional cases in households with an index 2151 
case 2152 
 To calculate transmission prevalence in households with an index case 2153 
 To estimate the prevalence of asymptomatic carriage in households with an 2154 
index case 2155 
 To identify specific household-level and case characteristics associated with 2156 
homes that have additional cases and with homes that do not 2157 
 To determine the number of cases by species and compare these in homes 2158 
that have additional cases and in homes that do not 2159 
Study population 2160 




Figure 23: Map of UK showing NW England and Wales 
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Figure 23 shows the position of these in the UK, with additional boxes to highlight 2162 
local boundaries.  2163 
The North West of England has a population of over 7 million people and is the third-2164 
most densely populated region in the United Kingdom (ONS, 2011). In 2016 over 600 2165 
laboratory-confirmed Cryptosporidium cases were reported from the North West 2166 
(8.4/100,000 population) (PHE, 2017). 2167 
Wales has a population of over 3 million people (Welsh Government | Census of 2168 
population, 2015). In 2016, over 400 laboratory-confirmed Cryptosporidium cases 2169 
were reported from Wales, the highest rate of Cryptosporidium laboratory reports per 2170 
100,000 population in England and Wales (15/100,000) that year (PHE, 2017). 2171 
Sampling frame 2172 
The sampling frame was derived from the two relevant surveillance systems 2173 
previously described (Surveillance system descriptions), which capture laboratory 2174 
confirmed reports of Cryptosporidium in England and Wales: The Second-Generation 2175 
Surveillance System (SGSS) in Public Heath England (PHE), and Tarian in Public 2176 
Health Wales (PHW).  2177 
All cases of laboratory confirmed Cryptosporidium reported from primary diagnostic 2178 
microbiology laboratories in North West England and Wales, in the study year, were 2179 
initially eligible. These were considered index cases. 2180 
Sample size 2181 
The North West & Wales report around 1,000 cases per year (PHE data, 2015). I 2182 
assumed a participation rate of somewhere in the region of 40-60%, based on similar 2183 
studies and approaches (Tam et al., 2012; Waldram et al., 2017)). I anticipated that I 2184 
might initially enrol around 400 index cases. Using the 2011 Census indications of 2.4 2185 
persons on average per household (ONS, 2011), I calculated a target overall 2186 
recruitment number of 960 - 1,000 participants. 2187 
Assuming that the rate of household transmission, defined as the proportion of 2188 
households with more than one case, is anywhere between 0% and 20% (Newman 2189 
et al., 1994; MacKenzie et al., 1995; Harrison et al., 2002; Perry et al., 2005; Johansen 2190 
et al., 2014; Waldram et al., 2017), a range of required sample sizes was estimated 2191 
(between 118-402). Aiming to recruit 400 households seemed feasible given time and 2192 
resource and would allow confident demonstration of an odds ratio of 2.0, with type 1 2193 
error of 0.05 and type 2 error at 0.20. 2194 
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Study type 2195 
The identification of cases, and their subsequent recruitment, was cross-sectional, 2196 
although the study also involved retrospective data collection and some prospective 2197 
sampling. I based the design of the study on case ascertainment household cohort 2198 
study approaches (Tsang et al., 2016). This approach is often used in studying 2199 
respiratory illnesses, where multiple-occupant households are recruited prospectively 2200 
(usually from an entire community). Occupants are then followed up to identify 2201 
infections. As well as being more tenable in terms of resource and follow-up, 2202 
specifically these studies are useful in that the design allows for calculation of 2203 
secondary infection risk and serial interval where the data allow. This allows us to 2204 
capture heterogeneity in characteristics associated with secondary spread and 2205 
transmission.  2206 
Study period 2207 
The study period was for 12 months, to account for seasonal variation in cases and 2208 
Cryptosporidium species, and to allow maximum enrolment. The study began 2209 
recruiting from England in October 2018 and from Wales in January 2019. Both study 2210 
areas had an initial pilot phase of 1-2 months. 2211 
Ethical approval, governance, and registration information 2212 
The study design and approach to recruitment was approved by the North West – 2213 
Liverpool East NHS Research Ethics Committee (Reference: 18/NW/0300). Access 2214 
to surveillance data in order to identify cases and approach for recruitment was 2215 
reviewed and approved by the Confidentiality and Advisory Group (CAG) under a 2216 
specific support precedent, “Section 251: Accessing data prior to consent” (Reference 2217 
18/CAG/0084).  2218 
Contract study agreements and Data Sharing Agreements (DSA) between 2219 
PHE/PHW/University and CRN were drawn up and approved by the individual 2220 
organisations involved. 2221 
The project is registered on the National Institute for Health Research (NIHR) portfolio 2222 
(CPMS ID: 39458). 2223 
The sponsor and supplier of indemnity for the study was The University of Liverpool 2224 
(UoL001340). Additional internal governance was obtained from PHE and PHW in 2225 
order to support cross-working relationships and information sharing. 2226 
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Welsh approvals were granted by Health and Care Research Wales (NHS Wales 2227 
research permissions). 2228 
A published research summary can be found here on the Health Research Authority 2229 




Recruitment approach 2234 
Cases of cryptosporidiosis were identified using the routine surveillance datasets for 2235 
England and Wales (Surveillance system descriptions). Cases were recruited 2236 
according to the flow chart outlined in Figure 24 : Sketch of process to enrolment.   2237 
Eligible cases were contacted via post, by the relevant public health organisation, in 2238 
the first instance. (Invite letter available in Appendix 6) 2239 
 
 
 2240 Figure 24 : Sketch of process to enrolment 
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Following this, if cases did not opt-out, they were contacted via telephone by an NHS 2241 
research nurse at the local Clinical Research Network (CRN) to chat about the study 2242 
and determine if they would like to take part. 2243 
This unusual opt-out approach to the recruitment process was driven by necessity 2244 
and feasibility and I explored several options at the protocol drafting stage of the 2245 
project, balancing data needs with possible patient burden. As the capture of cases 2246 
in the surveillance systems is retrospective (i.e. the case has already been ill) and 2247 
diagnosis of Cryptosporidium in the stool sample is undertaken by laboratory staff, 2248 
there was no opportunity to consent individuals at the time of diagnosis. Thus, the 2249 
recruitment process could not be achieved without initial access to patient information. 2250 
I submitted a successful application to the CAG for specific Section 251 support. In 2251 
this model, participants are given opt-out options at each contact and it is emphasised 2252 
that they can withdraw at any time. Previous research demonstrates a good 2253 
acceptability of this method13, recognising that an approach of ‘consent for each use’ 2254 
is burdensome for both researcher and participant (Willison et al., 2008) (Taylor and 2255 
Taylor, 2014). 2256 
A note on public and patient involvement (PPI) 2257 
Patients and the general public were not involved in the overall design of the study, 2258 
but I did elicit some public opinion when finalising the approach to recruitment. 2259 
Following valuable comments from the ethical review board, I undertook a short 2260 
survey among specific Patient and Public Involvement (PPI) groups to gauge general 2261 
attitudes towards accessing data prior to consent, specifically to support recruitment 2262 
to research. I drafted a survey, which outlined the approach to recruitment and the 2263 
framework of the study. I accessed a lay PPI group from the Infection and Global 2264 
Heath (IGH) panel at the University of Liverpool, and one from Health and Care 2265 
Research Wales. The survey was sent directly to these groups for dissemination to 2266 
members, and additionally the University of Liverpool IGH PPI group promoted the 2267 
survey on Twitter.  2268 
Participants were asked to think generally about the method of recruitment proposed 2269 
and how they felt about this approach. In general, the feeling was that it is acceptable 2270 
to access public health or clinical data for recruitment, especially to support much 2271 
needed research. However, considerations and worries included the credentials and 2272 
                                               
13 Studies recruiting based on disease surveillance are common for IID, and many projects have taken this approach 
– the methodology for the epiCrypt Study has been influenced by design aspects of large-scale studies such as 
Enigma, IID2, and Integrate. 
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affiliations of the person accessing the data, with NHS/public health staff generally 2273 
viewed as more favourable than non-NHS (e.g. University). (Full report on PPI in 2274 
Appendix 7) 2275 
Enrolment 2276 
Identification and first contact with the index case 2277 
Laboratory diagnosed reports of Cryptosporidium, and the corresponding patient 2278 
contact details, were extracted from the relevant surveillance system by health 2279 
protection staff. These were considered the potential ‘index’ cases – i.e. the first case 2280 
in the home to be identified in the surveillance system. 2281 
Exclusion criteria applied 2282 
 Index case is in a single person household 2283 
 Index case is a visitor to a household in the study area, but is registered with     2284 
a GP outside the study area 2285 
 Household is outside the study area 2286 
 The index case is resident in an institution: retirement home, nursing home, 2287 
prison, barracks, boarding school, or college/university halls of residence. 2288 
All potentially eligible participants were issued a unique sequential study identifier. 2289 
This unique number was used on all documentation from there on in to follow cases 2290 
and households anonymously through the study. I was unable to access any patient 2291 
identifiable data until the case (and household) had consented. 2292 
Potentially eligible index cases were sent an invite letter (Appendix 6) through the 2293 
post from the relevant organisation. The aim was to recruit the household. 2294 
Approaching to recruit 2295 
If a contacted index case did not opt-out within two weeks, their details were shared 2296 
securely (using internally agreed practices) with named NHS research nurses at the 2297 
NIHR Clinical Research Network North West Coast (CRN). The research nurses 2298 
would then attempt to contact the index case (or parent/guardian of) via telephone 2299 
(using internally agreed practices) to inform them about the study and offer them the 2300 
opportunity to participate, if eligible. A maximum of three attempts were made, and 2301 
nurses did not leave voicemails. If the approached index case was successfully 2302 
contacted and interested in participating, or wanted more information, the research 2303 
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nurses prepared a study pack (Appendix 8) with the documentation and the required 2304 
number of stool packs (1 per member of the home – the index case was not potted 2305 
again). These were posted using a secure post process.  2306 
Where a case could not be contacted by telephone, study packs were sent in the post. 2307 
Index cases could be excluded at this stage where discussions with the case revealed 2308 
that any of the previous exclusion criteria applied. 2309 
Participant consent 2310 
The study pack included consent forms and an explanation of the study. All outreach 2311 
was specifically designed to allow potential participants to clearly understand the 2312 
purpose of the study and to explain requirements of participation. A parent/guardian 2313 
was required to sign the consent form on behalf of those <16 years old, in line with 2314 
Gillick competence (House of Lords, 1985).  The index case was asked to discuss the 2315 
study with their household. Anyone wanting to take part was asked to fill in the consent 2316 
for. The index case or appropriate adult should complete the questionnaire, and each 2317 
additional consenting household member (not the index case) was asked to provide 2318 
a stool sample for testing. At least one household member, as well as the index case, 2319 
must have consented. 2320 
Study packs  2321 
Each index case identified, unless withdrawing, was sent a study pack in the post. 2322 
The study packs were one per household. Study packs were populated with the 2323 
required number of stool packs using Fe-Col® kits, which include a pre-addressed and 2324 
secure postal bag (compliant with UN3373 regulations for mailing Cat B biological 2325 
samples (Category B - Medical Packaging, medical pouches and biological 2326 




Figure 26: Photograph of the Fe-Col stool collection kit 2329 Figure 25: Photograph of study pack documents 
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Instructions for use were provided. For those index cases who were unable to be 2330 
contacted and were sent packs in the post, three stool packs were included. 2331 
 The study packs contained: 2332 
 A study information pamphlet 2333 
 A questionnaire booklet for the index case or a suitable representative (e.g. 2334 
parent, head of household) to complete, with a freepost envelope 2335 
 A consent form for each participating household member to read, initial, and 2336 
sign 2337 
 A stool sampling pack (Fe-Col®) for each participating household member, 2338 
with the required return postal envelope 2339 
 An information leaflet on cryptosporidiosis and relevant health advice 2340 
 An information sheet on General Data Protection Regulation (GDPR) 2341 
 Participation, reminders, and disenrollment 2342 
 2343 
If study materials were not received within 14 days of posting the pack, a reminder 2344 
letter was dispatched by the research nurses at the CRN (Appendix 9). If study 2345 
documentation was not returned within 14 days of posting the reminder letter, no 2346 
further attempt at contact was made and the index case was removed from the study 2347 
line list. (Figure 27: Flow-chart outlining steps to recruit a household and manage 2348 




Figure 27: Flow-chart outlining steps to recruit a household and manage information up until either 
exclusion or enrolment 
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Data management and oversight  2351 
Documentation 2352 
Questionnaires were returned directly to the University of Liverpool. Data were 2353 
entered from the paper format to a corresponding MS Access database and held 2354 
securely on a University of Liverpool drive in accordance with security protocols.  2355 
Household members’ stool samples 2356 
Stool samples provided were sent directly to the Cryptosporidium Reference Unit. For 2357 
purposes of data confidentiality and governance, stool samples returned to the CRU 2358 
were pseudonymised with the unique study number. Participants were asked to add 2359 
their sample date, age, and sex to their pots’ stickers in order to facilitate identification 2360 
of household members at analysis. 2361 
Identifying the index case samples 2362 
Original diagnostic laboratory numbers were retained with the index case information 2363 
in the original line lists at PHE/PHW so that the diagnostic stool sample could later be 2364 
identified at the CRU and grouped with the relevant household samples.  2365 
Where a consenting family member had also been ill and had a positive diagnostic 2366 
stool sample, these were recovered in the same way where possible. 2367 
A full laboratory protocol is available in Appendix 10.  2368 
Case definition(s) 2369 
Figures 28 & 29 outline case and household definitions used to categorise household 2370 









Individual case definitions 
Index case 
The first case from a household identified in the surveillance system (person reported to a PHE/PHW surveillance system(s) following detection of 
Cryptosporidium sp. in a faecal sample, with a specimen date in the study year) 
Additional household case 
A person in a household of an index case, with self-reported similar symptoms (in questionnaire) that started within two weeks of the index case’s 
onset 
Asymptomatic carrier 
A person in a household of an index case with: 
no reports of similar illness (in questionnaire); 
AND 
a Cryptosporidium positive stool sample 
Figure 28: Case definitions (individuals) 2372 
Household level definitions 
Household 
Two or more people (not necessarily related) living at the same address in North West England or Wales who share cooking facilities and share a 
living room or sitting room or dining area [18]. 
Household member 
A person who normally resides in the household and regularly shares food or toilet facilities (Public Health England, 2017b) 
Household contact 
A household member in a home where an index case has been identified 
Household with transmission 
A household that has at least one additional household case 
Household without transmission 
A household that has one case (the index case) 
Figure 29: Case definitions (households)2373 
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Data collection: Outcomes and measurements 2374 
Questionnaire data  2375 
Full questionnaire available as part of the study pack (Appendix 8) 2376 
The questionnaire was divided into four sections.  2377 
Section A asked questions to help determine the composition of the household, the 2378 
clinical details of the index case, and capture any other symptomatic household 2379 
members. A table was used to collect information on any other symptomatic 2380 
diarrhoeal illness in the house and capture relationships to the index case. 2381 
Section B recorded activities of the index case, and others in the home, in the two 2382 
weeks prior to the index case’s onset, based on known exposures for 2383 
Cryptosporidium.  2384 
Sections C and D collected household variables, including the number of bedrooms 2385 
and bathrooms, capturing those who share beds or baths, and asking about outside 2386 
space and animals. We also asked about nappy changing and toilet training in the 2387 
home, and about general hand-washing behaviour. 2388 
Stool collection and genotyping 2389 
All consenting household members of the index case were asked to provide a stool 2390 
sample using the Fe-Col® kit provided in the study pack.  2391 
Screening, confirmation, and species identification 2392 
Samples returned from household members were processed by the laboratory and 2393 
scored against the Bristol stool scale (BSS). They were then tested and quantified, 2394 
only for Cryptosporidium, using immunofluorescence (IF) microscopy (CryptoCel, 2395 
TCS BioSciences). Samples were then screened using an in-house real-time PCR 2396 
targeting the 18S gene (“CRU18S” assay) (Hadfield et al., 2011). Samples testing 2397 
negative by both methods were discarded14. 2398 
Positive samples were taken forward to undergo Cryptosporidium species 2399 
identification using an in-house, duplex real-time PCR designed to identify C. parvum 2400 
and C. hominis, and also enables identification of C. cuniculus and the horse genotype 2401 
(“RT2” assay) (Robinson, Elwin and Chalmers, 2020). Organism DNA from any RT2 2402 
                                               
14 The original index case sample, and any original additional household samples able to be located 
underwent a slightly different approach, as these were already confirmed and screened. These samples 
were submitted at the RT2 PCR stage and sequenced as per the others if needed. 
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negative samples was then amplified using another 18S PCR and sequenced to 2403 
identify any other species (or identify a false-positive screen) (Robinson, Elwin and 2404 
Chalmers, 2020). Ct values from the real-time PCRs, indicating amount of DNA, were 2405 
recorded. 2406 
Genotyping 2407 
C. parvum and C. hominis samples were further investigated by sequencing part of 2408 
the gp60 gene(Strong, Gut and Nelson, 2000). 2409 
C. parvum samples were also investigated using a newly validated multilocus variable 2410 
number of tandem repeats analysis (MLVA) scheme based on fragment sizing at 2411 
seven loci (Pérez-Cordón et al., 2020).   2412 
Data items recorded for each stool sample were as follows: 2413 
 Unique study household identifier (HH ID) 2414 
 Age 2415 
 Sex 2416 
 Specimen date 2417 
 Bristol stool scale 1-7 2418 
 IFM result – pos/neg and oocyst count 2419 
 CRU18S result - pos/neg, plus if positive Ct value  2420 
 RT2 result – pos/neg, plus if positive Ct value 2421 
 Species 2422 
 GP60 subtype 2423 
 MLVA profile 2424 
 2425 
Analyses approach 2426 
I wanted to ascertain if, in a home with a case of Cryptosporidium, there were any 2427 
other cases; my primary research aim was to quantify this and describe any 2428 
associated characteristics. This was established both by testing stool samples of 2429 
household members living with a case of Cryptosporidium and reporting the numbers 2430 
of additional cases (according to our pre-determined definitions) and also asking 2431 
about self-reported illness in the home. The presence of other cases in the home was 2432 
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used to infer transmission for the analytical work, and later I go on to present some 2433 
descriptive narrative and discussions around the certainty of this. 2434 
Descriptive analyses 2435 
I have presented the numbers of households and participants enrolled in the study, 2436 
describing their characteristics, and elements of recruitment such as uptake.  2437 
Categorical variables were compared using chi square tests and continuous data 2438 
using Wilcoxon rank sums, where appropriate. Additionally, I undertook some 2439 
separate descriptive analyses of households which had confirmed cases, including 2440 
an examination of clinical symptoms, time between cases’ onset of symptoms, 2441 
relationships to the index case, and total disease burden on the home. 2442 
Households with and without transmission 2443 
A household with transmission was defined as one with at least one additional report 2444 
of compatible illness within two weeks of the index case’s onset.  2445 
A household without transmission had no reports of compatible illness within two 2446 
weeks of the index case’s onset. 2447 
Households with and without additional cases were compared. I compared 2448 
household-level and case-level characteristics of households using univariable 2449 
analyses to calculate odds ratios (OR) and p values (Wilson’s/Fisher’s test). All risk 2450 
factors that had a p value less than 0.2 in a univariable analysis were considered in a 2451 
multivariable logistic regression to identify independent risk factors for household 2452 
transmission. 2453 
The following primary outcomes were calculated: 2454 
 The transmission rate/prevalence within households  2455 
= number of cases in the home/numbers in the home (minus index case)  2456 
= number of households with additional cases /number of households 2457 
 The amount of asymptomatic carriage among those exposed to symptomatic 2458 
case(s) 2459 
= number of asymptomatic cases 2460 
= number of asymptomatic cases per household/number in home (minus index case) 2461 
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 Odds of additional illness according to case/household characteristics and 2462 
genotype 2463 
= odds ratio (odds of a household reporting additional cases by organism species, 2464 
case age and sex, size of the home, presence of pets, and any other relevant 2465 
characteristics of interest from the descriptive analysis) 2466 
Missing data 2467 
Missing data points were excluded where appropriate, but the household record 2468 
remained. Where I was able to, I supplemented missing information from one 2469 
component, e.g. the questionnaire, with data from the other, e.g. laboratory data. 2470 
Where a questionnaire was not returned, I used the information provided on the stool 2471 
pots to estimate the number of people in the home. This is merely a proxy for total 2472 
number in the household, as not each household member will necessarily have 2473 
returned a stool sample.  2474 
Laboratory stool sample data and confirming infection 2475 
Each household’s questionnaire dataset was supplemented with the corresponding 2476 
individuals’ stool sample results, using the unique identifiers. I considered for each 2477 
result the clinical scores (aggregated Bristol stool scale (BSS) 1-7) and 2478 
microbiological results (positive/negative, Ct values, species, and genotype result). A 2479 
BSS of six or seven was considered a diarrhoeic indicator. An individual was 2480 
considered to have a confirmed Cryptosporidium infection if the IFM and/or 2481 
confirmatory PCR tests (i.e. RT2 or sequencing) were positive.  2482 
I describe those homes with confirmed additional cases of Cryptosporidium. I examine 2483 
the characteristics of these homes in more depth, including describing any likely co-2484 
primary cases, time to additional infections, and an examination of who in the home 2485 
gets ill. 2486 
Data analyses 2487 
I undertook all data management, input, and analyses. Data were held in MS Access 2488 
and MS Excel, with analyses undertaken in Stata v14 (StataCorp., 2015). 2489 
End of study 2490 





Recruitment and uptake 2494 
The study year ran from October 2018-October 2019 for England, and January 2019-2495 
January 2020 in Wales. Recruitment issues led to a possible dip in enrolment in two 2496 
periods: January, due to staffing and holidays, and an inability to reach index cases 2497 
on the telephone, and again in June when a postal licencing error led to undelivered 2498 
study packs over a 2-week period. 2499 
Over 1,000 cases were reported to both surveillance systems over the study year  2500 
(n=1,030). Over half (57%) were from the North West of England, and the remainder 2501 
from Wales (43%), in line with initial estimations in the sample size calculation. 2502 




England Wales Total 
Cases in study period 585 445 1030 
Cases initially eligible 581 435 1016 
Invite letters sent 578 405 983 
Opt-outs returned 42 35 77 
 
Index cases sent to CRN for contact to recruit 534 370 904 
Cases CRN contacted by ‘phone 287 154 441 
Cases that opted out at ‘phone contact stage 90 (31%) 51 (33%) 141 (32%) 
 
HH study packs sent out in total 401 301 702 
HH packs returned (questionnaire or stool, or 
both) 76 52 128 
 
Percentage capture of all incident cases 13% 12% 12% 
Percentage uptake 
(packs returned/packs sent) 18.9% 17.3% 18.2% 
 
Households enrolled 2504 
We enrolled 128 index cases and their households into the epiCrypt study in the one-2505 
year period of recruitment. Over half of these were resident in the North West of 2506 
England (n=76; 59%) and 41% were recruited from Wales (n=52). (Figure 30:  and 2507 
Box 2) 2508 
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This amounted to 413 participants overall, of which 285 were HH contacts of an index 2509 
case15. 2510 
 
Box 2: Study elements returned  2511 
                                               
15 This uses a combination of the reported number of persons in the home from the questionnaire, and, 
where this was not returned, the number of household samples returned per index case. Numbers may 
not tally as not all household contacts who returned stool were included in the questionnaire data, and 
vice-versa. 




















Of these 128 households, 99 (77%) returned questionnaires and 123 (96%) supplied 2513 
at least one stool sample from someone other than the index case. Seventy-four 2514 
percent (n=94) of recruited homes supplied both elements. 2515 
We were able to locate the corresponding index case diagnostic sample in 109/128 2516 
(85%) cases. 2517 
Overall, 259 household member stool samples were returned to the reference 2518 
laboratory, which, along with the 109 index cases, yielded a total stool sample count 2519 
of 368. Figure 30  2520 
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Descriptive characteristics 2521 
Speciation and further typing results 2522 
Of the 128 participating households, 109 index case samples were retrieved, along 2523 
with 259 household member samples (n=368). The number of samples returned per 2524 
participating household, excluding the index cases, ranged from zero to six (mean=2).  2525 
Fifty-five percent (137) of household samples received were from female participants, 2526 
and 45% (n=112) were from male. This information was missing for ten households. 2527 
The age of household participants ranged from 8 weeks to 77 years old (n=250), with 2528 
a median of 34 years (mean = 29.9). 2529 
Speciation of typable index cases (n=106) revealed that most cases were C. parvum 2530 
(n=65: 59.6%) and a third were typed as C. hominis (n=36; 33%). The remainder were 2531 
C. cuniculus (n=3; 3%), C. ubiquitum (n=2; 2%), and three were untypable. Further 2532 
gp60 typing results of these index case isolates can be found in Table 9. 2533 
Eleven household contact samples (11/259; 4%) were positively identified and 2534 
confirmed as Cryptosporidium. This is further examined in Speciation and further 2535 
typing results. 2536 
Timing of specimens 2537 
The average time between the index cases' specimen date and the first household 2538 
member specimen was 43 days (median = 41) meaning that on average we were 2539 
mostly enrolling participants within six weeks or so.  2540 
An examination of onset and specimen dates of all participants (where usable data 2541 
were available) revealed that the average time from onset of illness to specimen date 2542 
was 22 days (median=11). Among index cases only (n=99; returned a questionnaire, 2543 
located sample, and were positive), the mean time from onset of illness to specimen 2544 
date was 10 days (median=8). This is most likely because this group would present 2545 
in a symptomatic period, or soon after. The difference in median time to sample might 2546 
suggest that the lag time from illness to receiving household samples played some 2547 
part in an under detection of infection. 2548 
A note: 2549 
Fifteen of the index case specimens were still to be sequenced at the point of writing 2550 
this thesis. Unfortunately, due to unforeseen restrictions on laboratory capability due 2551 
to COVID-19, these were unfinished. As it was unlikely that they would be completed 2552 
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before submission, I have proceeded without them. These have been recorded as 2553 
unknown. 2554 
Table 9: Speciation and gp60 subtyping results for included index cases 2555 
Species 
(total speciated 
isolates = 106) 
gp60 subtype n (%) 
C. parvum  
(n=65) 
 
IIaA15G2R1 15 23.1% 
IIaA17G1R1 11 16.9% 
IIaA19G2R1 2 3.1% 
IIcA5G3J 2 3.1% 
IIdA16G1 2 3.1% 
IIdA17G1 2 3.1% 
IIdA21G1 2 3.1% 
IIdA22G1 2 3.1% 
IIdA24G1 2 3.1% 
IIaA11G1R1 1 1.5% 
IIaA16R1 1 1.5% 
IIaA17R1 1 1.5% 
IIaA18G1R1 1 1.5% 
IIaA18G3R1 1 1.5% 
IIaA19G1R1 1 1.5% 
IIaA19G3R1 1 1.5% 
IIdA20G1 1 1.5% 
Unknown 17 26.2% 
C. hominis  
(n=36) 
IbA10G2 23 63.9% 
IbA12G3 6 16.7% 
Unknown 7 19.4% 
C. cuniculus 
(n=3) 
VaA13 1 33.3% 
VbA35 1 33.3% 
Unknown 1 33.3% 
C. ubiquitum 
(n=2) 
Unknown 2 100.0% 
 
Household size and composition 2556 
All participating households were families rather than friends or housemates. 2557 
I was unable to ascertain any differences between households that participated and 2558 
those that did not, due to the study design: no data or identifiers are available for those 2559 
who did not participate. 2560 
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Household size 2561 
Household size ranged between two and seven, with a median of four people per 2562 
household (mean = 3.4) (Figure 31). Forty-seven percent of households enrolled 2563 
reported three or fewer people currently living in the home. 2564 
 2565 
Figure 31: Frequency histogram of total number of people per household across all 2566 
homes enrolled in the study 2567 
 2568 
Household members 2569 
Data were derived from 99 questionnaires and 29 laboratory samples for all 128 2570 
households. Seven participants (household contacts) were missing age data. 2571 
Table 10 shows the make-up of participating households according to age group of 2572 
all participants. 2573 
The age range of participants in the 128 households ranged right across the age 2574 
profiles, with a high proportion of households represented by adults living with 2575 
younger children in parental capacity. Almost half of households (n=61; 48%) had at 2576 
least one child under five living in the home and eight (6%) had an infant under one 2577 
year old. Eleven (9%) households had at least one person over 65. In total, the 413 2578 
participants were mostly comprised of 25 to 44-year olds (37%), with a decent 2579 
proportion of young children represented (21% under 5 years).  2580 
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Households with a 
member in this category 
(n=128) 
Participants in this 
category 
(n=413) 
Number % Number % 
 <1  8 6.3% 8 1.9% 
1-3 44 34.4% 51 12.3% 
4-5 26 20.3% 29 7.0% 
6-14 50 39.1% 68 16.5% 
15-24 22 17.2% 27 6.5% 
25-34 52 40.6% 78 18.9% 
35-44 53 41.4% 76 18.4% 
45-64 9 7.0% 56 13.6% 
65+ 2 1.6% 20 4.8% 
 
Rooms and crowding 2583 
Information on rooms in the home was populated in all but two of the returned 2584 
questionnaires (n=97; 97%). Number of bedrooms ranged from one to six, with a 2585 
median value of three. I calculated a bed-to-person ratio as a proxy variable for 2586 
overcrowding, including all household members reported in the questionnaire16. 2587 
Ratios ranged from 0.4 to 2.5. If we consider anything less than 1 to indicate some a 2588 
level of overcrowding, 37 (38%) households fell into that category. No difference was 2589 
discernible in this by rural/urban residence (p=0.973). 2590 
Geography of households 2591 
Seventy-six households were enrolled from North West England (59%) and 52 were 2592 
recruited from Wales (41%). Cases originated from various local authorities. I have 2593 
not included an analysis at any lower geographical level due to the possibility of 2594 
deductive disclosure. 2595 
The IMD score data were determined using the LSOA derived from postcode. Due to 2596 
ethical restrictions, I was unable to retrospectively access the postcode of the index 2597 
case using laboratory data, and as such geographical analysis only includes those 2598 
households that returned questionnaires (n=99). 2599 
                                               
16 Measures of over-crowding ordinarily do not include those under 1 in the home, but my calculations 
include all members of the household 
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A corresponding LSOA and subsequent IMD score and quintile was available for 2600 
82/99 households (83%). The remainder (n=17) had partial or incorrect postcodes 2601 
reported on the questionnaire. There was no difference between participating 2602 
household’s deprivation quintile by the country of residence (Prob > |z| =   0.156). 2603 
Over a quarter of participating households fell into the lower five deciles, representing 2604 
the higher deprivation areas (28/82; 34%) while 66% of homes (n=54/82) were in 2605 
those in the more affluent areas. Of these 82 households, I was able to allocate 2606 
aggregated Welsh and English official rurality indicators: 30/82 (37%) were homes 2607 
considered to be in a rural area (6 NW England, 24 Wales), and 52 (63%) as urban 2608 
(37 NW England, 15 Wales).  2609 
Sixty-three of those 82 were either C. parvum (n=43) or C. hominis (20) index cases 2610 
(five other species, 14 not located) (Table 11). Among the participating cases that 2611 
resided in rural areas (and were speciated), most were C. parvum, while most C. 2612 
hominis cases were reported from urban areas (p=0.029). Eleven households (11%) 2613 
reported living on a farm and six (6%) reported using a private water supply (of which 2614 
five were the farm households). All six homes on a private water supply had a C. 2615 
parvum index case (p= 0.074) as did 9/10 (one not speciated) cases who reported 2616 
living on a farm. 2617 
Table 11: Index case species C. parvum or C. hominis among homes in either urban 2618 
or rural areas 2619 
Index case species 
 













21 (84.0%) 22 (57.9%) 43 (68.3%) 
C. hominis 
  
4 (16.0%) 16 (42.1%) 20 (31.8) 
 
Animals in the home 2620 
Over half of the homes recruited that returned a questionnaire reported having pets 2621 
(55/99) (Table 12). There was a slight difference in the distribution of Cryptosporidium 2622 
species of index case, with more C. parvum among those who had pets. However,  2623 
C. parvum cases were more frequently reported across the study overall, and this 2624 
result was not statistically significant (p=0.291). Additionally, 21/99 (21%) households 2625 
reported keeping some non-companion animals – mostly chickens, and cattle. 2626 
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Table 12: Reports of domestic/companion animals 2627 
Domestic/pet 
animal 
Number of households 










Index case characteristics 2629 
We enrolled 128 index cases into the study, 109 of which had corresponding stool 2630 
samples located at the reference unit (85%). Of the 109 index case samples tested, 2631 
most were C. parvum (50.8%) followed by C. hominis (28.1%). 2632 
Table 13: Frequency of species detected among index cases 2633 
Index case species Frequency % 
C. parvum 65 50.8 
C. hominis 36 28.2 
C. cuniculus 3 2.4 
C. ubiquitum 2 1.6 
Index case sample not located 19 14.8 
Not confirmed 2 1.5 
Not typable 1 0.8 
Total 128 100 
 
Sex and age of index case 2634 
Data on sex were missing for one case; all age data were complete. 2635 
Age of the index case ranged from 9 months to 78 years old with a mean age of 22 2636 
(21.8;95% CI 17.8-23.3) and a median value of 12 years, suggesting a preponderance 2637 
of cases among the younger age groups. Females represented 49.6% (n=63) of index 2638 
cases, and males 50.4% (n=64). There was a difference in distribution of ages among 2639 
the sex categories, with male cases tending to be younger (n=127; p=0.030). There 2640 
was no significant difference in the age distribution among cases of C. hominis versus 2641 
C. parvum (p= 0.256). However, despite similar ranges among the sexes in C. parvum 2642 
index cases, a wider range is observed in female C. hominis cases. (Figs 32 & 33) 2643 
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The index case was a child under five years old in almost 30% of the 128 recruited 2644 
households (n=38; 29.7%) and two-thirds of those were male (n=25; 65.8%; p=0.023). 2645 
Children under five years old represented over a quarter of the C. hominis index cases 2646 
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Clinical presentation and symptoms in the index cases 2651 
Clinical information was only available for those index cases who returned a 2652 
questionnaire (n=99).  2653 
The most frequently reported symptom was diarrhoea (95%) followed by stomach 2654 
pain (78%). Less than half of cases reported both diarrhoea and vomiting (49%). 2655 
More than a quarter (27.3%) of cases reported some other symptom(s). These most 2656 
frequently included foul-smelling stool, sleep disturbances, lethargy and exhaustion, 2657 
loss of appetite, and joint pain. In addition, several cases reported ongoing, long-term 2658 
and recurring illness and two people reported being admitted to hospital. 2659 
Age and sex 2660 
Table 14 shows reported symptoms in the index case by sex and selected age band. 2661 
Nausea, headache, and stomach pain were more frequently reported among older 2662 
cases (p=0.007, p= 0.002 and 0.002 respectively). Median age was lower in those 2663 
reporting vomiting, although not significantly so (p=0.137). Overall, fewer females 2664 
than males reported vomiting, (45.7% vs 52.8%), and in particular the proportion of 2665 
those under ten years old reporting vomiting was higher in males than in females. 2666 
Infecting species 2667 
In the main there were few differences between index case infecting species and 2668 
symptoms reported, although among C. parvum cases there were more reports of 2669 
high temperature (57% versus 24% in C. hominis cases; p= 0.007). (Table 15) 2670 
Length of illness 2671 
The number of days an index case was symptomatic was reported in 89/99 (89%) 2672 
returned questionnaires. Time ill ranged from one to 90 days, with a median of 14 2673 
days (mean=18 days). In 96% of cases (n=85) symptoms persisted for 7 days or 2674 
more, and 60% of index cases reporting persisting symptoms for at least two weeks 2675 
(n=53). There was no relationship between symptoms reported and length of illness.  2676 
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Diarrhoea Vomiting Nausea Pain Fever Headache 
Male 53 
 
50 94.3% 28 52.8% 25 47.2% 42 79.2% 22 41.5% 15 28.3% 
Under 5 20 
 
20 100.0% 11 55.0% 5 25.0% 14 70.0% 11 55.0% 1 5.0% 
5-9 10 
 
9 90.0% 8 80.0% 7 70.0% 8 80.0% 3 30.0% 3 30.0% 
10-19 6 
 
6 100.0% 3 50.0% 3 50.0% 6 100.0% 1 16.7% 2 33.3% 
20-34 5 
 
4 80.0% 4 80.0% 3 60.0% 4 80.0% 2 40.0% 2 40.0% 
35-49 7 
 
6 85.7% 2 28.6% 4 57.1% 7 100.0% 3 42.9% 5 71.4% 
50-64 4 
 
4 100.0% 0 0.0% 3 75.0% 3 75.0% 2 50.0% 2 50.0% 
65+ 1 
 
1 100.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Female 46 
 
44 95.7% 21 45.7% 26 56.5% 35 76.1% 22 47.8% 13 28.3% 
Under 5 11 
 
10 90.9% 4 36.4% 3 27.3% 2 18.2% 3 27.3% 0 0.0% 
5-9 3 
 
3 100.0% 1 33.3% 1 33.3% 3 100.0% 0 0.0% 0 0.0% 
10-19 5 
 
5 100.0% 4 80.0% 5 100.0% 5 100.0% 4 80.0% 2 40.0% 
20-34 15 
 
14 93.3% 6 40.0% 9 60.0% 15 100.0% 11 73.3% 8 53.3% 
35-49 2 
 
2 100.0% 1 50.0% 2 100.0% 2 100.0% 1 50.0% 1 50.0% 
50-64 4 
 
4 100.0% 2 50.0% 4 100.0% 4 100.0% 2 50.0% 2 50.0% 
65+ 6 
 
6 100.0% 3 50.0% 2 33.3% 4 66.7% 1 16.7% 0 0.0% 
               
All sexes 99 
 
94 94.9% 49 49.5% 51 51.5% 77 77.8% 44 44.4% 28 28.3% 
Under 5 31 
 
30 96.8% 15 48.4% 8 25.8% 16 51.6% 14 45.2% 1 3.2% 
5-9 13 
 
12 92.3% 9 69.2% 8 61.5% 11 84.6% 3 23.1% 3 23.1% 
10-19 11 
 
11 100.0% 7 63.6% 8 72.7% 11 100.0% 5 45.5% 4 36.4% 
20-34 20 
 
18 90.0% 10 50.0% 12 60.0% 19 95.0% 13 65.0% 10 50.0% 
35-49 9 
 
8 88.9% 3 33.3% 6 66.7% 9 100.0% 4 44.4% 6 66.7% 
50-64 8 
 
8 100.0% 2 25.0% 7 87.5% 7 87.5% 4 50.0% 4 50.0% 
65+ 7 
 




Table 15: Symptoms reported by index cases, by species (or other result) 2679 
Species/result N 
 
Diarrhoea Vomiting Nausea Pain Fever Headache 
C. cuniculus 3 
 
2 66.7% 1 33.3% 1 33.3% 3 100.0% 2 66.7% 2 66.7% 
C. hominis 25 
 
25 100.0% 11 44.0% 13 52.0% 19 76.0% 6 24.0% 7 28.0% 
C. parvum 51 
 
48 94.1% 28 54.9% 26 51.0% 41 80.4% 29 56.9% 13 25.5% 
C. ubiquitum 1 
 
1 100.0% 0 0.0% 0 0.0% 1 100.0% 0 0.0% 0 0.0% 
Cryptosporidium not confirmed 1 
 
1 100.0% 0 0.0% 1 100.0% 1 100.0% 0 0.0% 0 0.0% 
Cryptosporidium sp., not typable 1 
 
1 100.0% 1 100.0% 1 100.0% 1 100.0% 0 0.0% 0 0.0% 
Index specimen not located 17 
 
16 94.1% 8 47.1% 9 52.9% 11 64.7% 7 41.2% 6 35.3% 
Total 99 
 





Figure 36: Boxplot: Length of illness (days) in index case, by sex 17 2681 
 
There were some differences in length of illness by sex of case: males were more 2682 
likely to report a longer illness with a median symptom time of 21 days, versus 15 2683 
days among female cases (p=0.003). Figure 36  2684 
Of these 89 cases, 69 (77.5%) were either C. parvum or C. hominis, with C. hominis 2685 
cases reporting longer illnesses (p= 0.004). 2686 
                                               




Figure 37: Boxplot: Length of illness (days) in index case, by infecting species18 2687 
 
Season of reporting 2688 
I used the onset date provided in the questionnaire where available; otherwise, month 2689 
of onset was estimated using the specimen date provided with the laboratory data. 2690 
Data on onset/specimen date were missing for five cases. 2691 
Index cases were recruited in every month of the study year. Most of the cases 
reported onsets in August, September, and October. January and June had the 
lowest number of index cases, but this could be due to recruitment anomalies 
described earlier.  
Figure 38 shows cases the proportion of index case species received by month 2692 
(where the index case was genotyped and had a usable date) (n=101)). 2693 
C. parvum represented most cases overall, particularly from February to June, 2694 
inclusive. C. hominis cases increased later in the year, from September to December. 2695 
                                               





Figure 38: Proportion of index cases species reported, by month reported to 2696 
surveillance2697 
Month of report 
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Other illness in the home 2698 
For this analysis, I have used a combination of questions from the questionnaire: the 2699 
‘A8_Else’ question asked “Has anyone else in the home been ill with similar symptoms 2700 
within two weeks of the index case?” and ‘Table A’ allowed participants to add clinical 2701 
detail on those that had been ill in the home. Table A relates only to consenting 2702 
individuals, whereas ‘A8_Else’ can report on anyone in the home without divulging 2703 
detail. Additionally, ‘A8_Else’ identifies households where anyone was ill with similar 2704 
symptoms to the index case, within two weeks of the index case. This could be before 2705 
or after the index case’s onset. Table A reports on illness at any time, although I did 2706 
request onset dates. I have tried to combine where possible these questions. 2707 
Additional similar illness in the home within two weeks of the index case is used here 2708 
as a proxy measure for households with transmission. 2709 
 2710 
Burden of illness 2711 
Transmission prevalence  2712 
– within 2 weeks of the index 2713 
Twenty-seven out of 99 households (27%) indicated that there had been at least one 2714 
case of additional illness in the home within two weeks of the index case. Of these, 2715 
10 (37%) were prior to the index case. This amounted to 45 household members out 2716 
of 423 participants (using questionnaire data) giving rise to an attack rate of 10.6%. 2717 
– at any time 2718 
Forty-four homes reported in Table A that there had been some compatible illness in 2719 
the home (at any other time), with 25 of these in the last two weeks.  2720 
Excluding the index cases, 76 additional cases of illness at any time in the home were 2721 
reported, out of 242 at risk household contacts, giving rise to an attack rate of 31.4%.  2722 
Number of additional cases 2723 
Among the 99 households, the number of additional people in the home with any 2724 
illness reported within 2 weeks (i.e. excluding the index) per home ranged from one 2725 
to four (n=25; I excluded two records where they had replied YES to QA8 and NO to 2726 
“Any other illness in the home”). On average, 1.8 additional cases were reported per 2727 
household. This was generally higher in homes where the index was less than five 2728 




Figure 39: Boxplot: Additional cases per household, by age of index case in the 2731 
home 2732 
Table 16: Number of additional cases within 2 weeks, per household, plus range 2733 
data, by age of index case 2734 
Number of additional 
cases 
Index >5 Index <5 Total 
1 9 4 13 
69.23 33.33 52 
2 3 2 5 
23.08 16.67 20 
3 1 5 6 
7.69 41.67 24 
4 0 1 1 
0 8.33 4 
Total additional cases 13 12 25 
    
Range 1-3 1-4 
Median 1 2.5 




Index case characteristics 2736 
Sex 2737 
In 16 (59%) of these homes reporting transmission the index case was male (p=0.484) 2738 
and in 44% (n=12) the index was less than five years old (p=0.084).  2739 
Length of illness 2740 
There was no statistically significant difference in the length of index case illness 2741 
(p=0.838) in households that did and did not report other illness. There was no 2742 
relationship between the number of days of illness reported by the index case and 2743 
number of additional cases in the home (Spearman’s rank correlation p= 0.543). On 2744 
average, 13 days elapsed between onset in the index case and the next case (median 2745 
= 10). The shortest of these was zero days, possibly a co-primary case; these data 2746 
did not allow for further examination of this. 2747 
Potty/Toilet training 2748 
Of the 38 index cases under five, 17 were in nappies, and seven were currently 2749 
undergoing potty/toilet training. Where the index was under five and the home 2750 
reported additional cases, 40% reported using nappies, versus 68% in homes where 2751 
there was no transmission (p=0.149) There was no difference between species of 2752 
index and whether or not the index was in nappies (p=0.973) or potty training 2753 
(p=0.131). 2754 
Burden of additional cases by index case infecting species 2755 
The number of additional cases was greater in households where the index case was 2756 
infected with C. hominis species (rank sum p value= 0.03). Less than 20% of the C. 2757 
parvum index cases reported additional illness in their household (19.6%), compared 2758 
to 48% of the C. hominis indexes (p=0.010). 2759 








Index not located Not confirmed Total Anyone else ill in the 
home within 2 weeks of 
the index case 
C. hominis C. parvum C. ubiquitum C. cuniculus 
Yes 12 10 1 0 4 0 27 
44.4% 37.0% 3.7% - 14.8% - 100% 
No 13 41 0 3 13 2 72 
18.1% 56.9% - 4.2% 18.1% 2.0% 100% 
Total 25 51 1 3 17 2 99 




Who is at risk in the home? 2764 
Relationships 2765 
Table A in the questionnaire collated self-reported illness for individuals in the home. 2766 
This information is used for this analysis. Overall, 74 people reported having additional 2767 
illness, across the 99 households who completed the questionnaire. The most 2768 
affected person in the family was mothers, who represented 30% of this additional 2769 
illness (n=22; 95% CI: 21.2 - 43.9). This was followed by siblings who represented 2770 
27% of illness (n=20; 95% CI: 14.52 - 35.46). (Figure 40) 2771 
 
Figure 40: Proportion of additional illness in households by relationship to the index 2772 
case 2773 
 
Accessing a clinician/GP 2774 
Thirteen of the 74 participants reporting illness said they visited a doctor (17.5%). 2775 



















Relationship to the index case
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Characteristics associated with transmission in the home 2777 
Univariable analysis 2778 
Table 18 shows the number of households reporting selected exposures and 2779 
characteristics, by whether or not participants reported other compatible illness within 2780 
two weeks of the index case.  2781 
Infecting species 2782 
The variable most strongly associated with transmission was the infecting species of 2783 
the index case. Among homes that reported transmission, there was a preponderance 2784 
of C. hominis cases versus C. parvum cases and this exposure was three times more 2785 
likely in homes with additional cases (OR = 3.78). 2786 
Children in the home 2787 
Homes with additional cases were twice as likely to report the index case being a child 2788 
less than five years old (OR = 2.23) with 44% of households with transmission 2789 
reporting this exposure, compared to just over a quarter of homes without additional 2790 
cases (26.4%). Additionally, this relationship remained when examining any children 2791 
under five in the home. Having an index case who attended a nursery was more than 2792 
twice as likely in homes with transmission (OR = 2.5). 2793 
Household size and crowding 2794 
Although not statistically significant, being in a home with three or fewer people was 2795 
reported in a greater proportion of those homes without additional cases (OR = 0.56). 2796 
This is supported by the other crowding indicators; less than one toilet per person (OR 2797 
= 3.29) and less than one bedroom per person (OR = 1.96) were both more prevalent 2798 
in homes where there was transmission. 2799 
Deprivation, sex of case, symptoms 2800 
There was no statistically significant difference in IMD Score (0.6982) in households 2801 
that did and did not report other illness. Sex, deprivation decile, and illness symptoms 2802 
were not associated with differences in transmission.2803 
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Table 18: Households reporting selected exposures and characteristics, by whether or not participants reported other compatible illness within 
two weeks of the index case, with odds ratios and 95% CI 


















Odds ratio 95% CI P value 
n % n % n % 
Index case is C. hominis species (vs C. parvum (n= 76)) 25 32.9% 12 54.5% 13 24.1% 3.78 1.171, 12.236 0.01 
Fewer than 1 toilet per person (n= 96, excl. 3 values) 72 75.0% 23 88.5% 49 70.0% 3.29 0.839, 18.729 0.06 
Index case attends nursery 21 21.2% 9 33.3% 12 16.7% 2.50 0.786, 7.651 0.07 
Children (5 years old or under) in household 48 48.5% 17 63.0% 31 43.1% 2.25 0.898, 5.728 0.08 
Index case under 5 years old 31 31.3% 12 44.4% 19 26.4% 2.23 0.792, 6.158 0.08 
Crowded (fewer than 1 bedroom per person) (n=97, excl. 2 missing values) 37 38.1% 13 50.0% 24 33.8% 1.96 0.708, 5.378 0.15 
Nappies/potty training anyone in home 32 32.3% 11 40.7% 21 29.1% 1.67 0.591, 4.582 0.27 
Pets in household 55 55.6% 17 63.0% 38 52.8% 1.52 0.563, 4.246 0.36 
Index case in nappies or toilet training 23 23.2% 7 25.9% 16 22.2% 1.23 0.369, 3.735 0.70 
Index shares bed 39 39.4% 11 40.7% 28 38.9% 1.08 0.392, 2.906 0.87 
Length of illness > 14 days (n=89, 10 missing values) 41 46.1% 12 46.2% 29 46.0% 1.00 0.361, 2.767 0.99 
Both diarrhoea and vomiting in the index case 48 48.5% 13 48.1% 35 48.6% 0.98 0.398, 2.411 0.99 
Length of index case's illness >7 days (n=89, 10 missing values) 79 88.8% 23 88.5% 56 88.9% 0.96 0.197, 6.242 0.95 
Most deprived deciles (lowest 5 IMD  vs top 5) n=82 28 34.1% 7 33.3% 21 34.4% 0.95 0.280, 3.011 0.93 
Index cooks regularly for home 34 34.3% 9 33.3% 25 34.7% 0.94 0.322, 2.604 0.90 
Female index case 46 47.9% 11 40.7% 35 48.6% 0.73 0.266, 1.943 0.48 




Logistic regression 2805 
Associations with transmission in the home were features of the index case: being 2806 
infected with C. hominis versus C. parvum, and attending nursery, with a reduced 2807 
odds ratio among females. Only having an index case of C. hominis was 2808 
independently associated with transmission in the home in the multivariable model. 2809 





Odds ratio Std. error z P>|z| 95% CI 
C. hominis 4.46 2.68 2.48 0.013 1.37  14.53 
Attends nursery 4.21 5.14 1.18 0.239 0.38 46.14 




0.931 0.09 9.23 
Sex - Female 0.64 0.37 -
0.77 
0.44 0.20 1.99 
-cons  0.11 -
2.97 




Description of homes with confirmed additional infections 2813 
Positivity of samples and confirmation in household contacts 2814 
We were only able to confirm infection in a small proportion of household samples 2815 
(4%; n=12/259). Six out of the 88 samples amplified using the CRU18s screening 2816 
PCR were subsequently negative and were not Cryptosporidium. 2817 
From 137 confirmed positive samples, there were 85 gp60 and 58 MLVA results.  2818 
Description of households and results by species 2819 
C. cuniculus 2820 
Testing identified three C. cuniculus cases among the index samples. These cases 2821 
arose from three households, and all were adult cases. All returned questionnaires 2822 
None of these reported any other compatible illness in the home and corresponding 2823 
household member samples were negative. 2824 
C. ubiquitum 2825 
Three C. ubiquitum cases were identified across two households; two index cases 2826 
and one additional confirmed household infection. All were in children. The samples 2827 
have yet to be sequenced at the gp60 gene.  2828 
The index case from household (HH) 1 was nine years old. This household returned 2829 
a questionnaire and did report compatible illness in the home, but no additional detail 2830 
was recorded in the questionnaire. The onset was in July and the case reported being 2831 
ill (with diarrhoea and abdominal pain) for 30 days. No household contact samples 2832 
were received from this home. 2833 
The index case from HH 2 was a two-year-old female. The household member who 2834 
was positive was 10 months old, likely a sibling, with a BSS of five. One additional 2835 
stool was provided from this home (adult female) which was negative, and the stool 2836 
was formed (BSS = 3). The participants did not return a questionnaire; consequently, 2837 
I was unable to ascertain reports of additional illness.  2838 
C. hominis 2839 
Forty-three C. hominis positive samples were reported overall: 36 index cases and 2840 
seven household samples. Of the 33 that had corresponding GP60 results, there were 2841 
two subtypes identified: lbA10G2 (n=27; 81.8%) and lbA12G3 (n=6; 18.2%). 2842 
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The lbA12G3 cases were all index cases – no confirmed household samples were 2843 
identified with this subtype. However, of the six cases, five returned questionnaires 2844 
and all of them reported additional illness in the home. These were mostly male (n=5; 2845 
83.3%) and in a range of children and adults. Of those records for which data were 2846 
available, time from onset to specimen date was 11 days and the mean duration of 2847 
illness was 21.6 days (median = 20). 2848 
The lbA10G2 cases were from a range of index and (n=230 household (n=4) 2849 
samples. One case occurred in January and the remainder had specimen dates 2850 
between June and December. They occurred in a range of ages, from 1-71 years, 2851 
with 14 females (51.8%) and 13 (48.1%) males. Of those records for which data were 2852 
available, average time from onset to specimen date was 11 days and the mean 2853 
length of time ill was 26.5 days (median = 21). 2854 
C. parvum 2855 
Sixty-nine samples were positive for C. parvum: 65 index cases and four household 2856 
member samples (across three households). Of these, 50 had GP60 results, and 17 2857 
subtypes were identified. These were predominantly IIaA15G2R1 (15; 30%) and 2858 
IIaA17G1R1 (11; 22%). 2859 
The IIaA15G2R1 cases were all index cases – no confirmed household samples were 2860 
identified with this subtype. They occurred in all ages although tended to be in young 2861 
children (range 1-68; mean 11, median 3). Males and females were equally 2862 
represented, and cases occurred across most of the year. Fourteen households had 2863 
returned a questionnaire and six of these reported other illness in the home. Of those 2864 
records for which data were available, average time from onset to specimen date was 2865 
6 days and the mean length of time ill was 11.8 days (median = 11). 2866 
The IIaA17G1R1 cases were also all index case samples. Five of the 11 returned 2867 
their questionnaire and two of these households reported other illness. These 2868 
subtypes occurred in both adults and children, but all cases were in under 40-year 2869 
olds (range 1-38; mean 21). Of those records for which data were available, the 2870 
average time from onset to specimen date was 6 days and the mean length of time ill 2871 
was 18.5 days (median = 21). 2872 
Other clinical indicators in household contact samples 2873 
The BSS was used as an additional clinical indicator, with a score of 6/7 considered 2874 
indicative of diarrhoea. (This indicator was only applied to household samples 2875 
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returned via post, as the original index case sample material was not available for 2876 
assessment and they are presumed symptomatic). Of all specimens submitted, 88 2877 
(33.9%) were considered diarrhoeic. Nonetheless, 28 (31.8%) of these said they had 2878 
no symptoms of illness. All of these specimens were subsequently not confirmed as 2879 
Cryptosporidium. Conversely, all those household member samples that were 2880 
confirmed had BSS scores of under six (i.e. formed). 2881 
Asymptomatic infection 2882 
There were two positive samples identified in participants (1.6% of households) who 2883 
did not report illness: both were from adult males, both C. hominis. One of these was 2884 
gp60 subtype IbA10G2, the other subtype was not identified. Both were parents of an 2885 
index case (both C. hominis lbA10G2). In both cases, other illness was reported in 2886 
the home. One of these samples was retrieved from an originally submitted diagnostic 2887 
specimen, which may question the validity of the case reporting no symptoms. 2888 
Confirmed infections and additional illness in the home 2889 
Of 128 households, 82 had both an index case located and returned a questionnaire, 2890 
allowing me to merge these data to complete a narrative description of homes where 2891 
confirmed additional infections were identified. Using responses from Table A in the 2892 
questionnaire, 39/82 (47.6 %) reported some additional illness at any other time in 2893 
the home (not necessarily within 2 weeks).  2894 
Table 20 shows the number of households that had any member samples confirmed 2895 
as Cryptosporidium, by the index case result. Overall, ten households in this study 2896 
had confirmed infection in at least one other person (7.8%). These were all in homes 2897 
where we were able to identify a corresponding original index case sample. These 2898 
ten homes with confirmed additional infection yielded 28 household member samples 2899 
in total. Of these 28 samples, 12 (42.9%) were confirmed: this comprised one 2900 
household member in each of eight homes, and two household members apiece in 2901 







Table 20: Number of households that had any member samples confirmed as 2903 




infection in any 
HH member 
sample 
Index case species All 
samples 
Yes %  
C. cuniculus 3 0 0% 
C. hominis 36 6 17% 
C. parvum 65 3 5% 
C. ubiquitum 2 1 50% 
Cryptosporidium not confirmed 2  0 0% 
Not typable 1  0 0% 
Total 109 10 9% 
 
In 6/10 (60%) of the households in which additional infection was identified, the 2905 
samples were identified from original previously submitted samples, rather than newly 2906 
collected ones. In this way, we know that in all of these cases it is quite likely that 2907 
symptoms were present, as this is what would drive the person to seek clinical 2908 
assessment and have a sample taken. This may be because of severity of symptoms, 2909 
or shorter time from onset to sample than those who submitted samples in the usual 2910 
way. I go on to discuss the possible impact of this in the discussion. 2911 
In those samples where we retrieved a subtyping result, all corresponding household 2912 
contact samples had the same gp60 as the index case and no multiple infections 2913 
were identified. 2914 
We were able to confirm infection in two individuals’ samples who reported no 2915 
symptoms. However, we did observe that 28/81 (34.6%) individuals who did not report 2916 
symptoms submitted stool samples that were scored a BSS of 6 or 7, indicating 2917 
diarrhoeic consistency. 2918 
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An overview of the burden of disease in homes with confirmed additional 2919 
cases2920 
2921 
Household A 2922 
Index: C. ubiquitum No typing 
HH sample 1: C. ubiquitum No typing 
 
One household had an index case of C. ubiquitum with one additional stool sample, 2923 
which was also positive. No further subtyping has been available. 2924 
The index case was a two-year-old female, and the positive household contact was 2925 
a 10-month-old female, likely a sibling. There were 39 days between the specimen 2926 
dates of these two cases, making spread a possible explanation. However, the 2927 
household did not return a questionnaire and no further examination of this home was 2928 
possible. 2929 
2930 
Household B 2931 
Index: C. parvum gp60 IIdA21G1 
HH sample 1: C. parvum gp60 IIdA21G1 
 
This household had an index case of C. parvum and returned one household sample, 2932 
which was also positive. An identical gp60 subtype was identified in both samples. 2933 
The index case was a child and the additional confirmed infection was in Mum, who 2934 
did report compatible illness. Their onsets were 17 days apart, and the index case 2935 
had been ill for three weeks in total, making this a likely case of transmission. Overall, 2936 
illness in the home extended over 24 days. 2937 
Mum’s sample was a previously submitted one, and time from onset to specimen 2938 
collection was 13 days, although symptoms had reportedly ceased by that time. 2939 
The questionnaire revealed that this index case also lived with Dad and two older 2940 
siblings, none of whom reported illness and whose samples were not submitted for 2941 





























Index: C. parvum gp60 IIdA16G1 
HH sample 1: C. parvum gp60 IIdA16G1 
HH sample 2: Cryptosporidium not 
detected 
-- 




The household C index case was C. parvum, with gp60 subtype IIdA16G1. Three19 2946 
additional household contact samples were received by the laboratory, of which one 2947 
was positive for C. parvum IIdA16G1.  2948 
The index case was ten years old, and the additional confirmed infection was in a 2949 
seven-year-old sibling. Samples were also submitted for Mum and Dad; 2950 
Cryptosporidium was not detected in either. The positive sibling did reportedly have 2951 
symptomatic illness, as well as Dad, who reported a short, two-day illness. Both 2952 
children reported illness of eight days and overall the home reported a duration of 2953 
illness of 15 days. (Mum was not ill and is not on the chart) 2954 
The time from index onset to the first (sibling) illness was five days, and a further eight 2955 
days elapsed until Dad began to get ill. This could represent co-primary infections in 2956 
the children with spread to the parent, or secondary or even tertiary levels of spread 2957 
from the index case. The family did report common exposures to the index, including 2958 
water sports, contact with pets, and travel. 2959 
The time between onset and specimen collection for the index and positive household 2960 
contact was 7 and 2 days, respectively. For Dad, who could not be confirmed, this 2961 
was 62 days. Although Mum did not report symptoms, the submitted stool sample 2962 
was considered diarrhoeic (BSS = 6). (Figure 42)2963 
                                               
19 This family returned four additional samples, but one of those was suspected to be the sibling again, 













Figure 42: Depiction of course of illness in the home, with laboratory results_Household C 
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Household D 2964 
Index: C. parvum MLVA sequence 4-14-5-8-27-28-16 
HH sample 1: C. parvum MLVA sequence 4-14-5-8-27-28-16 
HH sample 2: C. parvum MLVA sequence 4-14-5-8-27-28-16 
 
The household D index case was C. parvum. Two additional household contact 2965 
samples were linked to this household, and both were positive for C. parvum. 2966 
The gp60 subtype analysis could not be confirmed for these samples. However, the 2967 
laboratory was able to complete the MLVA and all three samples were prolife 4-14-5-2968 
8-27-28-16, and indistinguishable.  2969 
The index case was a two-year-old girl, and both household contact samples were 2970 
taken from siblings (aged two and four). All children reported symptoms: nine days 2971 
duration for the index case, and eight and ten days for the siblings. (Accurate onset 2972 
data were not available for one of the siblings). Mum and dad were also reported as 2973 
living in the home, but no samples were submitted. The household contact cases both 2974 
had samples submitted on the same day. This suggests that the index may have 2975 
infected both siblings at around the same time. 2976 
The time between onset and specimen collection for the index and one of the positive 2977 
siblings was five and four days, respectively. No BSS data were available, but each 2978 


















Figure 43: Depiction of course of illness in the home, with laboratory results_Household D 
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Household E 2980 
Index: C. hominis gp60 IbA10G2 
HH sample 1: C. hominis No typing 
 
The household E index case was five-year-old male with confirmed C. hominis 2981 
IbA10G2. One household sample was returned to the laboratory and confirmed as C. 2982 
hominis. The positive household contact was the child’s mum, a 34-year-old female. 2983 
The questionnaire revealed four in the household altogether: another sibling with no 2984 
illness, and dad, who did report symptoms. No samples were received for those two 2985 
participants. 2986 
The index case reported a long illness (35 days) and mum was symptomatic for a 2987 
week. The time from index onset to the next possible infection (dad) was 24 days, 2988 
and it was 28 days until mum’s symptoms began. This could represent spread to one 2989 
or both parents directly from the index, or tertiary levels of spread from the index case 2990 
to dad, and then from dad to mum. The family did report recent travel.  2991 
The time between onset and specimen collection for the index and positive household 2992 
contact was 9 and 14 days, respectively. Mum’s sample was taken seven days post-2993 
symptoms, with a BSS of two (formed stool), and Cryptosporidium was detectable. 2994 
The overall burden of illness on this home was considerable with 75% of occupants 2995 
























Figure 44: Depiction of course of illness in the home, with laboratory results_Household E 
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Household F 2998 
Index: C. hominis gp60 IbA10G2 
HH sample 1: C. hominis No typing 
 
The household F index case was 42-year-old female with confirmed C. hominis 2999 
IbA10G2. One household sample was returned to the laboratory, was speciated, and 3000 
confirmed as C. hominis (without typing). The positive household contact was a 42-3001 
year-old male.  3002 
There were 46 days between the two specimen dates, suggesting that this was 3003 
transmission. The household contact’s BSS was five, so he may have had some 3004 
symptomatic illness. The household did not return a questionnaire and no further 3005 
examination of this home was possible. 3006 
3007 
Household G  3008 
Index: C. hominis No typing 
HH sample 1: C. hominis gp60 IbA10G2 
 
The household G index case was one-year-old male with confirmed C. hominis. 3009 
Subtyping was not available from the original sample. One household sample was 3010 
returned to the laboratory, was speciated, and confirmed as C. hominis, with gp60 3011 
IbA10G2. The positive household contact was the child’s mum, a 31-year-old female. 3012 
The questionnaire revealed three people in the household altogether: no sample or 3013 
information was received for the additional participant. 3014 
The index case was reported as having a long illness (21 days) and mum was 3015 
symptomatic for two weeks. The time from index onset to mum’s infection was 14 3016 
days. This could represent spread from the index case to parent. However, the family 3017 
did report other exposures such as travel, swimming, and farm visits.  3018 
The time between onset and specimen collection for the index and positive household 3019 
contact was 18 and 10 days, respectively. Both samples were taken during a 3020 
symptomatic period. No BSS was recorded as both samples were retrieved from 3021 
original specimens.  3022 
The overall burden of illness on this home was considerable with two thirds of 3023 



















Figure 45: Depiction of course of illness in the home, with laboratory results_Household G 
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Household H 3026 
Index: C. hominis gp60 IbA10G2 
HH sample 1: C. hominis gp60 IbA10G2 
 
The household H index case was five-year-old female with confirmed C. hominis 3027 
IbA10G2. One household sample of a sibling, an eight-year-old female, was returned 3028 
to the laboratory and confirmed as C. hominis IbA10G2. This household contact 3029 
specimen had previously been submitted as part of routine surveillance, so it is likely 3030 
that this child also reported symptoms. 3031 
There were 12 days between the two specimen dates: this could represent 3032 
transmission or two co-primary cases with a common exposure. The household did 3033 
not return a questionnaire and no further examination of this home was obtainable. 3034 
3035 
Household J  3036 
Index: C. hominis gp60 IbA10G2 
HH sample 1: C. hominis gp60 IbA10G2 
HH sample 2: C. hominis gp60 IbA10G2 
 
The household H index case was C. hominis gp60 IbA10G2. Two additional 3037 
household contact samples were linked to this household and were indistinguishable 3038 
by gp60The index case was a seven-year-old boy, and the two household contact 3039 
samples were taken from dad and a two-year-old sibling. The sibling reported illness 3040 
(length of time unknown) but dad did not report any compatible symptoms. The index 3041 
was ill for 90 days, and additionally reported poor appetite: with two young children 3042 
ill, this is likely to have been a serious burden on this home. Common exposures were 3043 
reported: swimming, farm animal contact, and exposure to pets. The time between 3044 
onset and specimen collection for the index was 34 days, and for the sibling, 16 days. 3045 
There were 26 days between index onset and sibling’s illness. No BSS data were 3046 
available, but the index case’s sample would have been taken during a symptomatic 3047 
period. Anecdotally, for this household, mum reported that the case often stays at 3048 











Household K  3051 
Index: C. hominis gp60 IbA10G2 
HH sample 1: C. hominis No typing 
 
The household K index case was a four-year-old female with confirmed C. hominis 3052 
IbA10G2. One household sample was returned to the laboratory, was speciated, and 3053 
confirmed as C. hominis (no typing). The positive household contact was a 38-year-3054 
old male, possibly dad. The questionnaire was returned for this household but poorly 3055 
filled in and most of the data were missing. The index was reportedly ill for one day 3056 
and the household did not report any other illness in the home within two weeks of 3057 
the index. The index specimen date was the same as the onset, and there were 39 3058 





I undertook this study in order to begin to describe factors within the home 3062 
environment that might be associated with spread of Cryptosporidium. My primary 3063 
research objectives were to estimate the amount of secondary spread of infection that 3064 
occurs in homes with a case and examine any associated factors. This exploratory 3065 
study has highlighted several characteristics of cases, and of the environment in 3066 
which they live, that might be correlated with spread of infection. Significant 3067 
independent factors in multivariable analysis included attending nurseries and being 3068 
infected with C. hominis.  3069 
Representativeness 3070 
We enrolled 128 index cases into the study, most of which were C. parvum or C. 3071 
hominis. This represents about 10% of the cases reported in those regions over the 3072 
study year. Our recruitment uptake was good for a study of this type, with around 18% 3073 
of those contacted taking part and returning one or more elements of the study packs 3074 
(Tam et al., 2012). I think that one of the reasons our participation was so good was 3075 
due to the resource of the CRN nurses, who were able to directly contact participants: 3076 
a somewhat similar study to the epiCrypt study, conducted by Waldram and 3077 
colleagues reported a massive participation rate over 60%, using environmental 3078 
health officers to present study information face-to-face with families and to retrieve 3079 
samples at the point of contact (Waldram et al., 2017). More generally, a decrease in 3080 
‘volunteerism’ and perception of participant burden has been reported among 3081 
observational studies over recent years (Morton et al., 2012). Additionally, recent 3082 
changes in privacy laws and rules on recruitment, often dictated by ethics committees, 3083 
can lead to reduced participation rates and possible selection bias (Galea and Tracy, 3084 
2007; Morton et al., 2012). The complexity of the epiCrypt study most definitely lay in 3085 
the design, with much navigation required to accommodate legal and ethical 3086 
requirements for participant approach and data handling, and cross-organisational 3087 
contract obligations. I expand on some of my personal thoughts on this later in the 3088 
discussions. 3089 
Whilst an understand of the participation is informative, I do not think in isolation it 3090 
can proxy the study validity, and despite a definite lean towards recruitment of families 3091 
rather than other household compositions, the characteristics of our included 3092 
participants were fairly typical of both North West England and Wales. Participants 3093 
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were mostly comprised of 25 to 44-year olds but we also had a decent proportion of 3094 
young children represented (21% under 5 years), with male cases tending to be 3095 
younger. This fits with what we know about the descriptive epidemiology of 3096 
Cryptosporidium in England and Wales (Chalmers et al., 2009).  3097 
The age of the index cases ranged from 9 months to 78 years old with a 3098 
preponderance of cases among the younger age groups. The index case was a child 3099 
under five years old in almost 30% of the recruited households and two-thirds of those 3100 
were male. This is supported by other examinations of cases in the UK and beyond 3101 
that demonstrate an increased prevalence in infants and young children (Abubakar 3102 
et al., 2004; Hunter, Hughes, Woodhouse, Syed, et al., 2004; Chalmers et al., 2009; 3103 
Cacciò and Chalmers, 2016).   3104 
There were more C. parvum (n=69) cases than C. hominis (n=43) in the study. This 3105 
is quite likely representative of the circulating species over the year, although there 3106 
were two periods of reduced recruitment in January and June. This Is unlikely to have 3107 
affected the species results too much as both months are still in the C. parvum period, 3108 
with the increase in C. hominis happening in late summer, from August (Nichols et 3109 
al., 2006; Chalmers et al., 2019; Douglas et al., 2019). In line with what is expected, 3110 
in the rural areas, most cases were C. parvum, while most C. hominis cases were 3111 
reported from urban areas (McLauchlin et al., 1999; Deshpande et al., 2015).  3112 
The households that took part originated from all socioeconomic areas, but there were 3113 
slightly more households from the less deprived geographies. This is consistent with 3114 
the profile of Cryptosporidium infection across England and Wales where the most 3115 
deprived areas appear slightly underrepresented (I. I. R. Lake et al., 2007). This might 3116 
reflect difference in access to, or use of, services, or may be a reflection of differences 3117 
in recruitment and participation (Snel, Baker and Venugopal, 2009; Ellis et al., 2017).  3118 
Profile of illness 3119 
More than a quarter of index cases reported symptoms other than diarrhoea and 3120 
vomiting, including nausea, abdominal pain, and headaches. Moreover, vomiting was 3121 
not frequently reported at all, occurring in less than half of the index cases, which has 3122 
been noted previously (Hunter, Hughes, Woodhouse, Raj, et al., 2004; Johansen et 3123 
al., 2014; Adler et al., 2017) Symptoms differed somewhat by age with nausea, 3124 
headache, and stomach pain occurring more among older cases and vomiting in the 3125 
younger cases, particularly males. This could be due to differences in the symptom 3126 
profile of species. Differences in symptom presentation have been identified before, 3127 
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in an outbreak of C. hominis, where headache and abdominal pain were more 3128 
common in female cases (Adler et al., 2017).  However, as a high proportion of the 3129 
cases were children, it is important to remember that we are relying on secondary 3130 
reports of illness, usually via parents. Self-reported illness can be fraught with 3131 
reliability issues, especially with non-clinically obvious symptoms like pain or nausea, 3132 
which may be difficult for a young child to describe or articulate. 3133 
Of additional interest, this study revealed there were some differences in length of 3134 
illness by sex and infecting species: males were more likely to report a longer illness 3135 
(p=0.003) as were cases of C. hominis (p=0.004). As discussed in Chapter 2 Part A 3136 
(Clinical manifestation), a study of sporadic disease in the UK reported a mean 3137 
duration of symptoms for patients with C. hominis that was two days longer than C. 3138 
parvum cases (Hunter, Hughes, Woodhouse, Syed, et al., 2004). One curious finding 3139 
in this study was that additional, and possibly secondary, cases in the home were not 3140 
as long-lived as those in the index cases and might point to a decreased virulence in 3141 
person-to-person spread (R. Chalmers et al., 2016). This has been evidenced before 3142 
in homes with transmission of gastrointestinal pathogens, where secondary cases’ 3143 
average duration of illness was more than half that of primary cases (Perry et al., 3144 
2005). However, this study did not confirm aetiology of cases, and additionally 3145 
excluded secondary cases with onsets >5 days after cessation of index symptoms, 3146 
which might exclude a reasonable amount of Cryptosporidium infections, given its 3147 
longer than average incubation time. 3148 
A browse of the free text in the questionnaires revealed that case symptoms were 3149 
extensive: those most frequently reported included foul-smelling stool, sleep 3150 
disturbances, lethargy and exhaustion, loss of appetite, and joint pain. In addition, 3151 
several cases reported persistent and recurring illness and two people reported a 3152 
hospital admission. This demonstrates a substantial burden of illness on the individual 3153 
as well as on the home overall and is well corroborated in other literature which has 3154 
revealed duration of symptoms far beyond IID of other aetiologies (Robertson et al., 3155 
2002a; Kortbeek, 2009; Shirley, Moonah and Kotloff, 2012; Carter et al., 2019). 3156 
Crucially the longevity of illness might also amplify spread, by potentially increasing 3157 
the length of time the oocysts are shed (Jokipii and Jokipii, 1986; Chappell et al., 3158 
1996; Chalmers; et al., 2016), although here there was no association between length 3159 
of illness and burden of additional cases in the home. Nonetheless, complications this 3160 
long lasting and potentially burdensome warrant further examination.  3161 
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There is certainly a public health, and economic, argument for interventions to reduce 3162 
not only primary infections with Cryptosporidium, but also subsequent spread. This 3163 
might include work to provide more targeted advice for individual Cryptosporidium 3164 
patients or during outbreaks, and these strategic and population-level approaches are 3165 
critical given the lack of licensed treatment for this infection in the UK. This evidence 3166 
does reinforce the importance of speciation and subtyping of isolates where at all 3167 
possible, in order to better understand the clinical course of disease for the patient or 3168 
population and administer appropriate interventions and advice. 3169 
Asymptomatic infections 3170 
This work did not reveal any considerable proportion of asymptomatic infection. 3171 
Cryptosporidium was detected in 12/259 (4%) of household members’ samples of 3172 
whom two were asymptomatic, giving a prevalence of asymptomatic infection of 2%. 3173 
Both households were diagnosed with cases of C. hominis IbA10G2. From the small 3174 
number of relevant studies, carriage of Cryptosporidium appears to be low at between 3175 
0.1-1.3% (Tompkins et al., 1999; Davies et al., 2009) although this has once been 3176 
demonstrated as high as 9% following an outbreak of C. parvum in Norway (Johansen 3177 
et al., 2014). Identification of true carriage is difficult as we tend to capture diarrhoeal 3178 
cases and it is likely that all of the index cases here will have sought clinical 3179 
assessment following symptoms. In addition, recrudescence of symptoms 3180 
complicates the identification of differences between true asymptomatic infection and 3181 
shedding of oocysts in an asymptomatic period. In this study, because I used a 3182 
question covering compatible illness at any time, it is plausible that those who do not 3183 
report symptoms truly did not ever have symptoms. An asymptomatic prevalence of 3184 
2% would be in line with carriage expected for the UK (Davies et al., 2009) but the 3185 
design of this work did not allow any examination of this contribution to spread.  We 3186 
do not know the immune status of household members, but none of the index cases 3187 
reported any immune compromise or deficiency. 3188 
The time between initial onset of illness in the home and sample retrieval from others 3189 
was variable, and often long. This does raise some uncertainty about the capability 3190 
of the tests used to confirm infection. For this reason, we included both IFM and PCR. 3191 
Given that we have already demonstrated differences in length of illness by species, 3192 
it would not be implausible that asymptomatic, or indeed less protracted secondary 3193 
infections, might lead to shorter shedding times (Perry et al., 2005). If this were the 3194 
case, perhaps by the time that the laboratory had received samples the detection 3195 
power of the tests, and especially IFM was reduced. Also, with such a small sample 3196 
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size the power to truly detect asymptomatic infections would be fairly weak. In this 3197 
sense, the true asymptomatic infection burden may well be under ascertained here 3198 
and we know from previous work that lack of detection by routine diagnostic methods 3199 
does not necessarily equate to lack of infection (Chalmers et al., 2011; Chalmers et 3200 
al., 2016). Due to the study design, I was not able to determine if being asymptomatic 3201 
meant a reduced compliance with submitting stool samples, as I only had the 3202 
information that the household filled in on the questionnaire: if this excluded members 3203 
of the home I was unaware. 3204 
Whilst fairly confident about this result representing at least the minimum 3205 
asymptomatic carriage, it is important nonetheless to recognise issues that arise from 3206 
using self-reported data, and the differences in possible perception and experiences 3207 
of illness by individuals, affecting validity and possibly over estimating this effect 3208 
measure. Whilst we are selecting our at-risk individuals from the same homes as 3209 
cases, and thus will have certain similarities to cases, the generalisability of this is 3210 
questionable. There are complex biological and social factors that affect surveillance 3211 
data capture, of which illness severity has been shown to be important (Tam, 3212 
Rodriguez and O’Brien, 2003) and one person’s idea of ‘being ill’ might differ from 3213 
another’s. Nonetheless, this result is not insignificant. If asymptomatic infections are 3214 
indeed few, rather than this being something to be dismissed, actually this indicates 3215 
that if infected you are more than likely to be ill, and we know that with this illness 3216 
comes considerable symptomatic burden, and the risk of longer term sequelae 3217 
(Hunter, Hughes, Woodhouse, Raj, et al., 2004; Stiff et al., 2017). As such, this makes 3218 
tackling preventable secondary transmission of infection a crucial issue of public 3219 
health importance. 3220 
Additional illness in the home 3221 
We were able to confirm infection microbiologically in a small proportion of household 3222 
contact samples (4%; n=12). However, at least one additional case of self-reported 3223 
compatible illness within two weeks of the index case was identified in 27 households 3224 
(27%). Almost half of the homes for which data were available (39/82; 47.6%) 3225 
reported some additional illness at any other time in the home (not necessarily within 3226 
two weeks). Given the lengthy and often variable incubation period for 3227 
Cryptosporidium (Bouzid et al., 2013; Chalmers and Caccio, 2016) these cases 3228 
outside the two week window could still be due to onward spread from an index case. 3229 
An analysis by species revealed that less than 20% of the C. parvum index cases 3230 
reported additional illness in their household (19.6%), compared to 48% of the C. 3231 
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hominis indexes (p=0.01). This result is in line with similar studies evidencing C. 3232 
hominis as a species particularly associated with people, and probably the person-to-3233 
person transmission pathway. A case-control study in the Netherlands (Nic Lochlainn 3234 
et al., 2019) found that C. hominis cases in particular were three times more likely 3235 
than controls to have been exposed to a case in the home and were less likely to live 3236 
in homes with lots of adults. Also, in those years where C. hominis was the 3237 
predominant circulating species, other risk factors such as food items were reported 3238 
as associated with decreased odds of illness. This work adds to the body of evidence 3239 
that sources for C. hominis may be exclusively human and that person-person 3240 
transmission is the most likely pathway (Hunter, Hughes, Woodhouse, Syed, et al., 3241 
2004; Hunter and Thompson, 2005). 3242 
Burden on the home 3243 
Almost two additional cases occurred, on average, in households with an index case. 3244 
Additionally, the analyses suggested that almost a third (31%) of people in the home 3245 
could be expected to get ill from transmission of infection. This burden was even 3246 
greater in households where the index case was infected with C. hominis or the index 3247 
case was under five years old. Risk of infection in settings with young children has 3248 
previously been demonstrated and is known to facilitate spread (Hannah and Riordan, 3249 
1988; Hunter, Hughes, Woodhouse, Syed, et al., 2004; Johansen et al., 2014). This 3250 
work further highlights that person-to-person is a specific transmission pathway but 3251 
is first study to quantify the burden that this exacts on the home.  3252 
I examined case contact as a risk factor for illness in the systematic review chapter 3253 
revealing that this pathway does seem to contribute quite heavily to cases, albeit not 3254 
well understood. If we consider this in light of the results here, it makes sense that 3255 
underlying case contact is direct person-to-person transmission. If most index cases 3256 
are young children, and mums make up the burden of secondary cases, then it is 3257 
plausible that the driver here is direct contact, in a caring capacity; undertaking 3258 
activities which likely put the main carers in the home at high risk. Additionally, siblings 3259 
were also affected considerably by secondary infection, but where the adult was an 3260 
index case, their children were less frequently the secondary case. It has been 3261 
documented before that mums and siblings are most at risk of Cryptosporidium: in a 3262 
follow-on study in Norway, with 12 and 13-year-old index cases, a 17% secondary 3263 
transmission rate was mainly comprised of female caregivers and siblings (Johansen 3264 
et al., 2014). This is mirrored among other gastrointestinal aetiologies (Perry et al., 3265 
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2005), and indeed for E. coli O157 it has been suggested that separation of siblings 3266 
might be a key intervention in reducing secondary cases (Werber et al., 2008).  3267 
Gender roles influence both patterns of exposure to infectious agents and the 3268 
treatment of infectious disease (World Health Organization, 2007). Caring for the sick 3269 
carries an increased risk of exposure, especially for diseases that are spread directly 3270 
from person-to-person and in most societies females are more likely to care for the 3271 
sick than males (Anker, 1998). The heterogeneity of contact within the home has been 3272 
examined in respiratory diseases such as Influenza and Pertussis, and studies found 3273 
that contacts between mother and children and between siblings are most prevalent 3274 
(Goeyvaerts et al., 2018). 3275 
Some of the individual home analyses among the laboratory confirmed contact 3276 
isolates exposed a considerable burden on the home, with one home reporting illness 3277 
for 90 days. As these illnesses were often in young children, and mums represented 3278 
about 30% of additional illness (followed by siblings), this could signify a real societal 3279 
burden. Several cost and burden of illness studies have been undertaken in the 3280 
Netherlands, which have considered the economic and societal impact of 3281 
gastrointestinal infections. Overall, there is a considerable burden on productivity due 3282 
to absence from work for the ill or the caregiver(s) (Pijnacker et al., 2019), and one 3283 
study estimated that in 15% of cases where a child was ill, a parent had to remain off 3284 
work (Mughini-Gras et al., 2016). An additional analysis considering the longer-term 3285 
manifestations of Cryptosporidium in particular reported similar burdens on 3286 
productivity, with additional impact on disability adjusted life years (DALYs) due to 3287 
recurring diarrhoea and long-term joint pain (Monge et al., 2019). Further work 3288 
confirming and examining this disparity for Cryptosporidium would be a welcome 3289 
addition to work to describe the economic and societal burden of this disease.  3290 
The demonstration of a C. hominis-specific burden provides another argument for 3291 
swift and complete characterisation of isolates, with results fed into local and national 3292 
surveillance data. If we are able to identify a high-risk individual or population this 3293 
might help highlight those at specific risk of secondary infections and allow particular 3294 
clinical and public health advice to be followed.  3295 
Clinical assessment/Health-seeking 3296 
Fewer than 20% of secondary cases saw a clinician for their illness (17.5%). In 3297 
addition, secondary cases tended to report shorter symptom times than index cases, 3298 
and there were ten incidences where the index was not the first in the home. If we 3299 
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consider that almost a third of people in a home could get ill, but only a fifth of these 3300 
seek medical assessment this definitely represents an under-ascertainment of true 3301 
cases. However, these data are based on self-reported illness which can be 3302 
unreliable (Hunter and Syed, 2002; Hunter et al., 2005), and we cannot confirm that 3303 
similar symptoms were indeed Cryptosporidium. 3304 
Detecting Cryptosporidium in household contact stool samples 3305 
Cryptosporidium was detected in 12/259 (4%) of household members’ samples of 3306 
whom two were asymptomatic, giving a prevalence of asymptomatic infection of 2%. 3307 
This is much smaller than expected if the self-reported clinical illness does truly 3308 
represent secondary infections. An explanation for this may be the lag time from 3309 
illness to receiving household samples and the likelihood of detecting 3310 
Cryptosporidium. Despite a range of laboratory testing methods, including PCR, the 3311 
results demonstrated that confirmation was more likely in specimens taken during, or 3312 
soon after, a case’s symptomatic period. The average time between the index cases' 3313 
specimen date and the first household member specimen was 43 days. Oocysts 3314 
might also be shed intermittently but the study design did not allow for repeat 3315 
sampling. 3316 
Additionally, using a clinical indicator of BSS made no difference to microbiological 3317 
confirmation: all of the diarrhoeic specimens were subsequently unable to be 3318 
confirmed as infected with Cryptosporidium. Conversely, all those household member 3319 
samples that were confirmed had formed stools. This supports our prior 3320 
recommendation (Chapter 2: Part B) to eliminate stool consistency as a testing 3321 
inclusion criterion in local laboratories. 3322 
The laboratory was able to further characterise a large proportion of the 3323 
Cryptosporidium gp60 or MLVA profiles, which were representative of those 3324 
circulating in the study areas (Hunter et al., 2007; Chalmers et al., 2008, 2019; R M 3325 
Chalmers, RP Smith, et al., 2011). The C. parvum subtypes of IIaA15G2R1 and 3326 
IIaA17G1R1 are reported as most prevalent in England and Wales (using outbreak 3327 
data) and are mostly associated with animal contact. The C. hominis most prevalent 3328 
subtypes are lbA12G3 and lbA10G2, mostly associated with water. These profiles 3329 
were indistinguishable from the index case in all homes with confirmation, suggesting 3330 
direct transmission or at least common exposures. 3331 
This study detected possible household transmission of C. ubiquitum, with an index 3332 
case and a confirmed household infection. Unfortunately, the questionnaire element 3333 
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of the study was not returned for this home and so further examination of exposures 3334 
was not possible. But this was an interesting find: it is an unusual subtype, sources 3335 
of infections in humans are not entirely clear and transmission between people has 3336 
never been demonstrated (Li et al., 2014). 3337 
Factors associated with transmission in households 3338 
The variable most strongly associated with additional cases in the home was the 3339 
infecting species of the index case. Among homes that reported transmission, there 3340 
was a significant preponderance of C. hominis cases versus C. parvum cases and 3341 
this was four times more likely to be reported in homes with additional cases (OR = 3342 
3.78). The Netherlands recently reported similar results (Nic Lochlainn et al., 2019), 3343 
specifying that C. hominis cases were more likely than controls to have been exposed 3344 
to a case in the home. Additionally, the authors reported corroborating indicators 3345 
supportive of a person-to-person pathway, including living in smaller homes, and 3346 
living with children. Although not independently associated with transmission in the 3347 
logistic regression model, this study did highlight similar associated exposures, with 3348 
homes with additional cases twice as likely to report the index case being a child less 3349 
than five years old or attending a nursery (OR = 2.5). Although not statistically 3350 
significant, being in a home with three or fewer people was reported in a greater 3351 
proportion of those homes without additional cases and this has been demonstrated 3352 
previously for gastrointestinal infection transmission in the home (Perry et al., 2005). 3353 
This is additionally supported by the other crowding indicators; fewer than one toilet 3354 
per person (OR = 3.29) and fewer than one bedroom per person (OR = 1.96) were 3355 
both more prevalent in homes where there was transmission, although they did not 3356 
remain in the final model. 3357 
This work continues to buttress the existing literature but highlights quite clearly that 3358 
differences in species and transmission are quite likely. At risk homes can be 3359 
identified as those where the index is less than five years old and/or is infected with 3360 
C. hominis. Of particular risk are mums and caregivers, and siblings, and targeted 3361 
hygiene advice should be specifically directed here. 3362 
Limitations 3363 
Accurately identifying transmission 3364 
A study of this kind is not without its limitations. The main objective of this work was 3365 
to identify transmission in the home environment, and this is arguably the most 3366 
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evasive and difficult part of the project overall. Generally, contact with other cases is 3367 
used as a proxy measure for spread or transmission of infectious diseases between 3368 
people, but this does not always happen, or cannot be proven to happen, in one 3369 
specific environment (Bloomfield et al., 2012; Iyengar et al., 2015; Nic Lochlainn et 3370 
al., 2019). Studies oftentimes are unable to examine further underneath this to 3371 
ascertain specific differences in cases or identify modifiable risk factors, and very 3372 
specific study designs would be needed to examine this. Proving transmission is a 3373 
difficult task, and the ubiquitous nature of Cryptosporidium and of its exposures make 3374 
untangling these exposures and demonstrating causality difficult in a study of this set-3375 
up. Nevertheless, this study was intended as an exploratory piece, and the evidence 3376 
presented suggests that Cryptosporidium does transmit readily in the home 3377 
environment, and that person-to-person is the transmission pathway. This further 3378 
supports my assertion in Chapter 3 (Conclusions) that this pathway needs to be 3379 
considered for sporadic cases and warrants further investigation and work. 3380 
Demonstrating causation is fraught with problems, and more in-depth research 3381 
should take place prompted by this low-resolution piece of work. 3382 
Additionally, our limited understanding of the background prevalence of 3383 
asymptomatic infection of Cryptosporidium, and its effectors, make it difficult to 3384 
identify its importance in spread of disease in contained settings, and this study did 3385 
not reveal a large amount of asymptomatic infection. In addition, the study design was 3386 
not appropriate to demonstrate if an asymptomatic carrier was shedding oocysts or 3387 
was infectious to others in the home. However, previous work on secondary 3388 
transmission data has mainly stemmed initially from outbreaks, and data rarely 3389 
include laboratory confirmation of secondary cases (Johansen et al., 2014). The 3390 
epiCrypt study is unique in that it has allowed for an examination of secondary cases 3391 
at both species level and with further typing. A larger scale study of sporadic infections 3392 
would continue to build on our understanding of species-specific risks of spread and 3393 
also could examine heterogeneity in subtype populations (Morris et al., 2019).  3394 
Truly capturing secondary infections 3395 
Additionally, difficulties arise distinguishing between primary and secondary 3396 
infections as close contacts often have similar exposures (Johansen et al., 2014) and 3397 
the clinical course of Cryptosporidium infection can result in variable incubation, 3398 
symptoms, and onset between individuals making verifying person-to-person 3399 
transmission challenging. I had initially intended to use the clinical and exposure data 3400 
from the questionnaire to examine likely co-primary cases, but on reflection these 3401 
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data were just not adequate for this purpose. The design of the questions meant that 3402 
where participants left these blank, I was unable to assume this meant that they were 3403 
not reporting that exposure. It was curious that stool samples were returned more 3404 
readily than questionnaires, and in hindsight I think I would have perhaps had a better 3405 
return if the questionnaires had been shorter and more focused. By not being able to 3406 
accurately combine exposures and onsets to define possible co-primary cases, we 3407 
may be overestimating the amount of transmission, and actually, these additional 3408 
cases might be due to variable incubation periods from common exposures.  3409 
The considerable lag time from index symptom onset to household contact sample 3410 
collection meant that some infections may have been tertiary or beyond, as well as 3411 
secondary infections. We did initially consider a way to identify this in the first round 3412 
of study design. However, with limitations on the data access, time, and budget, and 3413 
the anonymity and self-reporting nature of the design (i.e. not having, for example, 3414 
Environmental Health Officers or research nurses able to go into the home and ask 3415 
questions) I felt that large matrix data collection like this would be tough to gather, 3416 
and may actually decrease participation. However, the primary research objective of 3417 
this study was simply to identify other infections in the home. Following this study, the 3418 
proposal will be for a more compact, but more in-depth, study, but initially this high-3419 
level, large-footprint study was undertaken as the first step to contribute to the 3420 
evidence base. Additionally, we had secured external funding for further genotyping 3421 
of some samples, which may support household level investigations of directionality 3422 
and population mixing, but due to the impact of COVID-19 this work has been delayed 3423 
indefinitely. 3424 
Study design biases 3425 
Some elements of the study design were retrospective in nature, as the index case 3426 
must have already been ill and been tested in order to be selected. As a result, some 3427 
ascertainment bias may lead to a skewed sample from which to choose the index 3428 
cases (The burden of illness pyramid). We may have captured more severe disease 3429 
as these cases are more likely to seek health care and be tested, and perhaps more 3430 
likely to test positive, given the variability of local testing methods (Error! Reference 3431 
source not found.) (Adams et al., 2018).  3432 
The study was designed using a model specifically for household transmission 3433 
studies, but these are most often applied in practice to respiratory disease. Of course, 3434 
respiratory illnesses have the advantage that you know the source of the infection in 3435 
a closed setting, but in this that is less clear. The sources of infection in this study, as 3436 
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well as being the index case, could additionally be ubiquitous or common sources. Of 3437 
course, other methodological biases do exist in this approach, mainly the inability to 3438 
estimate population-level rates or extrapolate results to a wider community, but in the 3439 
main this design suited the objectives of this work. I was interested in exploring 3440 
household transmission and examining if it was indeed likely to be driven on the 3441 
person-to-person transmission pathway, using associations in context to assess this. 3442 
It was not an objective of this study to present causation and thus, although not 3443 
perfect, this study design presented a feasible option in terms of resource, while 3444 
allowing me to meet the objectives of the study. The epiCrypt study has presented an 3445 
investigation of possible secondary infections in the home with some confidence and 3446 
with this I hope to be able to profile homes where this occurs, in order to springboard 3447 
further work. 3448 
A large proportion of our participants represented families with young children which 3449 
may have led to over-representation of these households. In addition, we might 3450 
expect that having young children who were ill, or being severely ill themselves, may 3451 
incentivise cases to participate in the study, more than adult, less severe cases. 3452 
Without the baseline data on all cases contacted and opting out or not returning study 3453 
materials there is no way to accurately measure this.  3454 
Case definitions 3455 
For ease the case definitions used were quite broad – anyone with compatible 3456 
symptoms in the prior two weeks to the index case, or two weeks after, was classed 3457 
as symptomatic and probably a case. In the restraints of this design it would be 3458 
impossible to know for sure (they would have to attend a healthcare facility AND get 3459 
tested AND have a positive sample) whether this additional case was truly secondary, 3460 
co-primary, recrudescence of a previous infection not picked up, or a previous 3461 
symptomatic case, now in a asymptomatic period of the same infection. These are all 3462 
limitations, but mostly logistical due to the size and scope of this study. For the 3463 
purposes of this work, identifying any additional reported or confirmed illness in the 3464 
home was enough, but these considerations would certainly be applied in a more 3465 
focused piece of work. 3466 
This study design did not allow us to look for other enteric pathogens that cause 3467 
diarrhoea, which could lead to both misattribution of index case illness to 3468 
Cryptosporidium, and to overestimation of Cryptosporidium household transmission 3469 
rates. We are not excluding from the study cases of Cryptosporidium where another 3470 
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organism has also been identified, and we would not be able to access that data. The 3471 
ethical approval only allowed testing of household samples for Cryptosporidium.  3472 
Estimating the prevalence of asymptomatic infection in households 3473 
As secondary transmission was the primary objective, the sample size calculation 3474 
was based on this. It is unlikely that this study was sufficiently statistically powered to 3475 
uncover the prevalence of asymptomatic infection, but there is little previous work in 3476 
the UK to estimate what the likely prevalence of this might be. 3477 
Time from onset of illness to identifying and recruiting the participants 3478 
One of the most noticeable issues I came across in this work was the time that 3479 
elapsed from identifying participants until their recruitment, which could create recall 3480 
bias, or affect the likelihood that people will take part. The most impactful of these 3481 
issues is arguably the time from illness to specimen collection, which might have 3482 
affected the detection of Cryptosporidium in the stool samples.  3483 
The study design only allowed for one sample from each household member, and not 3484 
re-sampling the index case, for time and resource reasons. This could lead to missing 3485 
intermittent shedding of oocysts and/or misclassifying recurring illness. The lab 3486 
confirmation rate was low, and perhaps with more samples detection would have 3487 
been better. 3488 
In this design, index cases were download from the system weekly, so that might be 3489 
10 days from specimen to our capture of the case (I know from a preliminary analysis 3490 
of the Public Health England surveillance data that the mean time from specimen date 3491 
(not onset) to showing on the surveillance system is six days). Following the invite 3492 
letter, it was a further 14 days at least before cases were contacted by the research 3493 
nurses. Participants were given two weeks to return their materials (questionnaire, 3494 
consent, stools), before a reminder was posted. The average time from index case 3495 
specimen date to retrieval of household samples might be six weeks or more. This 3496 
might have led to oocyst levels below a detectable level (Jokipii and Jokipii, 1986; 3497 
Chalmers et al., 2016). We tried to supplement this as far as possible by asking about 3498 
clinical symptoms of household members in the questionnaire and recording stool 3499 
consistency so some descriptive analyses could be carried out, even if 3500 
Cryptosporidium was not detected in stools. This consideration also led to the 3501 
implementation of the opt-out strategy for consent, which was a good and acceptable 3502 
way of reducing burden on both participants and study staff, perhaps increasing 3503 
uptake, and cutting out some time delay. Our recruitment uptake was good for a study 3504 
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of this nature, with around 18% of those contacted taking part and returning one or 3505 
more elements of the study packs. Interestingly, return of stool samples was better 3506 
than return of questionnaires. I think that some of the factors leading to this might 3507 
include the opt-out approach, which allowed participants to be contacted directly and 3508 
have the study explained to them personally.  3509 
We know that time constraints are a major contributor to issues in epidemiological 3510 
observational studies, and in research are due in some part to ethical considerations 3511 
(Wilson, Draper and Ives, 2008; Bennett, Dolin and Blaser, 2015). Although it is 3512 
imperative that as researchers, we retain the integrity and responsibility of our 3513 
research, oftentimes undertaking observation epidemiological studies is burdensome, 3514 
and the blanket application of rules can adversely affect the outcome of the work. A 3515 
paper discussing a way forward to improve collaborations is being prepared 3516 
separately.  3517 
Strengths of the work 3518 
A major strength of this study is that it identifies possible secondary cases of 3519 
Cryptosporidium to a species or subspecies level, informing differences in 3520 
transmission pathways and risk factors between genotypes. The results generated 3521 
here have demonstrated that Cryptosporidium is a considerable burden on the home, 3522 
identifying particular risk characteristics for targeted public health recommendations.  3523 
The complexity of the design of this study illustrates a novel approach to widespread 3524 
cross-organisational research and recruitment. Many lessons learned from approvals 3525 
processes and ethical delays are being digested and a paper is being prepared to 3526 
help change some of this for future work. The protocol for this work has already been 3527 
published (McKerr et al., 2019) and might provide a boiler plate template for some of 3528 
the further research. 3529 
Conclusions 3530 
In conclusion, despite limitations that restricted analyses, this work met the primary 3531 
objectives and demonstrated that additional cases of Cryptosporidium occur in over 3532 
a quarter of homes with a case. I was also able to quantify this. Spread is likely to 3533 
affect up to a third of the home and cause considerable burden of illness. This is 3534 
especially common where the index is a young child, with mums and other siblings 3535 
are most at risk of secondary infection, and where homes have cases of C. hominis. 3536 
Eighty percent of those additional cases do not seek any help for their illness, and for 3537 
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those that do, we may not even detect them as their illnesses are shorter, and testing 3538 
varies locally. Thus, we are likely under ascertaining cases of sporadic illness, under 3539 
examining person-to-person spread, and under-advising where we could be giving 3540 
specific clinical advice to high-risk households. Systematic changes that would 3541 
support better examination of this should include 100% speciation of Cryptosporidium 3542 
samples, fed routinely back into surveillance systems and local health protection 3543 
teams across England and Wales, and the consideration of specific clinical advice on 3544 
prevention for high-risk homes. This might include managing the patient’s 3545 
expectations on the length of illness, and the possibility of relapse, and giving specific 3546 
advice on preventing person-to-person spread (Chalmers and Davies, 2010). 3547 
An opinion………  3548 
Anecdotally, the research nurses in this study consistently reported that patients they 3549 
spoke to the telephone complained of terrible burden of illness on the home. They 3550 
often reported that others had been ill, that they (parents in particular) were astounded 3551 
and surprised at how ill their children had been and how much time and effort it took 3552 
to look after them and taking time off work. The considerable burden and nastiness 3553 
of this illness was often the impetus for these families to take part – in part evidenced 3554 
by our decent uptake and good response to returning stool specimens. Often parents 3555 
would claim that they “didn’t want this to happen to another child or family”. A review 3556 
of Cryptosporidium infection by Chalmers & Davies in 2009 included some 3557 
experiences from a patient and a parent of a case: the review reported long-term and 3558 
debilitating illness of several weeks alongside a period of worry and anxiety, not being 3559 
able to look after children, and recrudescence of symptoms two weeks after apparent 3560 
resolution (Chalmers and Davies, 2010). Whilst often dismissed as a mild and self-3561 
limiting infection, the burden can be considerable. I think that there a couple of things 3562 
that we, as public health professionals, could do here. Another piece of work, deeper 3563 
than this one, and perhaps using mixed methods, exploring physical, mental, and 3564 
economic burden of this disease would be a welcome examination. Also, short-term, 3565 
this work could help support clinicians to prepare patients, and their families if 3566 
appropriate, for the likelihood of a long and possibly unpleasant illness. This might 3567 
help with the management of these infections, in the family environment in particular 3568 
and give parents a chance to prepare. Longer-term, this would require close working 3569 
with laboratories to ensure all submitted stools are tested for Cryptosporidium and 3570 
any positive samples are expedited to the CRU for species identification at least. 3571 
Speciation might now not just be a requirement for research, but actually for public 3572 
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health action, intervention, and advice. Recently, changes to surveillance systems 3573 
means that results of speciation are fed back into surveillance data, but a reliable 3574 
pathway to health protection teams for action is still unavailable. 3575 
Any participants who did get in contact with me to ask questions or confirm their 3576 
participation were interested, involved, and keen to take part. In the questionnaires, 3577 
participants reported considerable burden of this illness on the home overall and were 3578 
really eager to be active in research that may make a difference. This does somewhat 3579 
jar with some of the detailed ethical considerations and access obstacles that arose 3580 
during the design of the study which led to a very difficult navigation of systems, 3581 
complex design pathway for getting data from patients and recruits, and excess time 3582 
delays which certainly had an impact on the results. This was largely down to the time 3583 
taken to navigate certain ethical requirements such as invitation letters directly from 3584 
health organisations prior to study invites with a minimum two week opt out period. 3585 
Whilst it is important as responsible researchers that we implement responsible 3586 
research designs, I found some aspects of the process challenging due to an inability 3587 
to appreciate the rationale for some of the requirements, which I felt, were barriers to 3588 
progress. I had undertaken a small piece of work looking at public involvement with 3589 
research studies as part of my NIHR funding requirements (Appendix 7). Accessing 3590 
data for research by well-trained staff in trusted organisations is generally well 3591 
received and acceptable to the public. Personally, I think I would like to have seen 3592 
some active researchers on the panel for the ethics committee: they gave excellent 3593 
advice and made useful suggestions based on their plethora of extensive clinical 3594 
experience, but demonstrated a lack of understanding about the ‘doing’. I think the 3595 
addition of researchers on ethics committees might be a route to attaining a better 3596 
balance for this. Additionally, I felt that early input from the ethical committee, or a 3597 
representative, in the infancy of the protocol would have minimised a lot of ineffective 3598 
and often fruitless rounds of review. I was lucky – I had a great supervisory team with 3599 
lots of experience on this, and yet still, many, many problems arose that took over a 3600 
year to negotiate and navigate. When thinking about PhD programmes it is important 3601 
for teams to consider this real burden and ensure that it does not get in the way of 3602 
good, sound epidemiological studies.   3603 
Further work 3604 
Further work should expand on this research, which was only intended to be 3605 
exploratory and low resolution. A better and closer examination of homes alongside 3606 
a methodology to identify true secondary transmission more accurately should be the 3607 
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next step. This work should be designed in a way that allows correlations to be 3608 
extrapolated more widely, and it is important that these are facilitated by all public 3609 
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The objectives of this overall piece of work and my attempts to address these are 3631 
outlined below. 3632 
Objective 1 3633 
To describe the distribution and burden of this infection in the UK, as well as 3634 
considering detection and approaches to testing that underpin the surveillance 3635 
data. I presented the most recent surveillance data and included exposures examined 3636 
in outbreaks, in particular. The main pathways were water, with both drinking and 3637 
recreational exposures, animal contact, food, and person-to-person, in various 3638 
settings. Outbreaks related to all of these have been reported, and the frequency of 3639 
some are changing. However, we are not entirely sure if the contribution of these 3640 
appears the same for sporadic disease. Cryptosporidium infection, and subsequent 3641 
disease, can present in all groups of people, although the greatest burden occurs in 3642 
the most vulnerable. The incidence of this infection is significant in England and 3643 
Wales, but inconsistencies in testing do exist, leading to possible presentation and 3644 
testing biases in specific groups (immunocompromised, younger children). The 3645 
results from the laboratory audit were able to confirm this, but also suggest that 3646 
changes to practices might see these inconsistencies reduce in the near future. 3647 
Additionally, I reported that submission of samples for genotyping and 3648 
characterisation is variable, leading to biases in our understanding of the different 3649 
contribution of transmission pathways to species-specific disease burden.  3650 
Objective 2 3651 
To examine and present exposures most associated with sporadic disease, and 3652 
calculate how much these contribute to infection. I conducted a literature review 3653 
to describe the reported exposures examined and associated with sporadic disease 3654 
in industrialised countries, and highlight any pathways to infection that should be 3655 
further considered. Results from the systematic review reflected the bimodal age-3656 
related pattern that Cryptosporidium follows in UK; a peak in young children, and a 3657 
further peak in adulthood, possibly driven by close contact with cases, with exposures 3658 
such as parenting and caring activities responsible. I was able to conclude that the 3659 
person-to-person transmission pathway is often, but not thoroughly, investigated. 3660 
This pathway represents a consistent exposure for infection. This seems to apply 3661 
particularly to the home environment, which is increasingly understood to be a 3662 
significant setting for spread of Cryptosporidium infection.  3663 
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Objective 3 3664 
To explore transmission in the home environment, and calculate the burden 3665 
this might have on people in the home, considering longevity and severity of 3666 
illness. Attempts at quantifying this in The epiCrypt study revealed that additional, 3667 
and mostly uncaptured, cases of cryptosporidiosis might occur in around a quarter of 3668 
homes with an index case. Spread of this infection in the home environment 3669 
represents a considerable burden, individually and societally. Almost two additional 3670 
cases are likely to occur, on average, in households with an index case and almost a 3671 
third of people in the home could be expected to become ill. Impacts on the family 3672 
can be great, with mums and siblings (often children) making up the burden of 3673 
secondary cases. It is plausible that the driver here is direct contact, in a caring 3674 
capacity; undertaking activities which likely put the main carers (often females) in the 3675 
home at particular risk. Homes reporting spread of infection are most often those with 3676 
C. hominis cases, and those with children under five years old. This knowledge can 3677 
help support targeted public health measures.  3678 
This work did not reveal any considerable proportion of asymptomatic infection, with 3679 
a detected prevalence of 2% in the study population. It seems unlikely that 3680 
asymptomatic carriage contributes to spread of infection in the home environment, 3681 
although there are specific limitations with identifying true asymptomatic carriage and 3682 
specifically designed studies are necessary to accurately measure this. Using 3683 
additional clinical indicators, such as stool consistency, has no correlation with 3684 
microbiological confirmation. 3685 
What does this work add overall? 3686 
 This work demonstrated that additional cases of Cryptosporidium occur in 3687 
over a quarter of homes with a case. This is likely to affect up to a third of the 3688 
home and cause considerable burden of illness. This is especially common 3689 
where the index is a young child, with mums and other siblings most at risk of 3690 
secondary infection, and where homes have cases of C. hominis. 3691 
 3692 
 We are likely under ascertaining cases of sporadic illness and under 3693 
examining person-to-person spread. The work supports recognition of this 3694 
pathogen as burdensome and of considerable significance in 3695 
immunocompetent individuals. Person to person spread should be considered 3696 




 Using additional clinical indicators such as stool consistency has no 3699 
correlation to microbiological confirmation. I have recommended that we 3700 
continue to support the removal of criteria for testing, and test all stools for 3701 
Cryptosporidium.  3702 
 3703 
 The protocol for this work can provide a boilerplate template for complex 3704 
cross-organisational research. 3705 
What are my recommendations? 3706 
 To eliminate stool consistency as a testing inclusion criterion in local 3707 
laboratories and to support testing of all stools submitted for the investigation 3708 
of gastrointestinal pathogens.  3709 
 3710 
 Systematic changes to surveillance to include 100% speciation of 3711 
Cryptosporidium samples, fed routinely back into local health protection teams 3712 
across England and Wales.  3713 
 3714 
 The consideration of specific clinical advice on prevention for high-risk homes 3715 
to be added to public health response documentation. High-risk homes should 3716 
be considered those with cases of C. hominis and/or children under five years 3717 
old. This might include managing the patient’s expectations on the length of 3718 
illness, and the possibility of relapse. 3719 
 3720 
 A further study with a specific methodology to identify true secondary 3721 
transmission with increased accuracy. Work should be designed to allow 3722 
correlations to be extrapolated more widely, exploring exclusions of co-3723 
primary cases. This might include working with partners on the production of 3724 
protocols which can be triggered during outbreaks, to follow up homes where 3725 
we know contacts have not been exposed to the source of infection. 3726 
 3727 
How might some of the limitations be addressed in further work? 3728 
It is quite possible that asymptomatic infections contribute somewhat to spread of 3729 
infection on this pathway, although these were tricky to determine in the design of this 3730 
work. I would like to see a specifically designed study, looking at this in the general 3731 
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population and in homes with cases. This would need to specifically to consider the 3732 
timing of specimen collection, and perhaps utilise follow-up and repeat sampling. 3733 
The systematic review was a large and demanding piece of work, that ultimately grew 3734 
beyond the scope of this work and restrictions were enforced. It would be interesting 3735 
to see this work followed up: a piece of research explicitly considering differences 3736 
between sporadic and outbreak cases in terms of transmission pathways would be 3737 
welcome. I am intending to take this forward myself in the future. 3738 
Variations in testing practices can have an impact on our understanding of the 3739 
incidence of this infection, and our confidence in the surveillance data. The audit I 3740 
undertook had a low response rate, and I would be keen to follow up on this work 3741 
later. Ongoing flexibility and evolution of the guidance for standard practice is key for 3742 
oversight of this pathogen in England and Wales, and I would hope that the upcoming 3743 
publication of the laboratory audit, and any further work, would be an impetus for this. 3744 
Despite an attempt at detailed collection of data in The epiCrypt study, some of it was 3745 
unusable for detailed examination of the home. Nonetheless, there was some 3746 
anecdotal evidence for differences in risk of secondary infection according to role in 3747 
the home. I would be keen to work with qualitative researchers to design a mixed-3748 
methods study to examine the impact of this infection in families; perhaps measuring 3749 
patient experiences, assess disproportionate gender burden, and economic impact in 3750 
England and Wales. 3751 
Some additional characterisation of samples was negatively impacted by the 3752 
occurrence of the global COVID-19 pandemic, which affected staff time, access to 3753 
equipment, and organisational priorities. The samples needed for WGS are prepped 3754 
and complete, and the CRU and I are hoping to continue with this work later. This 3755 
might allow for further understating of the populations of Cryptosporidium in this 3756 
study, and in homes with spread. 3757 
 
Personal reflections on the PhD experience 3758 
I began my PhD experience late in my career, and perhaps in my life compared to 3759 
most. It began with my desire to build a research piece alone, with my own hands, 3760 
and a massive leap of faith from four potential supervisors that I could actually do it! 3761 
I started out nervous, and tried everything to remain in my comfort zone. I ignored 3762 
advice that tried to impress on me the difficulties in implementing an observational 3763 
study. I thought I knew better. Well, as the process went on, I realised I really didn’t! 3764 
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And far from keeping me in my comfort zone, with every step I was further and 3765 
further at sea. I had to quickly navigate ethics procedures for two countries, get staff 3766 
from other organisations to engage with this on nothing but goodwill, and manage 3767 
many, many disagreements in between. I had to learn to stand on my own two feet 3768 
pretty quickly. Add to this a systematic review, which in hindsight was way too big 3769 
for this work (learning point!), changing reviewers once, and losing two supervisors 3770 
(but who remained ever on hand, much to my gratitude). 3771 
But, I loved it. I was always stretched. Always pushed. I was given every opportunity 3772 
to make more of my PhD than just a thesis. I went to conferences, published 3773 
papers, wrote funding bids for public engagement ideas and delivered them all over. 3774 
I was given time to pursue, and achieve, my FLTHE (Foundations for Learning and 3775 
Teaching in Higher Education) qualification to teach. This PhD is bigger than the 3776 
sum of its parts for me. Whilst I feel proud of this thesis, and especially the epiCrypt 3777 
study, I believe that I have embarked on a journey that goes beyond this; of self-3778 
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Appendix 1: Laboratory audit questionnaire 
An Audit of Laboratory Practices for Cryptosporidium Diagnosis in England 
and Wales 2018/19 
1. Name    
 
2. Position  
 
3. e-mail address   
 
4. Laboratory name   
 
5. Laboratory address   
 
6. Laboratory region  (highlight or delete) 
North of England - North East   
North of England - Cumbria & Lancs   
North of England - Yorks & the Humber   
North of England - Greater Manchester 
North of England - Cheshire & Merseyside   
Midlands & East of England - Lincolnshire, Leicestershire, Nottinghamshire & 
Derbyshire  
Midlands & East of England - W Midlands 
Midlands & East of England - Norfolk, Suffolk, Cambridgeshire & Essex  
Midlands & East of England -S Midlands & Hertfordshire  
London (all) 
South of England - Sussex, Surrey & Kent  
South of England - Thames Valley 
South of England – Wessex 
South of England - Devon, Cornwall & Somerset 
South of England - Avon, Gloucestershire & Wiltshire 
Wales 
 






8.  Stool samples tested for Cryptosporidium are: 
All stool samples   
All non-formed stool samples   
All except inpatient for >3 days (3-day rule)   
Other criteria applied  
 
9.  If you have answered 'other' and apply criteria, then please answer the rest 
of the questions on this page, indicating under which criteria you would test: 
Choice based on history and given clinical details 
Yes   
No   
 
If Yes, please specify the history and clinical details that you use in your testing 
criteria, e.g. overseas travel, immunocompromised etc.  
10.  In specific age groups 
Yes   
No 
 
If Yes, please give age groups in which you test/upper and lower range  
 
 
11.  Other criteria not already recorded (check all that apply) 




Exposure history   
If requested 
Other, please specify 
Testing methodology 
 
Please indicate which of the following methods you currently use as the 
primary test for Cryptosporidium within your laboratory (there is a question 




12.  Enzyme immunoassay (EIA) 




If Yes, Please specify which EIA kit you use 
 
 
Do you confirm positive reactions? 
Yes   
No  
 
If Yes, specify how  
 
 
13. Polymerase chain reaction (PCR) 
Yes   
No   
 
Please specify which DNA extraction kit or platform you use 
 
 





14.  Bright field microscopy stain e.g. modified Ziehl-Neelsen or Kinyoun 
Yes   
No   
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16. Please give details of any other diagnostic method you currently employ 
for Cryptosporidium   
 
 
17. Have you recently made any changes to the test method? 
Yes   
No   
 
If Yes, please indicate the relevant method and add date if known, below  
 
 
18. Are you planning any future changes to the test method?      
Yes   
No 
 




If other, please specify 
 
 




If Yes, which of the following will be tested?       
All stool samples 
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All non-formed stool samples 
All except inpatient for >3 days (3-day rule) 
Other 
If other, please specify 
 
     
When are these changes due to take place?    
   
 





If Yes, In what circumstances do you send positive Cryptosporidium samples to the 
reference lab for genotyping? 
Highlight all that apply 
All positive samples are sent routinely 
Only in an outbreak situation 
At the request of a Health Protection Team 
Never 
Other 








If No, If you don't presently send samples for genotyping, would you be willing to do 
so, either when they are diagnosed or in batches?  
Yes – when diagnosed 
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Appendix 2: Systematic review protocol manuscript 




Appendix 3: Final search terms for systematic review 
Question components and search terms  Term type  
  
Free      Mesh  
Boolean 
operator  
Population: cases of cryptosporidiosis  
1 cryptospor*  
2 humans  
        X  
  
                    X  
  
AND  
 3 1&2  
Exposure: risk factor(s)  
4 epidemiolog*  
5 risk factors  
6 exposure  
7 transmission  
8 association  
  
        X  
        X  
        X  
        X  





 9 or/4-8  
Outcome: study endpoints  
10 cohort  
11 case-control 12 “case 
control”  
13 case-crossover 14 
“disease outbreaks”  
15 meta-analysis  
16 longitudinal  
17 ecological  
  
        X  
        X  
        X  
        X  
                    X  
        X  
        X  










Appendix 4: Minimum data set for extraction for included 
papers in systematic review 
Bibliographic detail Study detail 
Name of reviewer Study design 
Date of extraction Number of cases reported 
Publication type Age/sex cases/participants 
Country of origin/language 
Case definition (& any known 
co-infections) 
Study title Definition of exposure(s) 
Names of authors Definition of activities 
Journal/source reference Species identified 
Year published Incubation period 
  Exposure window(s) 
Study outcomes General methodological 
Number (%) exposed among groups  Confounders 
Types of exposures Likely biases 
Comparator(s) (well controls, other infection)   
Selection and recruitment methods   
Availability of appropriate controls (from the 
same source population as the cases)   
Interview methods   




Appendix 5: The epiCrypt study protocol manuscript 
Please see attached additional file
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Appendix 6: The epiCrypt study invite letter to index cases 
 
PUBLIC HEALTH ENGLAND OR WALES HEADED PAPER 
 














Dear Name/Parent/Guardian of Name 
 
The epiCrypt Study – investigating how Cryptosporidium infection spreads at 
home 
 
We are inviting your household to take part in a study because you/your child recently had 
the Cryptosporidium bug. You may have already been contacted by someone from Public 
Health England/Wales or your local environmental health team, and asked to fill in a 
questionnaire.  It is no problem if you have already done this, you can still take part in this 
study. 
If you have not been made aware of this diagnosis yet you can contact your GP or clinician 
who took your sample, to confirm this with them. 
The study  
We are a team of researchers at the University of Liverpool, Public Health England, and 
Public Health Wales who are interested in finding out more about the spread of a 
common tummy bug called Cryptosporidium. 
Some people pick up the bug and feel fine. Other people can feel poorly for some time. 
We want to find out if Cryptosporidium spreads between people in the same house, and 
look for clues as to how this might happen. This will help us to stop others getting sick. 
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Why have we chosen your household? 
You or your child have recently had Cryptosporidium. We are asking everyone who lives 
in the North West of England or in Wales, who has recently had the Cryptosporidium bug, 
to take part along with other people in their household.   
What we would like you to do 
We would like to test the poo of everyone else in your household to see if anyone has had 
Cryptosporidium, even if they haven’t been sick. You will not need to gve another poo 
sample as you have already been tested. 
There is also a short questionnaire to fill out asking some general questions about 
your/your child’s illness and your household. 
Further information 
A member of our team from the National Institute for Health Research (NIHR) Clinical 
Research Network will be in touch in the next few days to explain the study and chat things 
over. This gives you a chance to take your time to decide if you want to take part and talk 
to us about the study itself.  
You may be contacted by post if we cannot reach you. 
If you would rather not be contacted about this study, you can let us know by: 
 email: FES.NorthWest@phe.gov.uk OR Surveillance.data@wales.nhs.uk 
 ‘phone:  0344 225 0562 - Option 6 [Field Epidemiology Service] OR +44 2920 10 
4488 
 post: Just return the slip below in the envelope provided 
Quote your study ID when you contact us. 
If you have any further questions please feel free to contact a member of the team on 




Dr. Roberto Vivancos 
Consultant Medical Epidemiologist 
 
Dr Christopher Williams 
Consultant Medical Epidemiologist 
……………………………..………………………………………… 
 
ID      |____|____|____|____|____|____|____| 
 




Appendix 7: The epiCrypt study - justification of recruitment 
approach and short PPI survey 
 
Justification of approach to recruitment 
Our approach to the recruitment process has been driven by necessity and feasibility, 
and previous research supports the acceptability of this method. In addition, following 
valuable comments from the CAG on the application, we undertook a short survey 
among the general public and specific PPI groups to gauge general attitudes toward 
accessing data prior to consent, to support recruitment to research. 
This document outlines the main considerations, in brief, in our decision to recruit 
using the methods described in the protocol. We feel that our approach to recruitment 
is well established and understood, and is supported not only by previous research in 
other settings, but also by the small PPI activity undertaken for this piece of work. 
Ethics committee feedback 
Whilst the researchers recognise the importance of patient and public involvement 
(PPI) in driving and shaping research, the scope for a large PPI study within this 
project, as part of a 3-year doctorate, is limited. The researchers were questioned on 
their reasons for the absence of engagement (The NHS REC Committee - Liverpool 
NE REC – committee meeting 19 April 2018) and outlined that scope, time and 
resources, including expertise in the methods, were significant limiting factors. After 
discussion on the resource requirements for this, and patient response and 
engagement with similar studies20, the committee were satisfied that this was not 
feasible or required. In addition the CAG recognised that as detection of 
Cryptosporidium was retrospective and undertaken by laboratory staff, there was no 
opportunity to consent individuals at the time of diagnosis and the recruitment 
process could not be achieved without access to confidential patient information. 
However, the CAG report contained useful comments and suggestions on this, and 
recommended that we gauge the feeling on his approach by testing the acceptability 
of using confidential patient information without consent in order to facilitate the study 
recruitment procedures.  
                                               
20 Studies recruiting based on disease surveillance are common for GI infections, and many projects have 
taken this approach – the methodology for the epiCrypt Study has been influenced by design aspects of 




Considerations when drafting the protocol 
We considered the acceptability of many recruitment process in our decisions at the 
protocol drafting stage of the project and explored several options. We used previous 
literature and experience of other studies to help us to achieve the best model for 
recruitment, which balanced the data needs with patient choice. Several publications 
exist which support our approach to recruitment and confirm that although not always 
the preferred approach to consent, such an approach is nonetheless acceptable. 
Because our inclusion criteria, and indeed means of identifying a case, can only be 
met using laboratory records it is essential that we access these records in order to 
get contact details to approach potentially eligible participants. This step is necessary 
as cryptosporidiosis is only confirmed via laboratory testing and as such there is no 
other method of identification of cases available to the study team. We designed our 
approach based on several key factors known to be important considerations for the 
public when engaging in research: 
1. General acceptance of accessing data, but with opt-out routes 
While generally the public support health research, some research does suggest that 
most people would find data use without any possibility of objection, to be 
unacceptable (Willison et al., 2008). However, people also tend to recognise that an 
approach of ‘consent for each use’ is burdensome for both researcher and participant, 
and can hinder research. In addition, a recent study in England and Wales (Taylor 
and Taylor, 2014) reported that people who would prefer to be asked explicitly before 
data were would however accept an ‘opt out’ model of consent if the reasons for not 
seeking explicit consent are clear. In this work, a model similar to ours emerged as 
the preferred and most acceptable model, where explicit consent is not necessarily 
disclosed but participants are given a route to opt-out, for sufficient/any reason. In our 
model, participants are given opt-out options at each contact and it is emphasised 
that they can withdraw at any time, even if they have provided information, this can be 
deleted at any point. 
2. Differences in acceptability of accessing data, with and without explicit 
consent, according to who is accessing it 
Research suggests that in general the public do have some concerns relating to the 
appropriateness of access, irrespective of the model of consent adopted. But with a 
less favorable but acceptable model, if an individual’s data are to be used without 
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explicit consent, then it appears to be considered important that research was carried 
out by somebody owing a duty of confidentiality: 
“We are talking about data that is only going to researchers. These 
researchers inherit a duty of confidentiality by dealing with this. If it was being 
passed on to a third party who did not have a duty of confidentiality under the 
NHS, then that would be very different”. [TH7, Group 3] (Taylor and Taylor, 
2014). 
Other work suggests that alternatives to explicit consent may be acceptable if 
participants are confident that data are used by persons, and for purposes, that they 
trust and accept as reasonable (Wilson, Draper and Ives, 2008) 
In our methods, we do not use any existing data prior to consent, and are only 
accessing for purposes of recruitment contact details. In addition we have specifically 
set this up so that the contact details are shared with NHS staff who are researchers 
but with a clinical background, in order to improve acceptability and instill trust in 
participants. Evidence from a pan-European survey looking particularly at the transfer 
of contact details to a research team reported that the acceptance of this scenario 
appeared to be based upon the choice patients had to return a questionnaire once 
contacted by researchers, and that only names and addresses were being released 
(Patil et al., 2016). Some concerns were expressed around ensuring and believing in 
the credibility of the “researcher” amid concerns about their duty of confidentiality. It 
seems that NHS and/or clinical staff are more acceptable to the public when in a 
model of accessing data for contact, prior to consent, and using a “research nurse” to 
contact patients was favourably greeted. In our model, only NHS/Public Health staff 
access laboratory records initially – then if the case does not opt out via the 
mechanisms provided, their details are shared only with NHS research nurses in 
order that they can be contacted. The University research staff only access data 
following consent, and only the data that the participant provides themselves. 
3. Participants’ study information 
A 2008 paper recommended that good practice for recruiting primary care patients 
into research studies should include detailed patient information that describes the 
proposed research and emphasizes that withdrawal of consent, or refusal to 
participate, will not affect their clinical care (Wilson, Draper and Ives, 2008). Our study 
pack contains a tri-fold pamphlet outlining the study, as well as links to the study 
webpage hosted by NHS Wales. There is also a cryptosporidiosis health advice 
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leaflet and participants are expressly informed that their rights to health/clinical care 
are not affected by any decision about participating in the study. They are also given 
several points of contact and means of contacting the study team and chatting 
anything over. The research nurses’ call also gives participants another opportunity to 
discuss and understand the study and again opt out of participation or further contact 
if they choose. 
 
4. The trust in the confidentiality of patient data and security of systems.  
The pan-European survey showed that there is general support for using data for 
research, and storing more detailed electronic health data was generally preferred, 
but respondents were averse to wider access to and sharing (Patil et al., 2016). 
Another study looking at attitudes of lay persons in South Wales, UK., reported that 
unauthorised access to data by external agencies was a specific, common fear 
(Robling et al., 2004).  
Our model of recruitment is set up using only established, secure internal systems. 
Any data transfers (contact details) are supported by contracts and data sharing 
agreements which have been reviewed and authorised appropriately. The methods 
for accessing patient details, transferring, and recording opt-out preferences are laid 
out in the protocol and staff members will all be trained in the process. Data are not 
used for any other purposes, nor are they retained beyond required terms, and no 
data are shared with any other person/study/team. Recruitment data are only 
accessed by existing NHS/PHE trained staff bound by confidentially and who would 
access and see the records anyway. There are agreed data transfer protocols in 
place between PHE/PHW and the Clinical Research Network. 
Comments from the CAG and subsequent PPI 
The CAG report contained useful comments and suggestions on this, and 
recommended that we gauge the feeling on his approach by testing the acceptability 
of using confidential patient information without consent in order to facilitate the study 
recruitment procedures.  
We drafted a short survey which outlined the approach to recruitment and the 
framework of the study. We accessed a lay PPI group from the Infection and Global 
Heath panel at the University of Liverpool, and one from Health and Care Research 
Wales. The link was circulated via email and participants were also encouraged to 
email or call the research team directly if they had specific comments. Participants 
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were asked to think generally about the method of recruitment and how they felt 
about this approach, about who was accessing the data, and about what information 
materials they would like to be provided with if they were taking part. 
This was a quick approach to gathering some feedback in support of our work. We 
were unable to gather personal data on participants and so cannot make any 
conclusions about representativeness or sampling. In addition the survey questions 
and responses have been simply posed and analysed. A large scale PPI study, 
although suitable, is beyond the scope of this study and far outside the resource and 
expertise available to this team. Nonetheless, it is hoped that the responses will help 
support the CAG and ethical approvals, and also may help buttress our recruitment 
process decisions, and study materials. 
These data have been analysed as of 12/06/2018. 
More responses may be due in and in addition, the study lead has two further 
appointments face-to-face with PPI groups at the University of Liverpool, and at Royal 
Liverpool and Broadgreen Hospital. These group discussions may well reveal further 
thoughts and comments, and the team will put these together in a broader document 
and submit these with the study write-up. We were unable to access these meetings 
prior to the CAG deadline of 30/06/2018. 
Survey users were asked to read and consider the scenario and then answer 
questions, with the option of additional comments. 
There were also some broader, free-text questions reported at the end. Individual 
results are available in the appendix. 
In general the feeling echoes some of the previous research we have touched upon.  
It is generally considered acceptable to access data for recruitment, especially in 
order to support much needed research. However, considerations and worries include 
the person accessing data, with NHS staff, or at least those with a clear 
science/medical link, generally viewed as more acceptable. Contact from researchers 
(non-NHS) is generally not viewed as favourably. All users reported that they would 
be happy to take part in this piece of work if contacted. Participants would like to 
receive as much information as possible and would like health and disease advice 
and information. One user stated in particular that they would like to see the 
benefits/objectives of the research and the proposed dissemination. We are happy 




Extracting cases from surveillance data is often normal practice for gastrointestinal 
disease research and techniques are well studied and agreed. 
 
In this study, participants can only be identified using surveillance data as 
Cryptosporidium is diagnosed via laboratory confirmation. No identifiable data will be 
shared with the University study team members until consent is given. Only those 
staff in NHS or in public health will be able to access contact data and data are 
managed and held securely and in line with security and protection requirements of 
each organisation. We feel that this attention to detail and integrity of our approach to 
accessing personal information from surveillance data helps to support acceptability. 
 
The study is low risk but has many benefits – results may highlight the possibility of 
secondary illness pathways in this disease: Participants may be better placed to stop 
future spread of illness in the home. 
 
By identifying and understanding secondary transmission, public health measures 
can be reiterated or improved to stop onward transmission so participants are 
involved in supporting longer-term research and knowledge 
 
We feel that our approach to recruitment is well established and understood, and is 
supported not only by previous research in other settings, but also by the small PPI 
activity undertaken for this piece of work. 
 
We will continue to work on this PPI activity; we aim to present this further and gather 




Appendix A: The survey questions and current results 
Participants were given this scenario 
SCENARIO FOR RECRUITMENT TO A RESEARCH PROJECT    
This research project is about Cryptosporidium. 
This parasite causes over 4,000 cases of diagnosed illness in England and Wales 
every year. It particularly affects children and can spread between family members. 
 
This project will be a year-long study to identify secondary transmission in 




We will recruit 400 cases across England and Wales, ask general questions about 
their household composition and behaviours, activities, and pets. We will test stool 
samples from consenting household members. 
 
Cryptosporidium is only diagnosed by testing a stool sample. This positive lab report 
then goes into a national disease surveillance database. 
 
So, in order for this research team to identify potentially eligible study participants, 
we need to get all the lab reports of Cryptosporidium cases in England and Wales, 
and get their name and contact details from the surveillance records. This way, we 
can contact these cases to ask them if they are interested in taking part in our study. 
The data are only downloaded and viewed by existing, trained NHS or Public Health 
staff – not researchers at the University. 
Cases will be then contacted initially by research nurses (part of the NHS/National 
Institute for Health Research). 
These data are only accessed for contact purposes and no data are retained or used 
for research. Staff only see the necessary contact details and all access will have 
been approved by the relevant ethics committees. 
After the case is contacted, if they want to participate they then fill out a consent 
form to take part and we collect fresh data from a questionnaire. 
 
In order to support good, transparent research, and alongside our CAG/ethics 
applications, the research team would like to understand the views of the public on 
this approach. 
Think of the scenario you have been given and then say how much you agree 
with the statements 
 Strongly 
Agree  




It is acceptable for a 
member of NHS staff to 
access your records so 
that they can contact you 
about a study you would 
be eligible to take part in 
5 2 0 0 0 7 
It is acceptable for a non-
NHS researcher to access 
your records so that they 
can contact you about a 
study you would be 
eligible to take part in 
3 1 2 1 0 7 
It is acceptable for a 
researcher to access your 
existing records and use 
that data for research 
purposes, without seeking 
consent 
3 0 1 2 1 7 
I would be happy about 
participating in this 
research if I was contacted 
by Public Health England 
or Public Health Wales 
6 1 0 0 0 7 
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I would feel more 
comfortable with NHS staff 
accessing my data and 
contacting me than non-
NHS researchers 
3 0 2 1 1 7 
I have heard of disease 
surveillance systems 
3 3 0 1 0 7 
I understand that when I 
have a lab test the results 
go into national 
surveillance databases 
2 5 0 0 0 7 
This method is acceptable 
in an outbreak or 
emergency situation 
4 3 0 0 0 7 
This method is acceptable 
if there is no other way of 
identifying potential 
participants 
4 2 1 0 0 7 
I trust those in our health 
and research 
organisations to handle my 
confidential data with 
respect 
4 2 1 0 0 7 
This approach is 
acceptable (Accessing lab 
records, contacting and 
asking if you would like to 
take part.  If so, then taking 
consent through a consent 
form) 
4 2 1 0 0 7 
Free-text responses 
How do you feel (in general) about researchers accessing data without explicit 
consent in order to identify potential study participants?  
 This should not happen, these records are confidential and this should be 
respected no matter the importance of the research. 
 As long as my details are not shared further 
 If this is the only way to identify them then I think this is acceptable and 
appropriate, especially if you are seeking consent later 
 If the data is there and used correctly And anonymously I think it’s ok 
 I feel that such research is done in the public interest and so am happy with 
the method 
Is this more or less acceptable in this case where there is no other way of 
identifying this cohort of cases?  
 For this to be done by NHS staff I feel is more acceptable, but this should not 
be from anyone else. 
 Yes 
 More acceptable 
 More (acceptable) 
 More acceptable 
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How do you feel about who accesses your data? Does it matter? Would it 
matter to you if non-NHS research staff could see your records? Is it more or 
less acceptable if it is clinical and/or NHS staff?  
 Yes because it is the principal of privacy. 
 As long as it’s for research purposes and identifiable details are not shared 
further 
 NHS don’t always has the resources to conduct these surveys so it is only 
natural that outside agencies need to complete them. Would prefer ones who 
have a medical/scientific background 
 It is more acceptable if it is clinical or NHS staff ordinarily. However, I have an 
understanding that such staff have not got the time to do this important work 
and so a clear letter of explanation in lay terms to explain why I am being 
contacted I would feel re assured. 
If you were taking part in this study, is there anything specific you would like to 
see included in your study information pack? Any certain documentation or 
explanations? Would you rather have posted materials or speak to a research 
nurse on the ‘phone or in person?  
 I would like both an information pack and a contact with whom I could discuss 
any concerns or questions relating from the information pack 
 How to control the spread within a family. How does one become infected in 
the first place? How can I protect myself and my family? 
 Probably on the phone or post. 
 clear letter of explanation in lay terms to explain why I am being contacted 
Additional thoughts from others who did not fill in the survey but contacted us 
directly 
 “A person’s consent and confidentiality should always be 
paramount.  However, I don't see that contacting people to ask their consent 
to be involved is a problem.  They have the right then to say 'yes' or 'no'.  I 
also feel that people would be more inclined to be participants in research if 
they were firstly approached by NHS staff, rather than researchers”.   
 “If I was taking part in a study myself, I would like information as to what the 
study hoped to achieve (i.e. the outcomes), what my participation would 
involve, and how the results would be disseminated”. 
 “Even if there was no other way to conduct this study, I would still have an 
issue with patient confidentiality and data protection - I would like to be asked 




Appendix 8: The epiCrypt study participant study packs 
Please see attached additional file for full study pack
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Clinical Research Network 
NWC 
2nd Floor  





Dear -------------/parent/guardian of --------------------------, 
Re: The epiCrypt Study – investigating how Cryptosporidium infection spreads in the 
home 
We recently contacted you about taking part in a study about the spread of tummy bugs. 
You should have had your information pack by now, and we are writing to remind you to 
send in your questionnaire and stool pots if you want to take part in the research. 
It is completely up to you and your household to decide whether to take part. If you decide 
to take part you are still free to change your mind at any time and without giving a reason. 
You can contact us about anything you want to chat over.  If you need another pack, or 
more sample pots, just contact the team on the below number or email, and let us know. 
Further information 
If you would like to discuss the study or have any questions or concerns, feel free to 
contact The epiCrypt Study team via email (c.mckerr@liv.ac.uk) or ‘phone (0151 795 
8334) 
Thank you for helping us with our research! 
CRN North West Coast 
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Appendix 10: Laboratory protocol for the processing, testing 
and recording of stool samples in the epiCrypt 
Cryptosporidium household transmission study 
 
This study is being undertaken as part of a PhD by Caoimhe McKerr, University of 
Liverpool, in collaboration with PHE and PHW. It is being funded by the National 
Institute for Health Research (NIHR). 
The aim is to estimate the frequency of transmission of Cryptosporidium in households 
and understand more about it. 
This study is scheduled to run for 12 months. The first month will be a pilot phase and 
processes will be reviewed for any changes that need to be made. Samples from the 
pilot will be included in the main study in the event that there are no, or minimal, 
methodological changes. See below for the sample processing workflow. 
Stool samples from consenting household contacts of index cases will be self-collected 
using Fe-Col kits and the pots sent to the CRU in the post. Index cases will have been 
identified through routine surveillance, recruited and consented with their household for 
the study. 
Pots will have a sticker attached with a household-level study ID beginning NW (for 
North West England) or WS (for Wales). This is the study ID, used later to cross-
reference CRU results with questionnaire data at Liverpool University. The label should 
also have the subject’s age and sex and sample date, filled in by the subject 
themselves. 
When an epiCrypt sample pot arrives in the laboratory: 
1. Pre-print a series of stickers HH0001 - HH1000 to provide HH sample numbers 
2. Date stamp the required number of pre-printed HH stickers with today’s date 
dd/mm/yyyy 
3. Allocate a dated, HH sample number sticker to each pot, but do not cover the 
handwritten information on the pot. 
4. Book samples in using the project lab database (maybe one person reading 
from the pot, the other booking in). During the pilot phase an Excel spreadsheet 
will also be used, and reviewed at the end of the pilot phase. To record at 
booking in (compulsory fields are shown in bold): 
 Date received as per sticker just applied   dd/mm/yyyy 
 Unique HH sample number (HH0001-HH1000) as per sticker just 
applied. 
 The study ID (beginning NW or WS) which is on the stool pot 
 Age in whole years (from the stool pot). Anyone <1 year is 0. 
 Sex (from the stool pot) M, F or U 
 Date of stool sample (from the stool pot)  dd/mm/yyyy 
 Consistency using the Bristol Stool Scale 
5. Store in Fridge 2 in the project tray until testing. 
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Screening the samples 
Screen the samples in routine IFM batches as this avoids the need for new algorithms 
and paperwork and is an efficient use of QC. Samples don’t have to be screened daily 
but don’t leave them longer than a couple of weeks. 
1. Screen samples using IFM (2 wells) (CRU SOP17). Use the routine 
microscopy form (CRU SOP17F1) to record the results but “report” on the 
project database. Enter the reason on the microscopy sheet as “HH study”. 
Use the microscopy scores in CRU SOP17; if “scanty” record the actual 
number of oocysts seen: 
  No. of (oo)cysts seen per field of view (x40 
objective)  
 Record as: 
None in the entire well Neg 
1 or fewer (but at least 1 in the entire well) Scanty, and record the 
number of oocysts seen 
2-5  + 
6-10 ++ 
11-50 +++ 
50 or more ++++ 
 
2. For positive samples, add the HH sample number to the batch record sheet 
for salt float, CRU SOP 004 F1 
3. For negative samples, dispose of immediately and record this on the project 
database. 
Further processing and testing IFM positive samples 
1. For positive samples, do a salt float21 (batches of 8 or more, no need for pos or 
neg controls, using CRU SOP 65 i.e. re-suspend in 200 µl RO water).  
 
2. On the same day, proceed to bleach treat all of the 200 µl oocyst suspension and 
do the freeze-thaw process as per CRU SOP 65. If there is no time to extract the 
DNA, store frozen.  
 
3. Do Mini kit DNA extraction as per CRU SOP 65 using record sheet F3. 
 
4. Store DNA in freezer 5 until use for species ID (see point 5 below), future 
subtyping and possible WGS. 
  
5. For species ID, perform RT2 PCR (CRU SOP 61), then if RT2 is negative 18s 
(CRU SOP 28).  Record results in the project database. 
 
6. Once the species result is finalised, stool samples should be discarded in the 
usual way; the stool samples must not be retained for any further use. Record that 
the Cryptosporidium positive stools have been discarded when the species results 
have been entered on the sample database.  
Other information 
                                               
21 Benefits of salt float and bleaching before DNA extraction: separates parasites from human material; 
sample is ready for gp60/MLG and for WGS in a single preparation. 
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 To identify the routine samples from index cases that have been enrolled 
in the study22 
 Enter the sample in database, with accession number, the original sample 
receipt date, and the study ID. Record the Bristol Stool Scale as 99 i.e. not 
relevant23. Enter the sample in into the workflow for salt float, bleach, DNA 
extraction, testing and storage of DNA.  
 Notification. As Cryptosporidium is a causative agent listed in Schedule 2 of 
The Health Protection (Notification) Regulations 2010 and The Health 
Protection (Notification) (Wales) Regulations 2010, the operator of a 
diagnostic laboratory has a duty to notify detection in human samples. In 
Wales, notification is to the proper officer of the relevant local authority (i.e. 
that of the person soliciting the test). Once a week, send an email notifying of 
the number of Cryptosporidium positive HH stools identified in the previous 7 
days.   
                                               
22 Health protection/CDSC staff from PHE/PHW will keep a record of those Index cases who have 
consented (according to protocol agreed between CMCK and the HP teams). Once a known Index case 
has consented to their sample being used in the study, the HP staff will look up the corresponding specimen 
number on the original case record. They will share this, age, sex, date of sample, and the study ID via 
monthly email with the CRU. The laboratory ID will allow staff at the CRU to identify and locate the index 
case sample. Once retrieved, include the sample in the salt float batch for subtyping and possible WGS. 
23 The patient would have had diarrhoea to visit GP in the first place, and the sample will have been mixed, 
stirred and possibly water added by this stage 
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IFM x2 within two weeks of receipt (CRU SOP 017; F1).Update study d/b 
with date and result. 
NEG PO
S 
Archive DNA in study box (freezer 4).  
Index case identified.  
Retrieve stool from 
fridge 1 or 5 
Enter details and results 
on d/b 
Household contact sample received in project packaging 
HH sticker date stamped and applied to sample pot 
Sample details (from pot) “booked in” to study database (EpiInfo7 / xlsx) 
RT2 PCR (CRUSOP061; F1) HH samples 
only. Update study d/b (date and result). 
DNA extraction (CRUSOP 65; F3) 
Oocyst float (CRU SOP 004; F1); resuspend in 200 µl. 
Bleach oocysts (CRU SOP 065). 






Discard stool sample.  
Update study d/b (tick) 
 
18s PCR (CRU SOP 028; F1) and 
sequencing (CRU SOP 030;F1).                                     
Update study d/b (date and result). 
Discard stool sample.  




Bristol Stool Scale 
 
PROTOCOL Open Access
Exposures associated with infection with
Cryptosporidium in industrialised countries:
a systematic review protocol
Caoimhe McKerr1,2,5* , Sarah J. O’Brien1, Rachel M. Chalmers3, Roberto Vivancos1,2,4 and Robert M. Christley2,5
Abstract
Background: Cryptosporidium is a protozoan parasite of humans and other animals worldwide and is one of the
greatest contributors to human diarrhoeal illness. Transmission can occur indirectly via contaminated food or water,
or directly via contact with animals or other infected people. Risk exposures are often identified from outbreak
investigations, but a subset of cases remains unexplained, and sources for sporadic disease and pathways to
infection are still unclear.
Given the few systematic syntheses of reported evidence in industrialised populations, the aim of this review is to
consolidate the literature to describe exposures associated with human cryptosporidiosis in industrialised countries,
specifically including the UK, and describe any differences between outbreak-associated and sporadic disease.
Methods/design: Where relevant, methods will follow the recommendations made in the Cochrane Handbook for
Systematic Reviews of Interventions. Three steps will be used to identify the literature including electronic database
searching using PubMed, Scopus, Embase and Web of Science; reference list trawling; and an exploration of the grey
literature. Screening of results will be undertaken by two reviewers using pre-defined criteria. Studies conducted in
industrialised countries and reporting on human subjects will be included. All observational studies will be included
where they report exposures and relevant quantitative results.
Data will be extracted using a standardised form. Study quality will be assessed using the ROBINS-I tool. Data will be
summarised presenting the papers’ main findings including population under study, outcomes, and exposures, and
whether these were considered outbreak or sporadic cases. A narrative summary will also be included. Where populations
are appropriate, available data will be pooled in a meta-analysis combining the significant exposures across studies.
Discussion: This review aims to consolidate the evidence for transmission routes and exposures for Cryptosporidium in
industrialised countries, with particular reference to how these may apply to the UK. In addition, the review will seek to
describe differences between outbreak and sporadic cases. This will help to identify those most vulnerable, highlighting
pathways where interventions and public health response may be appropriate.
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Background
Cryptosporidium is a protozoan parasite which can infect
humans and other animals, and the most prevalent species
identified in humans are Cryptosporidium parvum and
Cryptosporidium hominis [1, 2]. Cryptosporidium is distrib-
uted worldwide and is suspected to be one of the greatest
contributors to human diarrhoeal illness [3]. Cryptosporid-
ium is reported in 1–3% of immunocompetent patients
with diarrhoea in industrialised countries and 7–20% in de-
veloping countries [4–8]. The dissimilarities are probably
driven by variation in exposure due to sanitation, infra-
structure, and housing and health factors such as acquired
immunity and nutrition. The highest prevalence is observed
among children under 5 years old, in particular the under
twos [3, 9]. The parasite has a complex life cycle and char-
acteristics which favour the faecal-oral transmission route,
which may facilitate outbreaks via person-to-person (C.
hominis and C. parvum) or animal-to-person (C. parvum),
as well as indirect transmission through ingestion of water
and food contaminated with infectious oocysts [10].
Reported risk exposures for both C. parvum and C. homi-
nis often overlap and include consumption of contaminated
drinking water [11–15] and exposure to recreational waters
[16–18] and food-related outbreaks (likely contaminated
via water or by food handlers) [19–22].
C. parvum is frequently associated with exposure to farm
animals [23, 24] due to its zoonotic nature and C. hominis,
more anthropo-zoonotic, with person-to-person spread
[25–28] and foreign travel [29]. Risk factors and associated
exposures are often hypothesised/identified from outbreak
investigations; however, outbreaks may only represent a
small proportion of cases. Estimates in the United Kingdom
(UK) suggest, of all cases reported to national surveillance
in England & Wales, < 10% are likely to be linked to an
identified outbreak [30]. However, the accuracy of the
case numbers captured by surveillance may be imprecise
[31, 32]. As a consequence, pathways may be under-
reported and we cannot be certain that transmission
routes for sporadic disease are the same as those which
drive outbreaks [33]. Despite case-control studies which
have investigated differences in risk for endemic and out-
break disease [34, 35], sources for sporadic disease and
pathways to infection are still unclear and a substantial
subset of reported cases remain unexplained.
Previous reviews
A search of PubMed and the Cochrane Library revealed
five previous systematic reviews which have synthesised
evidence on risk factors for infection, all published be-
tween 2006 and 2016.
Two reports dealt with only immunocompromised
populations: a review of Cryptosporidium prevalence in
HIV/AIDS patients [36] and another assessing the treat-
ment in immunocompromised patients [37]. A 2006
global review by Gualberto and Heller of drinking water
sources found that unboiled water was associated with
an increased risk of endemic cryptosporidiosis [38].
Another paper looked at seasonal patterns of five gastro-
intestinal pathogens together, including Cryptosporid-
ium, in the Organisation for Economic Co-operation
and Development (OECD) countries [39]. The paper
hypothesised that environmental factors, e.g. land use,
rainfall, temperature, and host characteristics, e.g. social
contact, travel, and animal proximity, were drivers for
seasonal patterns of cryptosporidiosis, and this was fur-
ther buttressed by the existence of comparable evidence
from New Zealand for other enteric pathogens [40].
However, these reviews were unable to report results by
Cryptosporidium species, which may impact on risk fac-
tors, or investigate separately sporadic and outbreak-
related cases for any variation in associations.
Given the absence of any systematic synthesis of re-
ported evidence in the UK, and the few reviews in the
rest of the industrialised countries, the aim of this review
is to search the literature, including unpublished work,
and describe the purported exposures associated with in-
fection with Cryptosporidium in industrialised countries,
specifically including the UK. In addition, there may be
scope for a meta-analysis to support assessment of the
available evidence and to explore differences that may
exist in exposures or associations between sporadic and
outbreak-related cases.
Research question
In industrialised populations, what exposures are associated
with human infection with Cryptosporidium and are these
different for outbreak-associated and sporadic disease?
Methods
To improve the transparency and completeness of the
protocol, a copy of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses for Protocols
2015 (PRISMA-P 2015) [41] checklist can be found in
Additional file 1. This protocol is written following this
checklist and guidance.
Population
The review will include human populations only.
To avoid missing papers that may be useful to this re-
view, a decision was made not to exclude key at-risk
groups, where known, such as HIV/AIDS patients. The
wealth of literature available indicates that these are
well-studied groups and may act as good sentinels for
the identification of transmission risks or pathways for
immunocompetent populations. At the data collection
and analysis stages, high-risk or highly susceptible popu-
lations, where known, can be separated for a more nu-
anced interpretation.
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Searches will be restricted to reports from industrialised
countries given that the literature suggests that transmis-
sion pathways and exposures, as well as susceptibility of
populations, are different between these and countries
with less infrastructure [42]. An industrialised country will
be defined using OECD category of countries based on
membership (Table 1) [43]. Where studies report results
from a mix of industrialised and non-industrialised coun-
tries, and it is not possible to disentangle outcomes and
exposures, the study will be excluded.
Exposure
All exposures, including food, water, animal, environ-
mental, and human, will be considered for inclusion.
Outcome
Primary outcomes will include identifying exposures associ-
ated with Cryptosporidium infection and/or disease among
both sporadic disease and outbreak-related cases. Out-
comes among exposed populations will be compared to
those in unexposed populations, where the study design al-
lows. We are also interested in capturing molecular detail
such as species where possible, as risk factors and expo-
sures may vary.
Inclusion/exclusion criteria (Table 2)
Only studies conducted in industrialised countries (as
previously described) and reporting on human subjects
will be included. All observational studies will be in-
cluded where they report risk factors and relevant quan-
titative results. To allow us to capture the most relevant
and robust information on risk factors at a population
level, individual case reports will be excluded.
Where the information is clearly communicated, we
will exclude information describing cases who acquired
their infection in a non-industrialised country and there
is no further follow-up, for example, reporting on sec-
ondary spread. Where we cannot accurately determine
country of infection, these will be excluded.
To capture any changes in incidence and factors associ-
ated with Cryptosporidium over time, there will be no
limitation on publication period. We are also interested in
capturing molecular detail, such as species, where pos-
sible, as risk factors and exposures for these may vary and
this may be pertinent for comparisons of pathways and of
value to the knowledge of zoonotic transmission routes.
There are no restrictions on language, provided the
abstract can be made available in English for the first
round of screening.
Search strategy and terms
Where relevant, methods will follow the recommenda-
tions made in the “Cochrane Handbook for Systematic
Reviews of Interventions” [44].
The search strategy proposed comprises three ap-
proaches, designed to collect as much relevant literature
as possible from both peer-reviewed and grey sources.
The choice of databases was following advice from a
University of Liverpool Medicine and Dentistry Liaison
Librarian, as those deemed to be most relevant to the re-
search question and likely to yield the highest number of
relevant papers.
Step one—peer-reviewed literature
One reviewer (CMCK) will conduct electronic searches
in the following databases of published literature consid-
ered most likely to yield the relevant papers:



















Table 2 Criteria for inclusion in the search
Inclusion criteria Exclusion criteria
Any language—abstract
(if available) in English
Cases known/defined as travel-
related/acquired in non-
industrialised country
Publication period—any Individual case reports
Human cases




groups where risk factors are
reported
Known outbreaks
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 PubMed
 Web of Science
 Scopus
 Embase
The search terms were developed initially for PubMed
and piloted in an iterative process ahead of commencing
the review to ensure they successfully captured relevant
papers. Where possible, terms were exploded to broaden
the search. In the review, terms will be adapted as per
the functionality of each database.
A more complete documented approach to develop-
ing the choices and finalising search terms is available
on request.
Terms include the following categories:
 Organism terms: e.g. crypto*, Cryptosporidium,
cryptosporidiosis
 Population term: e.g. “human”, patients, population,
 Transmission terms: e.g. transmission, risk factor,
exposure, sporadic, infection, outbreak(s)
 Outcome terms: e.g. multivariate analysis, odds
ratio, risk*, relative risk
Additional file 2 is an example of final search terms
used for PubMed.
Search terms will be sought within the title, abstract,
and keywords of the documents contained in each data-
base. Filters within the three databases will be applied if
required to restrict the results as appropriate according
to inclusion criteria.
The publications captured using the final agreed search
terms will be exported into reference managing software
(Mendeley) and duplicates removed. The remaining publi-
cation titles will then be screened for relevance by two re-
viewers (CMCK and AW), using the inclusion and
exclusion criteria.
Step two—hand-searching in papers
Reviewers (CMCK and AW) will search reference lists to
identify any further literature or relevant publications
not previously captured in the other strategies. The ab-
stracts of any references considered potentially relevant
will be sought and screened for inclusion using the in-
clusion and exclusion criteria.
Step three—accessing grey literature
One reviewer (CMCK) will access grey literature rele-
vant to the review question using published online re-
sources which may include bulletins and reports from
relevant agencies, conference proceedings, and other
relevant published outputs.
A search of Google Scholar (and any other relevant
agencies’ sites, e.g. WHO) will be undertaken by entering
the term ‘cryptosporidium’ with ‘risk factors’, ‘outbreak(s)
’, ‘sporadic’, ‘endemic’, and/or ‘transmission’ into the appli-
cation and reviewing the first 100 results for relevance.
Using the same search terms and inclusion criteria, the
same reviewer will carry out an additional search for un-
published theses work in the ProQuest database.
Abstracts (or relevant variations thereof) will be shared
with the second reviewer (AW). Following agreement on
inclusion, the work will be reviewed as per protocol.
To refine and clarify the inclusion criteria and search
terms and ensure that the criteria can be applied consist-
ently by all reviewers, the selection process will be
piloted by applying criteria to a sample of papers.
Abstract and paper selection
Following title selection, abstracts of the final included
publications will be screened independently by two mem-
bers of the review team (CMCK and AW) to ensure
consistency in the application of the inclusion and exclu-
sion criteria. Any discrepancies will be discussed and re-
examined until an agreement is reached. A third reviewer
is available for irreconcilable opinions on inclusion.
The full texts for all included works will be retrieved
via the online library where possible and, if required,
with the help of the University Liaison Librarian or by
contacting authors. All full-text studies will be screened
independently by the same reviewers (CMCK and AW)
to ensure that they conform to the inclusion and exclu-
sion criteria and discrepancies tackled as before.
Full-text papers which appear in a language other than
English will be shared with colleagues in the Health Protec-
tion Research Unit (HPRU) and wider university teams for
assistance with translation. An online translation tool (Goo-
gle translate) will be used for initial screening where needed
and where electronic papers are available for input.
Searching will cease when no further relevant and/or
not previously identified work is being discovered.
Data collection
A standardised data collection form will be developed in
Covidence software. Each reviewer will be able to input
data and update this as they each extract data from the
papers. A minimum dataset of information from each
paper will be extracted and recorded in duplicate, by
each reviewer and, where information is available, will
include variables outlined in Table 3.
Studies will be allocated a unique identifier (automat-
ically generated) and will be categorised according to the
following groups:
 Included studies—studies that meet the eligibility
criteria and are included in the review
 Excluded studies—studies that do not meet the
eligibility criteria and are excluded from the review
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 Studies awaiting classification—relevant studies that
have been identified but cannot be assessed for
inclusion until additional data or information are
obtained
 Ongoing studies—studies that are ongoing and meet
(or appear to meet thus far) the eligibility criteria
Disagreements will be discussed and, if required, rely
on the input of a third reviewer as previously described.
Assessing risk of bias
The ROBINS-I tool (Risk Of Bias In Non-randomized
Studies - of Interventions) will be used as the framework
for assessing quality of the studies. This instrument is well
piloted and is specific to non-randomised study types [45].
The instrument provides an overall judgement on risk of
bias using signalling questions across seven domains includ-
ing bias, confounding, and missing data. Following assess-
ment, each reviewer will label a study as ‘low’, ‘moderate’,
‘serious’, or ‘at critical’ risk of bias.
Strategy for data synthesis
Search results and numbers of titles selected will be pre-
sented in the PRISMA 2009 flowchart [46].
In order to accurately report on the content of papers
and to explore relationships between disease outcomes
and risk factors, data will be summarised in a table pre-
senting the main findings of each paper individually, in-
cluding population under study, outcomes (infection with
Cryptosporidium sp.), exposures, and general results
(rates, prevalence, number of cases, odds, relative risks). A
narrative summary of the characteristics and quality of the
papers will also be included, alongside, and in the context
of the strength of evidence results from ROBINS-I.
Meta-analysis
A certain level of heterogeneity is expected between
studies which may include outcomes measured, popula-
tion groups, type of study, and measures of association.
Following these results, and a discussion about compar-
ability of studies reported, a decision will be made re-
garding moving forward with a meta-analysis.
Where the populations are appropriate, and study qual-
ity allows, data will be pooled in a meta-analysis combin-
ing the significant exposures, and categories, across
studies and presented as a summary of effects in their in-
dividual groupings, for example, ORs or RRs. Forest plots
will be created for each exposure category (where paper
numbers are high enough to retain validity) and examined
to identify heterogeneity. Odds or risk of exposure among
cases of Cryptosporidium will be presented according to
the study design and outcome measured.
The summary measure and I2 statistic will be used to
assess heterogeneity in the studies and will inform the
use of meta-analysis techniques and the choice of a fixed
or random effects model. Values of 30 to 60%, 50 to 90%
and 75 to 100% will be used to denote moderate, sub-
stantial, and considerable levels of heterogeneity accord-
ing to the Cochrane Handbook for Systematic Reviews
of Interventions [44].
Data analyses will be carried out using RevMan, MS
Access and Stata v12.0.
Data analysis plan
The data analysis will include a description of the cases
and putative risk factors/exposures in each study, includ-
ing the overall proportion of studies which report each
exposure and the number of times a transmission path-
way or risk factor is associated with illness.
Where possible, analyses of subgroup data may include:
 Outbreak vs non-outbreak disease
 Urban vs rural residence/populations
 Region of world
 Cryptosporidium species/genotype (e.g. C. parvum
and C. hominis)
 Age groups of cases/non-cases
Table 3 Minimum data set of information extracted from
included papers
Bibliographic detail Study detail
Name of reviewer Study design
Date of extraction Number of cases
reported
Publication type Age/sex cases/
participants
Country of origin/language Case definition (and any
known co-infections)
Study title Definition of exposure(s)
Names of authors Definition of activities
Journal/source reference Species identified
Year published Incubation period
Exposure window(s)
Study outcomes General methodological
Number (%) exposed among groups Confounders
Types of exposures Likely biases
Comparator(s) (well controls, other
infection)
Selection and recruitment methods
Availability of appropriate controls
(from the same source population as
the cases)
Interview methods
Effect measures (type and result)
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 Study design (such as cross-sectional, prevalence
studies with risk factors, case-control, cohort, and
other observational study designs, outbreak investi-
gations, or surveillance analyses with risk factor
information)
Aggregated study data by subgroup will be reported
according to data type (e.g. mean and SD and percent-
ages, ratios) and outcome measures (e.g. incidence, odds
ratios, and relative risks). Studies will be further grouped
by outcome measurement for consistency; studies
reporting odds ratios will be aggregated separately to
those reporting relative risk, for example. Exposures will
be defined as per the paper under review, but where
possible, they will be grouped into categories to allow
for meaningful exposure group analyses. Categories are
likely to include environmental exposures, water, animal
exposures, exposure to a case, etc., and may also, where
possible, include settings such as home, hospital, or nur-
sery. Where data and number of papers allow these will
be sub-grouped as much as possible.
Where data are missing or not reported in disaggre-
gate form, the authors may be contacted in order to as-
sist with further analyses. If the data allow, a more
granular grouping of the studies may be undertaken to
accurately address the research question.
Interpretation of findings
Given that we have not included any element of study
design as part of the selection criteria for inclusion,
interpretation of findings will begin with a description
of the publication bias funnel plots where numbers of
papers are sufficient. Discussions will include an ex-
ploration of all the strengths and weaknesses of the
studies and a summary of the quality of evidence,
using the Grading of Recommendations, Assessments,
Development and Evaluation approach [47]. Most of
the initial studies will likely be classed a priori as
‘low’ due to being observational in nature but may be
upgraded after assessment of various domains of the
tool, including bias, effect size, and precision. Papers
will then be assigned a final grade for the quality of
evidence as ‘high’, ‘moderate’, ‘low’, or ‘very low’ for all
the critically important outcomes. Results will be re-
ported using summary tables.
Interpretations of measures of effect may be stratified
by study quality, and aggregated analyses of measures of
effect will be assessed in the context of the populations
under study.
Dissemination
The protocol and the report will be prepared for peer-
review publication.
The review will form part of a larger project submitted
in partial fulfilment of a Doctor of Philosophy degree at
the University of Liverpool.
Where appropriate, data may be presented as confer-
ence proceedings.
Discussion
Many of the putative risk factors for cryptosporidiosis can
have high exposure proportions and cases often report
multiple risk factors, so well-designed studies are key in
trying to elucidate clear pathways for transmission. More
accurate understanding of the drivers behind continued
apparent sporadic cryptosporidiosis has implications for
public health intervention, control, and targeted treat-
ment. This systematic review aims to describe the epi-
demiology and transmission of Cryptosporidium infection
in industrialised countries, with particular reference to
how this may apply to the UK. In addition, the review will
seek to describe differences between outbreak and spor-
adic cases, investigating changes in prevalence and pat-
terns among species and subtypes over time, and explore
mechanisms for transmission of disease.
The results of this review will help support current
knowledge and add to the evidence base on transmission
pathways and risks for cryptosporidiosis, identifying
those vulnerable and highlighting pathways where inter-
ventions may be of use.
The review will also help inform the development and
direction of an analytical study as part of a PhD project.
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AbstrACt
Introduction Infection with the Cryptosporidium 
parasite causes over 4000 cases of diagnosed illness 
(cryptosporidiosis) in England and Wales each year. Risk 
factors are often estimated from outbreak investigations, 
and in the UK include ingestion of contaminated water and 
food, farm/animal contact and person-to-person spread in 
institutions. However, reported outbreaks only represent 
about 10% of cases and the transmission routes for sporadic 
disease may not be the same. Contact with other people 
has been highlighted as a factor in the transmission of 
Cryptosporidium, but the incidence of sporadic disease 
has not been sufficiently established, and how frequently 
this arises from contact with other infected people is not 
well documented. This project will estimate the amount of 
secondary spread that occurs in the home and potentially 
identify asymptomatic infections which might have a role in 
transmission. Risk factors and characteristics associated with 
secondary spread will be described including any differences 
in transmission between Cryptosporidium species.
Methods and analysis The study will prospectively identify 
cryptosporidiosis cases from North West England and Wales 
over 1 year and invite them and their household to take part. 
Each household will complete a questionnaire and each 
household member will be asked to provide a stool sample. 
Clinical, demographic and home variables will be described, 
and further analyses undertaken to investigate associations 
with secondary spread in the home. Cryptosporidium-
positive stool samples, identified by immunofluorescence 
microscopy, will be characterised using molecular methods 
to describe patterns of transmission. Data collection is 
expected to take 1 year, beginning in September 2018.
Ethics and dissemination The study has been approved 
by the North West–Liverpool East NHS Research 
Ethics Committee (Reference: 18/NW/0300) and the 
Confidentiality and Advisory Group (Reference 18/
CAG/0084). Outputs will include scientific conferences and 
peer-reviewed publications. In addition, a short, lay report 
of findings will be produced for participants, who can opt 
to receive this when they take part. 
trial registration number CPMS ID: 39458.
IntroduCtIon
Cryptosporidium is a protozoan parasite which 
can infect humans and other animals, and 
the most prevalent species identified in 
humans are Cryptosporidium parvum and 
Cryptosporidium hominis.1 2 Cryptosporid-
iosis is the subsequent diarrhoeal disease 
following infection with Cryptosporidium. The 
disease affects all ages and although gener-
ally self-limiting, can be life threatening in 
some immune-compromised patients. Acute 
diarrhoea follows an incubation period of 
between 2 and 10 days (mean 7 days) and 
symptoms can include non-bloody diarrhoea, 
abdominal cramps, vomiting and/or nausea, 
low grade fever, lethargy and general malaise.
Public Health England (PHE) receive labo-
ratory reports of over 4000 diagnosed cases 
per year (2000–2012 data) in England and 
Wales; however, research indicates that many 
infections may go undiagnosed, and the true 
incidence of disease may be much greater.3 4
The parasite has a complex life cycle and 
characteristics which favour faecal-oral and 
environmental transmission routes, which 
may facilitate outbreaks via person-to-person 
(C. hominis and C. parvum) or animal-to-person 
strengths and limitations of this study
 ► This prospective household study will provide de-
tailed information on the incidence of, and risk fac-
tors for, secondary spread of cryptosporidiosis in the 
home.
 ► This study will characterise Cryptosporidium iso-
lates to ascertain likely mechanisms of spread by 
species.
 ► This study will potentially identify the prevalence of 
asymptomatic infections with Cryptosporidium.
 ► Common exposures across households may present 
problems with accurately identifying true secondary 
spread.
 ► Biases may lead to a skewed sample of index cas-
es because of under-ascertainment and bias in 
health-seeking behaviours.
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(C. parvum) contact, as well as indirect transmission 
through ingestion of water and food contaminated with 
infectious oocysts.5
Risk factors and associated exposures are often 
hypothesised/identified from outbreak investigations, 
however recognised outbreaks may only represent a 
small proportion of cases; estimates in the UK suggest, 
of all cases reported to national surveillance, <10% are 
likely to be linked to an identified outbreak6 and 
contact with other people is highlighted as a factor in 
the transmission of Cryptosporidium. In a 1988 paper, 
onward transmission of Cryptosporidium was reported 
in households in the UK following a nursery outbreak, 
probably propagated by person-to-person spread in the 
home.7 An analysis of outbreak reports from surveil-
lance data in Ireland reported that ingestion of water 
and person-to-person spread were the most important 
mechanisms of transmission in outbreaks.8 In the USA, 
in a case–control study evaluating sporadic cryptospo-
ridiosis among immunocompetent persons, risk factors 
associated with increased odds of being a case were 
international travel, contact with cattle and contact with 
a child with diarrhoea.9 In 2001–2002, a case–control 
study conducted in the North West of England exam-
ined species-specific risk factors for sporadic crypto-
sporidiosis.10 The authors compared risk factors for 
infection with genotypes 1 and 2 (currently recognised 
as C. hominis and C. parvum, respectively) and found 
that contact with another person with diarrhoea was a 
risk factor for infection with Cryptosporidium, and that 
changing children’s nappies was a specific risk factor 
for infection with C. hominis whether the child was symp-
tomatic or not symptomatic. Studies of Giardia, another 
gastrointestinal parasite, similar in terms of likely trans-
mission routes, have recently been undertaken in the 
UK, and secondary spread and person-to-person trans-
mission seems a likely and under-recognised route of 
transmission.11 12 In a 1988 paper, onward transmission 
of Cryptosporidium was reported in households in the 
UK following a nursery outbreak, probably propagated 
by person-to-person spread in the home.9 An analysis 
of outbreak reports from surveillance data in Ireland 
reported that ingestion of water and person-to-person 
spread were the most important mechanisms of trans-
mission.10 In the USA, a study evaluated sporadic cryp-
tosporidiosis among immunocompetent persons using 
a case–control design. Risk factors associated with 
increased odds of being a case were international travel, 
contact with cattle and contact with a child with diar-
rhoea. In 2001–2002, a case–control study conducted 
in the North West of England examined species-specific 
risk factors for sporadic cryptosporidiosis. The authors 
compared risk factors for infection with genotypes 1 
and 2 (currently recognised as C. hominis and C. parvum, 
respectively) and found that contact with another 
person with diarrhoea was a risk factor for infection with 
Cryptosporidium, and that exposure through changing 
children’s nappies was a specific risk factor for infection 
with C. hominis whether the child was symptomatic or 
not symptomatic.
Asymptomatic spread
The burden of asymptomatic infection is less well docu-
mented in Cryptosporidium research than for other infec-
tions but may be an important factor in household 
spread. A study in the UK reported a point prevalence of 
1.3% among asymptomatic pre-school children attending 
daycare13 suggesting that asymptomatic infection does 
occur. A Norwegian study looking at follow-on spread 
after two outbreaks found both asymptomatic and symp-
tomatic infections in the households, which were likely to 
have been a result of secondary transmission.14 Overall 
though, most of the work examining household spread 
has been undertaken in Cryptosporidium-endemic coun-
tries, where a high prevalence and repeated exposure 
to the organism might facilitate transmission, although 
immunity following repeat exposure is still poorly under-
stood.15 16 Newman et al undertook a prospective cohort 
study in Brazil to examine the transmission of Cryptospo-
ridium infection in households where there was an identi-
fied case.17 Secondary cases of infection occurred in 58% 
of households, and around a quarter of the identified 
secondary cases had diarrhoea, indicating the presence 
of asymptomatic infection in almost three-quarters of the 
participants. Similar results were reported from a longitu-
dinal study in Bangladesh, where asymptomatic infection 
was more prevalent than diarrhoeal disease.18 The same 
authors followed up with a case–control study in which 
the secondary attack rate was over 35%, and evidence 
of transmission in the home was further supported by 
genotyping results.19 If person-to-person spread is driven 
by both cases and those with asymptomatic infections of 
Cryptosporidium, then sporadic cases may subsequently 
arise following exposure to either, and outbreaks in close 
settings such as the home or institutions may happen 
more frequently than is currently recognised. Few studies 
exist which refute or confirm this, especially in industri-
alised countries.
AIMs And objECtIvEs
The aim of this study is to estimate the amount of onward 
spread of Cryptosporidium that happens in the home, 
and to describe associated factors and case characteris-
tics. (We use the term ‘secondary spread’ to mean any 
apparent onward transmission of disease originating 
from a case, while recognising that this may be secondary 
or even tertiary levels of spread.) This study will support 
our understanding of continued apparent sporadic cryp-
tosporidiosis in England and Wales and has implications 
for appropriate public health messages to help mitigate 
spread and infection. Further molecular characterisation 
of Cryptosporidium isolates may also help define the likeli-
hood of secondary transmission by infecting species.
objectives
 ► To estimate the number of secondary cases in house-
holds with an index case.
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 ► To calculate the secondary transmission rate in 
households.
 ► To estimate the prevalence of asymptomatic carriage 
in households with an index case.
 ► To identify specific household-level and personal 
characteristics associated with secondary spread.
 ► To determine if factors and characteristics asso-




The study population will comprise residents of North 
West England and Wales.
The North West of England has a population of over 
seven million people and is the third-most populated 
region in the UK.20 In 2016, over 600 laboratory-con-
firmed Cryptosporidium isolates were reported from the 
North West (8.4/100 000 population).21
Wales has a total population of over three million 
people.22 In 2016, over 400 laboratory-confirmed Crypto-
sporidium isolates were reported from Wales, the highest 
rate of Cryptosporidium spp laboratory reports per 100 000 
population in England and Wales (15/100 000).21
surveillance/sampling frame
The sampling frame will be taken from the two relevant 
surveillance systems which capture laboratory confirmed 
reports of Cryptosporidium: The Second-Generation Surveil-
lance System in PHE, and Tarian in Public Health Wales 
(PHW). Systematic national surveillance of laboratory 
confirmed Cryptosporidium in England and Wales has been 
established for many years.23 In the UK, Cryptosporidium is a 
notifiable causative agent, meaning laboratories have a stat-
utory duty to notify the relevant public health authority of its 
identification in any human samples.24 25 Cryptosporidiosis 
may present similarly to other causes of gastroenteritis, and 
laboratory confirmation of infection with Cryptosporidium 
is necessary for a diagnosis. Clinical practice may differ, 
and clinicians would likely submit a sample to a primary 
diagnostic microbiology for a diagnosis of gastroenteritis. 
Local diagnostic laboratories across the UK use different 
methods to test for Cryptosporidium, and various criteria 
to decide whether to test for this parasite, including stool 
consistency, history or clinical details, duration of hospital-
isation or clinician requests.26 Positive samples identified 
in the diagnostic laboratories are routinely forwarded to 
the national Cryptosporidium reference unit (CRU) which 
provides expert management, prevention and control 
advice as well as Cryptosporidium typing and confirmation 
services for speciation and surveillance.27
All cases of laboratory confirmed Cryptosporidium sp. 
reported from primary diagnostic microbiology laborato-
ries in North West England and Wales, in the study year, 
will initially be eligible.
study type
The identification of cases, and their subsequent recruit-
ment, is cross-sectional, although the study also involves 
retrospective data collection and some prospective 
sampling (figure 1).
Cases of cryptosporidiosis will be identified via the 
relevant surveillance system(s). Once participants are 
recruited, they will complete a questionnaire (one per 
household), collecting clinical (onset date, symptoms of 
any household member, other illnesses of index case), 
demographic (age, sex, relationship to the index case) 
and household composition (type, number of bath-
rooms and bedrooms, animals) information. In addition, 
consenting household members (excluding the index 
case) will be asked to supply a stool sample.
study period
The study period will be 12 months, to account for 
seasonal variation and allow maximum enrolment, up to 
400 households. The study is expected to begin with a 
pilot phase of 1–2 months in autumn 2018.
sample size
Given that the North West & Wales report around 1000 
cases per year (PHE data, 2015) and assuming a partic-
ipation rate of 40%–60%, and some exclusions (based 
on similar studies/approaches11 28) we anticipate a 
sample size of 400 households. Using 2011 Census indi-
cations of 2.4 persons on average per household,20 we 
can expect to recruit around 960–1000 participants in 
total. Assuming that the rate of household transmission, 
defined as the proportion of households with more than 
one case, is between 0% and 20%,11 14 17 29–31 a range of 
sample sizes was estimated (118–402). Recruitment of 
400 households is feasible and is sufficient to allow us 
to demonstrate a statistically significant minimum odds/
risk ratio of 2.0, with type 1 error 0.05 and type 2 error 
at 0.20.
Case definition(s)
Boxes 1 and 2 outline case and household definitions used 
to categorise household members and define secondary 
transmission.
Figure 1 Outline of study.
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Cases of cryptosporidiosis are identified from routine 
surveillance (from diagnostic laboratories) and are 
contacted via post, by the relevant public health organi-
sation, in the first instance. Following this, if they do not 
opt-out, they are contacted via telephone by a National 
Health Service (NHS) research nurse at the local Clin-
ical Research Network (CRN) to chat about the study and 
determine if they would like to take part.
Our approach to the recruitment process was driven by 
necessity and feasibility and we explored several options 
at the protocol drafting stage of the project, balancing 
data needs with patient choice. As our capture of cases 
in the surveillance systems is retrospective and diagnosis 
of Cryptosporidium in the stool sample is undertaken by 
laboratory staff, there is no opportunity to consent indi-
viduals at the time of diagnosis and the recruitment 
process could not be achieved without access to patient 
information. In our model, participants are given opt-out 
options at each contact and it is emphasised that they 
can withdraw at any time. Previous research supports 
the acceptability and understanding of this method, 
recognising that an approach of ‘consent for each use’ 
is burdensome for both researcher and participant,32 33 
as does patient response and engagement with similar 
studies. (Studies recruiting based on disease surveillance 
are common for GI infections, and many projects have 
taken this approach – the methodology for the epiCrypt 
Study has been influenced by design aspects of large-scale 
studies such as Enigma, IID2 and Integrate.)
Public and patient involvement
Patients and public were not involved in the overall 
design of the study, but we did elicit some public opinion 
when finalising our approach to recruitment. Following 
valuable comments from the ethical review board we 
undertook a short survey among the public and specific 
Patient and public involvement (PPI) groups to gauge 
general attitudes toward accessing data prior to consent, 
to support recruitment to research. We drafted a survey 
which outlined the approach to recruitment and the 
framework of the study. We accessed a lay PPI group from 
the Infection and Global Heath panel at the University 
of Liverpool, and one from Health and Care Research 
Wales. Participants were asked to think generally about 
the method of recruitment and how they felt about this 
approach. In general, the feeling was that it is acceptable 
to access data for recruitment, especially to support much 
needed research. However, considerations and worries 
included the person accessing data, with NHS/public 
health staff generally viewed as more favourable that 
non-NHS (eg, university) researchers.
box 1 Case definitions
Index caseIndex case
The first case from a household identified in the surveillance system 
(person reported to a Public Health England/Public Health Wales surveil-
lance system(s) following detection of Cryptosporidium sp. in a faecal 
sample, with a specimen date in the study year).The first case from 
a household identified in the surveillance system (person reported to 
a Public Health England/Public Health Wales surveillance system(s) 
following detection of Cryptosporidium sp. in a faecal sample, with a 
specimen date in the study year).
household casehousehold case
Any household member of a index case who reports symptoms con-
sistent with Cryptosporidium (diarrhoea and/or vomiting) and/or has 
a Cryptosporidium positive stool sample.Any household member of a 
index case who reports symptoms consistent with Cryptosporidium (di-




A person in a household of an index case, with symptoms:
of diarrhoea and/or vomiting
AND
that started after another case’s onset date in the household.
Confirmed secondary case
A person in a household of an index case, with symptoms:
of diarrhoea and/or vomiting
AND
that started after another case’s onset date in the household
AND
a Cryptosporidium positive stool sample.
AsymptomaticAsymptomatic
A person in a household of an index case with:
no reports of gastrointestinal illness
AND
a Cryptosporidium positive stool sample.
*We use the term ‘secondary spread’ to mean any apparent onward 
transmission of disease originating from an index case, while recognising that 
this may be secondary or even tertiary levels of spread.
box 2 household definition
householdhousehold
Two or more people (not necessarily related) living at the same address 
in North West England or Wales who share cooking facilities and share 
a living room or sitting room or dining area.18Two or more people (not 
necessarily related) living at the same address in North West England 
or Wales who share cooking facilities and share a living room or sitting 
room or dining area.18
household memberhousehold member
A person who normally resides in the household and regularly shares 
food or toilet facilities.38A person who normally resides in the household 
and regularly shares food or toilet facilities.38
household contacthousehold contact
A household member where an index case has been identified.A house-
hold member where an index case has been identified.
household with transmissionhousehold with transmission
A household that has more than one case.A household that has more 
than one case.
household without transmissionhousehold without transmission
A household that has one case (the index case).A household that has 
one case (the index case).
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Identification and first contact with the index case
Laboratory diagnosed reports of Cryptosporidium, and the 
corresponding patient contact details, will be extracted 
from the relevant surveillance system by health protection 
staff and saved in a line list (the Master copy of a confi-
dential, separate table (MS Excel spreadsheet) holding 
patient details of all downloaded cases).
All potentially eligible participants will be issued a 
unique sequential study ID by PHE/PHW staff. This will 
be on all relevant study documentation and stool pots 
and follow each person and household through the study 
journey. This will allow data to be linked pseudonymously 
and helps with data management.
Staff from either PHE or PHW (depending on case loca-
tion) will send an invite letter through the post to these 
potentially eligible index cases. The invite letter outlines 
the study, describes why the case has been contacted and 
explains that a research nurse may be in touch over the 
coming weeks to discuss the study. The letter allows the 
case to choose several ways of opting-out of this contact 
(email, freepost, telephone) and provides a named, clin-
ical study lead for each public health organisation should 
they wish to discuss any aspect of this.
Approaching to recruit
If a contacted index case does not opt-out within 2 weeks, 
their details will be shared securely (using internally 
agreed practices) with the NHS research nurses at the 
CRN North West Coast. The research nurses will attempt 
to contact the index case (or parent/guardian of) via 
telephone (using internally agreed practices) to inform 
them about the study and offer them the opportunity to 
participate, if eligible. A maximum of three attempts will 
be made, and nurses will not leave voicemails. If a case is 
unable to be contacted, or does not wish to participate at 
this stage, their details will be deleted from the line list. 
If the approached index case is successfully contacted via 
telephone and interested in participating, or would like 
more information, the research nurses will prepare and 
post a study pack. Index cases may be excluded at this 
stage where discussions with the case reveal that any of 
the following exclusion criteria apply:
 ► Index case is in a single-person household.
 ► Index case is a visitor to a household in the study area, 
but is registered with a general practice (GP) outside 
the study area.
 ► Household is outside the study area.
 ► The index case is resident in an institution: retire-
ment home, nursing home, prison, barracks, 
boarding school or college/university halls of 
residence.
study packs
The study packs contain:
 ► A study information pamphlet.
 ► A questionnaire booklet for the index case or a suit-
able representative (eg, parent, head of household) 
to complete, with a freepost envelope.
 ► A consent form for each participating household 
member to read, initial and sign (forms part of the 
questionnaire)).
 ► A stool sampling pack (Fe-Col) for each participating 
household member, with the required return postal 
envelope.
 ► An information leaflet on cryptosporidiosis and the 
relevant health advice.
 ► An information sheet on General Data Protection 
Regulation for health and care research.
Consent
The index case and any household members who wish 
to take part will sign and return the consent form at the 
front of the questionnaire. The return of study materials 
such as a completed questionnaire and/or stool samples 
will be considered implied consent.
disenrollment 
If study materials are not received within 14 days of 
posting the pack, a reminder letter will be dispatched by 
the research nurses at the CRN. If study documentation 
is not returned within 14 days of posting the reminder 
letter, no further attempt at contact will be made, and the 
index case will be removed from the study line list.
Participation
If the household wants to take part, all interested members 
will sign and return the consent form. At least one house-
hold member, as well as the index case, must consent.
Consent forms and questionnaires are returned to the 
University of Liverpool in a stamped addressed envelope 
provided in the pack. The unique study IDs of those 
consenting will be shared weekly with the research nurses 
at the CRN to cross-match those contacted index cases 
that have been recruited and enrolled. Each consenting 
household member will also be asked to provide a stool 
sample for testing, using the provided Fe-Col kits, which 
include a pre-addressed and secure postal bag (compliant 
with UN3373 regulations for mailing Cat B biological 
samples34). Instructions are provided, and samples will be 
returned directly to the CRU.
data management and oversight
Documentation
Questionnaire data will be inputted from the paper 
format to a corresponding MS Access database and held 
securely on a University of Liverpool drive in accordance 
with their security protocols. Figure 2 shows the data flow 
expected. Double data entry will be undertaken on a 
sample of questionnaires and discrepancies resolved using 
internal validation checks. When data entry is complete 
the data will be exported to the final study database (MS 
Access) where the data are pseudonymised for analyses: 
Name, date of birth and full postcode will be removed 
and replaced with unique study ID, age and Lower Super 
Output Area (a type of geographic area in England and 
Wales, comprised >1000 residents35).
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All data storage, cleaning and analyses will be under-
taken by the study team at the University of Liverpool. 
Data will be stored on institutional network drives with 
appropriate security measures in place. Hard copy 
records will be stored in a locked cabinet in a secure loca-
tion and access to records and data are limited to study 
personnel. Paper documents will be stored separately 
from the corresponding electronic data. The sponsor and 
data controller for this study is the Clinical Governance 
Team at the University of Liverpool.
data security protocol available on request
Stool sample management
For purposes of data confidentiality and governance, 
stool samples returned to the CRU are pseudonymised 
with the unique study ID, and participants will be asked 
to write their age, sex and date of sample on their sample 
pot before they collect the stool. Stool sample results will 
be added to a study-specific database held at the CRU. 
The stool sample results will be added to the study data-
base at the end of data collection using unique study ID 
in a secure file transfer.
Identifying the index case samples
Original diagnostic laboratory numbers will be retained 
with the index case information in the original line lists 
at PHE/PHW so that the sample can be identified later 
at the CRU and grouped with the relevant household 
samples. This sample, when located at the CRU, will be 
processed in the same way as other study samples.
Full laboratory protocol available on request
Outcomes and measurements
Questionnaire data
The questionnaire is divided into sections and is mostly 
composed of dichotomous and multiple-choice questions. 
Section A asks questions to determine the composition of 
the household, the clinical details of the index case, and 
captures any other symptomatic household members. A 
table is used to collect information on any other symp-
tomatic diarrhoeal illness in the house and will attempt to 
capture relationships to the index case (table 1).
Section B records activities of the index case, and others 
in the home, in the 2 weeks prior to the index case’s onset, 
based on known exposures for Cryptosporidium. Informa-
tion on outdoor and leisure activities may help determine 
possible co-primary infections and distinguish them from 
those that are secondary (table 2).
Sections C and D collect household variables, including 
the number of bedrooms and bathrooms, and capturing 
those who share beds/baths, and asking about outside 
space and animals. We also ask about nappy changing 
and toilet training in the home, and about general hand-
washing behaviour.
Table 1 An example table showing information collected in the questionnaire about other illness in the house
Age Sex
Relationship to first 
case
Been ill with diarrhoea 
and/or vomiting
(Yes/No/Don’t know)
When they became ill
(Date if known, otherwise 
before/after the first 
case)
How many days 
were they ill with 
these symptoms?
Did they see a 
doctor about this 
illness?
39 F Mother Yes 18/12/2017 10 No
42 M Father Yes Before About 3 days No
6 months M Brother No –
24 F Lodger/housemate Don’t know – 
Table 2 An example table showing information collected in 




Anyone else in 
the home
Travel outside the UK
Swimming—outdoors in a lake, river, 
stream, etc (wild swimming)
Swimming—in a treated swimming pool, 
either indoors or outdoors (such as a 
pool at a leisure centre or a lido)
Other water activities/sport (such as 
surfing, rowing, water-skiing, etc)
Other outdoor activities (such as 
camping, climbing, hiking, cycling, etc)
Gardening (at home or elsewhere, such 
as an allotment)
Contact with pets (at home or with pets 
at another house)
Visiting or working on a farm or had 
contact with farm animals
Visiting or working at a zoo or had 
contact with zoo or wild animals
Figure 2 Study flow diagram.
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Full questionnaire available on request
Stool collection and genotyping
All consenting household members of the index case (but 
not the index case) will be asked to provide a stool sample 
using the Fe-Col kit (figure 3) provided in the study pack, 
and post to the CRU.
The stool pots will be labelled with the unique house-
hold ID which identifies them as part of the study but 
allows the samples to remain anonymous to the refer-
ence laboratory team. Samples will be scored against the 
Bristol stool scale and tested and quantified, only for Cryp-
tosporidium, using immunofluorescence microscopy and 
real-time PCR. Positive samples will be speciated using 
validated PCR techniques which are part of normal prac-
tice.36 Cryptosporidium DNA will be retained for subtyping 
and possibly whole genome sequencing at a later date.
Full laboratory protocol available on request
Analyses
The primary objective of this study is to determine the 
amount of spread that happens in the home where there 
is a case of Cryptosporidium. This will be established by 
testing stool samples of household members of a case 
for Cryptosporidium and reporting the numbers of other 
cases (according to our predetermined definitions in 
box 1). A household with more than one case of any 
type will be a household with transmission. As we are 
only able to capture cases of Cryptosporidium using labora-
tory confirmed cases reported to surveillance, we recog-
nise that what we may define as an ‘index’ case, may not 
be, in true epidemiological terms, the first case that has 
driven transmission. While it is important that cases are 
identified and recruited based on the same diagnostic 
criteria, we accept that the identification of index cases is 
a pre-enrolment definition. Following enrolment of the 
household into the study, and the return of documenta-
tion, an index case may be categorised differently, and 
may actually fit the definition for a secondary case. This 
will be analysed at the household level and depends on 
the accurate population of fields in the questionnaire. 
In doing this, we are able to more accurately describe 
transmission in the home, and this may well allow us to 
describe the characteristics of these true index cases, and 
why we do not pick them up in surveillance, for example, 
if they exhibit different health-seeking behaviour.
We will calculate the following:
 ► The secondary transmission rate/prevalence within 
households (number of cases in the home/numbers 
at risk in the home, number of households with 
secondary spread/number of households)).
 ► The amount of asymptomatic carriage among those 
exposed to symptomatic cases (number of asympto-
matic cases/number at risk)).
 ► OR/RR of secondary illness according to activities 
and case/household characteristics;
 ► OR/RR of secondary illness according to organism 
species.
Confounding (eg, host factors such as age, comor-
bidity) will be considered, where known, using multivar-
iable techniques. Also, we will, where possible, examine 
environmental level exposures using stratification, for 
example, those households/cases which are exposed to 
other known sources or risk factors, such as those living 
on farms.
Data will be analysed using Stata V.12.
Limitations and biases
Some elements of the study design are retrospective in 
nature, as the index case must have already been ill and 
been tested in order to be selected. As a result, some ascer-
tainment bias may lead to a skewed sample from which to 
choose the index cases. We do not expect to capture the 
full profile of cases and households in the population that 
might have Cryptosporidium due to differences in risk or 
vulnerability, severity or health-seeking behaviour.37 We 
may get an over-representation of severe disease as these 
cases are more likely to seek healthcare and be tested, 
and perhaps more likely to test positive.
We are only collecting one sample from each house-
hold member, and not re-sampling the index case, for 
time and resource reasons. This may well lead to missing 
intermittent shedding of oocysts, tertiary household 
infections and/or misclassifying recurring illness.
As Cryptosporidium is common in younger age groups, we 
expect a large proportion of the participants to represent 
families with young children which may lead to over-rep-
resentation of these households. In addition, we might 
expect that having young children who were ill, or being 
severely ill themselves, may incentivise cases to participate 
in the study, more than adult, less severe cases.
Any likely over- or under-representation in the data 
collected will be considered when assessing and describing 
results. Further unidentifiable limitations may include 
Figure 3 Fe-Col kit.
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recall biases around dates of onset or activities, and classi-
fication biases as we are asking about self-reported illness 
and information may be inaccurate.
There is a possibility that we could see ongoing 
outbreaks in the study year. If this happens, we might 
try to identify these where possible and may consider 
excluding households from this study where all or most 
members have been exposed, including a definition of a 
co-primary case.
End of study
The study will be declared as ended when the database is 
closed to recruitment—after 1 year or when the maximum 
number of households has been enrolled.
Pilot arrangements
A pilot phase of 1 month is anticipated before data collec-
tion begins to assess and evaluate processes. Pilot data 
will be included as study data if no major methodological 
changes are proposed.
Ethics and dissemination
The study has been approved by the North West – Liver-
pool East NHS Research Ethics Committee (Reference: 
18/NW/0300) and the Confidentiality and Advisory 
Group (Reference 18/CAG/0084). The project is regis-
tered on the National Institute for Health Research port-
folio (CPMS ID: 39458).
Outputs will include scientific conferences and peer-re-
viewed publications. In addition, a short, lay report of 
findings will be produced for participants, who can opt to 
receive this when they take part.
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How to collect and send a stool sample for laboratory tests 
Your stool sample pack contains: 




The stool pot (blue top) has a small plastic spoon fitted to the underside of the lid and can be 
found inside the strong plastic container. 
Your household study ID will be written on the stool pot.  
Please write the age and sex of the person providing the sample, and the date the sample is 
collected, on the label on the pot. Do this before collecting the sample. 
Use a clean toilet which has been well flushed. Do not allow toilet cleaner or disinfectant to 
come into contact with the stool sample. 
Follow the instructions provided in the kit. Try to get at least three or four scoops – 
but do not worry if you are under or over that! Whatever you can manage is fine. 
To collect from a nappy, use the plastic spoon fitted to the container lid to scoop some poop 
out of the nappy and into the stool pot.   
Once the sample has been taken, make sure the cap is screwed tightly onto the stool pot. 
Just leave the spoon attached. 
Wash your hands thoroughly, using soap and running water, then dry well. 
Put the stool pot into the strong, plastic container, then into the prepaid postal bag. 
Only one sample should be added to each envelope. 
Please ensure that the postal bag is securely closed. 
Post the sample as soon as possible on the same day. If you are unable to do this, keep the 
package in a cool place (but not your fridge) and post as soon as possible the next day. 
Thank you for helping us with our research!  
 
                             
 
The epiCrypt Study 







General Data Protection Regulation for health and care research 
 
The epiCrypt Study is sponsored by the University of Liverpool. 
 
As a University we use personally-identifiable information to conduct research to improve health, care 
and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when 
we use personally-identifiable information from people who have agreed to take part in research.  This 
means that when you agree to take part in a research study, we will use your data in the ways needed to 
conduct and analyse the research study. Your rights to access, change or move your information are 
limited, as we need to manage your information in specific ways in order for the research to be reliable 
and accurate. If you withdraw from the study, we will keep the information about you that we have 
already obtained. To safeguard your rights, we will use the minimum personally-identifiable information 
possible.  
 
Health and care research should serve the public interest, which means that we have to demonstrate 
that our research serves the interests of society as a whole. We do this by following the UK Policy 
Framework for Health and Social Care Research. 
 
The University of Liverpool takes great care to abide by our legal and moral obligations when handling 
your personal and healthcare data. Due to changes introduced in the EU General Data Protection 
Regulation (GDPR), we are writing to provide you with information on the lawful basis on which we are 
processing your data. The lawful basis for the processing of your personal data for the research study 
which you have participated in is a task in the public interest.  
 
The data you have provided for the epiCrypt Study will be stored for six years. You are free to withdraw 
your consent for your data to be collected, processed, or stored at any time. However if the data has 
already been anonymised it will not be possible to withdraw your data. 
 
We will not share your data unless you have provided explicit consent for us to do so. 
 
The data controller for this study is the University of Liverpool, Research Support Office, 2nd Floor Block 
D Waterhouse Building, Liverpool L69 3GL 
Tel: 0151 794 8373 
Email: sponsor@liverpool.ac.uk  
 
The University Data Protection Officer, Mrs Victoria Heath, can be contacted on 0151 794 2148. 
 
The University strives to maintain the highest standards of rigour in the processing of your data. 
However, if you have any concerns about the way in which the University processes your personal data, 
it is important that you are aware of your right to lodge a complaint with the Information Commissioner's 
Office by calling 0303 123 1113. 
 
INFORMATION SHEET 
Before you decide whether you wish to take part, please take time to read the following information carefully. 
Ask us if there is anything that is not clear or if you would like more information, and feel free to discuss it 
with your friends and family. 
Who are we?  
We are a team of researchers from the University of 
Liverpool, Public Health England, and Public Health 
Wales who are interested in finding out more about 
the spread of tummy bugs. 
This study is being done to find out more about a 
common tummy bug called Cryptosporidium.  
What are we doing? 
Some people pick up the bug and feel fine. Other 
people can feel poorly for some time. We want to 
find out if Cryptosporidium spreads between people 
in the same house, and look for clues as to how this 
might happen. This will help us to stop others 
getting sick. 
Why are we doing this? 
Cryptosporidium is important because it affects 
many people, especially children, and some people 
may get very sick. Sometimes many people are 
affected at once, which is what we call an 
‘outbreak’.  
Why have we chosen your household? 
You or your child have recently had 
Cryptosporidium. We are asking everyone who lives 
in the North West of England or in Wales, who has 
recently had the Cryptosporidium bug, to take part 
with their household. We would like to test all the 
people in the household to see if anyone else has 





What will we want you to do? 
We will ask you to read all the information we have 
given you and then sign the consent form. There is 
also a simple questionnaire to fill out – only one 
person needs to do this – asking some general 
questions about your household.  
We would then like each person in the house to 
collect a sample of their poo and send it back to the 
lab to be tested, even if they haven’t been sick. We 
will provide instructions, and stamped addressed 
envelopes.  
It will not cost you anything to take part. 
Do I have to take part? 
It is completely up to you and your household to 
decide whether to take part. If you do decide to take 
part you are still free to change your mind later 
without giving a reason. Whatever you choose will 
not affect your medical care or legal rights. If some 
household members do not want to take part but 
others do, that is also fine. You can contact us if you 
want to chat about any of this. 
How much time do I have? 
If we do not get the documents back after two 
weeks, we may call or write to you again to remind 
you. If you do not get back to us after that, we will 
not try to contact you again. 
What about my information? 
There are strict laws that make sure we treat your 
information in confidence, in the same way as any 
other medical information. Only members of the 
small study team will know your details. When the 
results are written up, all personal details will be 







































Can I change my mind? 
Of course! You can change your mind at any time 
and just let us know – your details will be 
removed. You do not have to give a reason and it 
will not affect your care, or how any medical 
professional treats you. We will not tell anyone if 
you change your mind. 
Has this study been approved? 
This study has been ethically reviewed and 
approved by the Health Research Authority (HRA) 
and NHS/HSC R&D for Wales. The HRA 
publishes summaries of research approved by 
Research Ethics Committees in the UK and you 
can find these online at www.hra.nhs.uk. Our 
approval number is 18/NW/0300. 
What happens after the study? 
We hope that the results we find will help us 
improve the information and advice we give to 
people who get Cryptosporidium and stop more 
people getting sick.  
The results will be put into reports and published 
in scientific journals and at conferences. In this 
way, other doctors and scientists can share the 
information and make recommendations to health 
organisations and the public.  
We are not able to return individual sample results 
back to participants, but please read the 
information leaflet provided – this advises what 
you should do if you feel ill or if you are not getting 
better. You can get a summary of the research 
when we are finished – just tick the box on the 
questionnaire. 
Who is paying for the study? 
The research is being funded by the National 
Institute for Health Research (NIHR). 
What if I have questions? 
If you have any questions or comments about the 
study you can call us on 0151 795 8334 or e-mail 
us at c.mckerr@liv.ac.uk and speak to The 
epiCrypt Study team. 
 
 
What happens next? 
1. Your study pack includes this document, called 
an INFORMATION SHEET  
Please make sure you have read it and you are 
happy to take part. Discuss this with others, and 
share it with the others in your home.  
Make a note of our contact details in case you 
want to chat over anything. 
2. Your study pack includes a includes a 
document called a QUESTIONNAIRE  
Please open the questionnaire booklet to the 
CONSENT FORM on the first page.  
Each adult (over 16) who wants to be in the study 
should initial after each statement, and sign in the 
table. A parent/guardian can consent, and sign, 
for those under 16 years old if needed. There is a 
box for this too.  
Instructions for filling in the questionnaire and 
consent form are on the front of the booklet. This 
tells you who should fill it in and how. Fill in the 
questionnaire as well as you can on behalf of 
yourself/the first case and the household, and 
send it back to us in the pre-paid envelope 
provided.  
Don’t worry if you can’t answer some of the 
questions - it is OK to put “don’t know”. 
3. Your study pack includes STOOL SAMPLE 
PACKS  
There is a stool pack for each person who wants 
to take part. The first case (you or your child) does 
not have to be tested again - just the others in the 
home.  
Follow the instructions that are with the stool 
packs, and don’t forget to add your details to your 
pot. Try to get at least three or four scoops into 
the stool pot, but don’t worry if you get more, this 
is fine.  
The pots have their own pre-paid envelopes to 
send back to the lab. Follow the instructions for 
packaging them up.  
We have made sure we use only specialist 
equipment, which is safe to send in the post. 
Investigating how Cryptosporidium  
infection spreads at home
Health Information
& Advice
Do I need to stay off work or school?
Yes. While you are ill and have symptoms, you 
are infectious to others!
You should not return to work or school until you 
have not had any diarrhoea and/or vomiting for 
48 hours.
If you work with vulnerable groups such as the 
elderly, the young, or those in poor health, or if 
you handle food, you should tell your employer 
you have had diarrhoea.
For further advice or if you have concerns about 
your health, contact or call your GP or NHS 111
Useful websites:
NHS Direct http://www.nhsdirect.nhs.uk 
Public Health England – cryptosporidiosis
Public Health Wales – Cryptosporidium
Health and Safety Executive (HSE) Factsheets
World Health Organization advice on  
hand washing
How do I wash my hands properly?
Washing your hands properly takes as long as singing ‘Happy Birthday’ twice, 













Wet hands with water
Right palm over left 
dorsum with interlaced 
fingers and vice versa
Dry thoroughly with a 
single use towel
Rotational rubbing of 
left thumb clasped in 
right palm and  
vice versa
Apply enough soap to 
cover all hand surfaces
Palm to palm with 
fingers interlaced
Use towel to turn off tap
Rotational rubbing, 
backwards and 
forwards with clasped 
fingers of right hand in 
left palm and vice versa
Rub hands palm to 
palm
Backs of fingers to 
opposing palms with 
fingers interlocked
...and your hands are 
safe
Rinse hands with water
What is Cryptosporidium?
Cryptosporidium (sometimes called crypto) is a 
tiny parasite affecting people and farm animals. 
It causes an illness known as cryptosporidiosis. 
The disease is most common in spring and 
autumn.
What are the symptoms? 
Not everyone will have symptoms but they 
usually include:
• diarrhoea 
• stomach cramps 
• fever 
and sometimes:
• vomiting and loss of appetite 
• headache 
Who is at risk?
Anyone can get crypto, but it is most common 
in children under 5 years old. People who care 
for, or work with, young children or have contact 
with farm animals are more at risk. It can make 
children, the elderly, and those with immune 
problems, very ill.
How does it spread? 
Transmission happens if you swallow the 
parasite, which is found in infected animal or 
human poo. You can get it directly from another 
person or animal by touching poo (for example 
when changing a nappy or stroking a dirty animal) 
and putting your hands near or in your mouth 
without washing them thoroughly. 
You can also get infected from drinking 
contaminated water or eating contaminated food. 
Swimming pools and other recreational waters 
can get contaminated too.
What should I do if I am ill?
For most healthy people the illness is unpleasant 
but you will recover in a week or so. Drink plenty 
to replace lost fluids, and get lots of rest.
Antibiotics do not help. 
You should contact your GP if symptoms 
become severe or if you have other medical 
conditions. 
You can tell your doctor about this study and let 
them know that someone else in your home has 
had crypto.
People who have any problems with their 
immune system, or the very young or elderly, may 
have a more severe illness and should see their 
GP if they are ill. 
How can I avoid spreading Crypto?
Do not go swimming until you have been free of 
symptoms for at least 14 days. 
Clean toilet seats, toilet bowls, flush handles, 
sinks, and taps thoroughly, especially after 
someone at home has had diarrhoea or vomiting. 
If possible, poorly people should use a separate 
toilet.
Pay special attention to hygiene – especially 
hand washing. Make sure all members of your 
household wash their hands thoroughly with soap 
and hot water after going to the toilet, before 
preparing, serving, or eating food, and after 
handling soiled clothing or bedding.
Wash all soiled clothes and linen on as hot a 
machine wash as possible.
Do not share towels with other ill people.
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Who should complete this document?
It is best that the questionnaire is completed by the FIRST CASE, or their 
parent/guardian if the first case is under 16 years old.
The FIRST CASE is the person who had Crypto and was contacted 
by the research team, or their parent/guardian if they were a child.
This may not have been the first person in the home to be ill - 
don’t worry. Still answer the questions about the FIRST CASE that 
was contacted by the research team.
• BEFORE COMPLETING THIS QUESTIONNAIRE PLEASE READ  
 ALL THE INFORMATION IN YOUR STUDY PACK.
• PLEASE INITIAL THE STATEMENTS ON THE CONSENT FORM  
 ON THE FIRST PAGE OF THIS BOOKLET AND SIGN.
• WHEN YOU HAVE COMPLETED THE QUESTIONNAIRE,   




HOW TO COMPLETE THIS FORM
Each person who wants to take part should read the statements 
on the following page and initial in the box to show they 
understand them and agree.
Then add your names AND sign in the table.
Children aged 16 & 17 must consent for themselves.
Children under 16 years old may consent for themselves if a parent 
or guardian feels it is appropriate, or a parent or guardian may 
consent on their behalf. Just initial and sign this portion of the 
form to confirm.
You do not need to detach this form. Just return the whole 
questionnaire booklet. Returning these documents will be taken as 
consent to take part.
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Each person in the household who wants to take part or is 
consenting for others must initial a box beside each statement
I have read, and understand, the information 
pack explaining the study and have been 
given the contact details of the study team if 
I have any questions
I understand that taking part in this study is 
voluntary and I (or anyone I consent for) can 
leave at any time
I understand that any stool sample I provide 
(or any I consent for) will be tested for 
Cryptosporidium species and genotypes
I understand that all sample results are 
confidential, and my data may be shared 
securely with Public Health England/Public 
Health Wales to locate laboratory records 
relevant to this study
We agree to take part in this study
     
    
    
    
 NAME  SIGNATURE
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IF YOU ARE ALSO CONSENTING FOR ANYONE UNDER 16 YEARS
Please mark with parent/guardian ’ s initial
I am the parent/legal guardian of the child/children in the 
household and I consent to my child/children taking part 
in this study
   
 NAME OF  
PARENT/GUARDIAN  SIGNATURE  NAME OF CHILD
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QUESTIONNAIRE
How to complete this questionnaire
Start at Section A on the following page
Write the date in the space at the top of the page
Some questions are about the first case and some are about the 
household. Follow the instructions to help.
You should: 
• use pen to answer
• tick or cross your answers within the box like this:   
• follow any ‘if YES’ or ‘if NO’ instructions and leave blank any   
 questions you do not need to answer
Don’t worry if you don’t want to answer anything – you can leave it   
blank. But it helps our research to get as much of the information as  
possible.
Some of the questions are about others in the household - 
these will be clearly worded. You may want to get some information  
from others in the home or some help answering some of the 
questions. This is fine.
Try to think about when you/the FIRST CASE had their Crypto illness.
You may have already answered some questions like this on a 
questionnaire, or for your local environmental health officer, but we need 
to get these answers separately on this questionnaire.
Just answer as best you can – any information helps.
Remember: The FIRST CASE is the person who had Crypto and 
was contacted by the research team, or their parent/guardian if 
they were a child.
This may not have been the first person in the home to be ill - 
don’t worry. Still answer the questions about the FIRST CASE that 
was contacted by the research team.

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DATE FILLED IN ______/______/______
SECTION A
A1. What is the postcode of the home? _________________________
A2. How many people live in the household in total (including the 
first case)? 
_______________
Please fill in the table below telling us how many people live in the 





























A3. How old is the FIRST CASE?
Date of Birth    /   /         OR Age __________
A4. What symptoms did the FIRST CASE have when they had 
Crypto?
(Tick all that apply)
  Diarrhoea (3 or more loose stools/runny poos in a day)
  Feeling sick/nausea      Vomiting/being sick 
  Stomach pain/Cramps   High temperature/feverish   Headache
  Other ______________________________________________________
_______________________________________________________________
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A5. When did the FIRST CASE start to feel ill with these 
symptoms?
  /   /    
A6. Is the FIRST CASE still ill with these symptoms?
  Yes
  No
If YES, and they are still unwell, for how many days have they had it now?
_________________
If NO, and they are better now, for how many days did the symptoms 
last?
______________
A7. In the TWO WEEKS before symptoms started, did the FIRST 




If YES, was that someone who lives:
  In the home?
  Elsewhere?
A8. In the TWO WEEKS before or after the FIRST CASE was 





Who’s who in the household and who else has 
been ill?
Please fill in table A on the next page, including all members of the 
household that are taking part in the study. This will be all the people on 
the consent form on the front of this booklet.
Please tell us whether others in the household have also been ill with 
diarrhoea or vomiting recently or around the same time as the  
FIRST CASE.
Try to think roughly about the month before and after the FIRST 
CASE was ill.
Don’t worry if the dates are estimates – as accurate as you can get is fine. 
If you cannot remember, just let us know if you think it was before or after 
the first case started to get ill. This is still useful information.
Adding the age and sex helps us to identify the household members and 
match up their samples.
Look at the example to help:
Age Sex Relationship 



























39 F Mother Yes 18/12/2017 10 No
42 M Father Yes Before About 3 
days
No
6 M Brother No - - -
24 F Lodger/
Housemate




Age Sex Relationship 





























B1. Sex of FIRST CASE
  Female 
  Male
  Other
  Prefer not to say
B2. Is the FIRST CASE:
(Tick all that apply)
  At nursery or pre-school
 In education (school/college/uni etc.)
 Working (paid work, either outside the home or from home)
 A stay at home parent or carer
 Retired
 Other
If OTHER, please describe
_______________________________________________________________
If the FIRST CASE is working, what is their main occupation?
_______________________________________________________________
_______________________________________________________________




If YES, please describe 
_______________________________________________________________
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Activities of the first case and others in the home in 
the 2 weeks before illness
Please fill in table B on the next page.
We want to find out if the household has been involved in any activities in 
the table.
Please fill in the first column in the table with a cross or tick if the FIRST 
CASE did any of these things in the TWO WEEKS before their symptoms 
started.
Also tick the second column if anyone else who lives in the home was 
there and did those things at the same time.
Don’t worry if you’re not too sure – as much as you can remember is fine. 
This is still useful information.
Look at the short example to help: 
ACTIVITY  FIRST CASE  ANYONE ELSE IN THE HOME
Travel outside the UK  
Swimming – outdoors (lake, 
river, stream etc.)
Swimming – in a treated 
swimming pool, either 




ACTIVITY  FIRST CASE  ANYONE ELSE IN THE HOME
Travel outside the UK
Swimming – outdoors (lake, 
river, stream etc.)
Swimming – in a treated 
swimming pool, either 
indoors or outdoors (such 
as a pool at a leisure centre 
or a lido) 
Other water activities/sport 
(such as surfing, rowing, 
water-skiing etc.)
Other outdoor activities 
(such as camping, climbing, 
hiking, cycling etc.)
Gardening (at home or 
elsewhere, such as an 
allotment)
Contact with pets (at home 
or with pets at another 
house)
Visiting or working on a 
farm or had contact with 
farm animals
Visiting or working at a zoo 




C1. How many bedrooms are there in the house? ________________
Do any adults share a bedroom to sleep in at night?  
  Yes
  No
Do any children (under 18 years old) share a bedroom to sleep in at night?
  Yes
  No
Do any infants (under 1 year) sleep in a bedroom with an adult at night?
  Yes
  No
C2. Does the FIRST CASE regularly (more than once a week) share 
a bed with anyone else in the home?
  Yes
  No
C3. How many bathrooms are there? __________________
How many other people use the same bathroom at home as the FIRST 
CASE?
 1 2 3 4 5 6 7 8 9 10
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C4. How many toilets/WCs are there in total? _______________
How many other people use the same toilet at home as the FIRST CASE?
 1 2 3 4 5 6 7 8 9 10
                  
C5. Does the FIRST CASE regularly (more than once a week) share 
a bath with anyone else in the home?
  Yes
  No
C6. Is your home on, or part of, a farm or smallholding?
  Yes
  No
C7. Does your home have any outside space/area?
  Yes
  No
If YES, what kind? (Tick all that apply)
  Yard (no grass)
  Front garden
  Back garden
  Other ______________________________________________________
C8. Is your home supplied by mains water (i.e. a water company 




C9. Are there any pets in the home?
  Yes
  No
If YES, what kind? (Tick all that apply)
 Cat(s)     Bird(s   Reptile(s) 
  Dog(s)    Horse(s)    Fish   Other _____________ 
C10. Are there any other animals at or around the home - such as 
livestock, chickens, cows, sheep etc.?
  Yes
  No





D1. Is the FIRST CASE a child under 5 years old?  
  Yes
  No
If YES, are they? (Tick all that apply)
  In nappies 
 Potty/Toilet training
  Neither
If NO, are they an older child (more than 5 years old) or an adult that 
needs help with any of the following? (Tick all that apply)
 Nappy changing 
 Assisting with going to the toilet
  Bathing
 None of the above 
D2. Does the FIRST CASE regularly (more than once a week) help 
a child (or children) under 5 with any of the following? (this could 
be at work or in the home) 
(Tick all that apply) 
 Nappy changing 
 Potty training
  Assisting with the toilet
 Bathing
 None of the above/not applicable
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D3. Does the FIRST CASE regularly (more than once a week) help 
a child over 5, or an adult, with any of the following? (this could be 
at work or in the home)
(Tick all that apply) 
 Nappy changing 
  Potty training
  Assisting with the toilet
  Bathing
 None of the above/not applicable
D4. Are there ANY children (under 5) living in the household who 
are in nappies and/or currently toilet training?
  Yes
  No
If YES, when changing nappies do you/others in the home generally use 
any of the following: (Tick all that apply)
Don’t worry if it applies to more than one child – just tick if anyone in the 
home generally uses these things when changing nappies or helping the 
children with the toilet
   Disposable nappies    Nappy cream 
  Cloth nappies    Hand gel 
   Disposable baby wipes/wet wipes    Nappy bags 
  Water and cotton wool    A nappy bin 
  Top/Tail bowl    A changing mat
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D5. Does the FIRST CASE regularly/usually prepare meals or cook 
for others in the household?
  Yes
  No
If YES, did they still prepare meals or cook for the rest of the household 
while they were ill with Crypto?
  Yes
  No
  Don’t know
D6. When hand-washing, do household members normally use: 
(Tick all that apply)
  Hot water    Hand wipes 
  Soap (bar or hand wash)    Don’t know 
   Antibacterial hand wash    None of the above/Not applicable 
  Alcohol gel
D7. Generally, do household members wash their hands before 
and/or after any of the following?
If you’re not sure, just try to think about what most people in the home do
Going to the toilet Helping someone with the toilet
  Before (if applicable)   Before 
  After      After 
   Both     Both 
  Neither     Neither  
Nappy changing (if applicable) Eating
  Before   Before 
  After   After 
   Both   Both 
  Neither   Neither 
Preparing food Handling dirty/soiled laundry
  Before   Before 
  After   After 
   Both   Both 
  Neither   Neither 
THANK YOU FOR COMPLETING 
THE QUESTIONNAIRE!
Please let us know if you would like a summary of the results when we 
have finished our study. 
  Yes
  No
Please let us know if you would be willing to be contacted again if we had 
any further questions about your illness or your household. 
  Yes
  No
If YES to either of the above, please give the preferred contact details:
 Email ______________________________________________________
 Post  ______________________________________________________
 Telephone __________________________________________________
Please place in the FREEPOST ENVELOPE PROVIDED and return 
to the epiCrypt study team. Thank you!
